(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁷: **G01N**

(21) International Application Number: PCT/US02/40271

(22) International Filing Date:
17 December 2002 (17.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/341,942   19 December 2001 (19.12.2001)   US

(71) Applicant *(for all designated States except US)*: **MILLENNIUM PHARMACEUTICALS, INC.** [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **GUILD, Braydon, C.** [US/US]; 109 Riverdale Road, Concord, MA 01742 (US). **LIAO, Hua** [CN/US]; 4 Village Green Lane, Apartment 7, Natick, MA 01760 (US). **JONES, Michael, D.** [US/US]; 14 Schouler Court, Arlington, MA 02476 (US). **ZOLG, Johannes, W.** [DE/DE]; Sportplatzweg 4A, 82372 Weilheim (DE). **WU, Jiang** [CN/US]; 23 Judith Lane, Apartment 6, Waltham, MA 02452 (US).

(74) **Agent: ALLEN, Theodore, R.**; Millennium Pharmaceuticals Inc., 75 Sidney Street, Cambridge, MA 02139 (US).

(81) **Designated States** *(national)*: AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF RHEUMATOID ARTHRITIS

(57) **Abstract:** The invention relates to composition, kits, and methods for detecting, characterizing, preventing, and treating human Rheumatoid Arthritis (RA). A variety of newly-identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with RA.

COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF RHEUMATOID ARTHRITIS

RELATED APPLICATIONS

5   The present application claims priority from U.S. provisional patent application serial no. 60/341,942, filed on December 19, 2001. The above application is expressly incorporated by reference.

FIELD OF THE INVENTION

The field of the invention is rheumatoid arthritis, including diagnosis,
10   characterization, management, and therapy of rheumatoid arthritis.

BACKGROUND OF THE INVENTION

Rheumatoid arthritis ("RA") is a chronic, inflammatory, systemic disease that produces its most prominent manifestations in the diarthrodial joints. Persistent and progressive synovitis develops in peripheral joints. RA encompasses a wide spectrum of
15   features, from self-limiting disease to progressively chronic disease with varying degrees of joint destruction to clinically evident extra-articular manifestations. Genetic and environmental factors control the progression, extent, and pattern of the inflammatory response and are thereby responsible for the heterogeneous clinical features.

RA has a worldwide distribution and involves all ethnic groups. Although the
20   disease can occur at any age, the prevalence increases with age and the peak incidence is between the fourth and sixth decade, although data from population- based prevalence and incidence studies have to be interpreted cautiously because there is no laboratory test, histologic finding, or radiographic-feature to confirm a diagnosis of RA.

The most widely used system to classify RA is the American College of
25   Rheumatology 1987 revised criteria for the classification of RA. Arnett FC, *et al.*, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 31:315-324. According to the criteria, a patient is said to have RA if the patient satisfies at least four of the following seven criteria and criteria 1-4 must be present for at least six weeks: 1) morning stiffness, 2) arthritis of three
30   or more joint areas, 3) arthritis of hand joints, 4) symmetrical arthritis, 5) rheumatoid nodules, 6) serum rheumatoid factor ("RF"), and 7) radiographic changes. These criteria have a sensitivity and specificity of approximately 90%. Depending on the stringency of

the criteria, prevalence estimates vary from 0.3% to 1.5% in the North American population. The prevalence is about 2.5 times higher in females than in males.

5

10

15

20

25

30

The histologic changes in RA are not disease-specific but largely depend on the organ involved. The primary inflammatory joint lesion involves the synovium. The earliest changes are injury to the synovial microvasculature with occlusion of the lumen, swelling of endothelial cells, and gaps between endothelial cells, as documented by electron microscopy. This stage is usually associated with mild proliferation of the superficial lining cell layer. Two cell types constitute the synovial lining: bone marrow-derived type A synoviocyte, which has macrophage features, and mesenchymal type B synoviocyte. Both cell types contribute to the synovial hyperplasia, suggesting a paracrine interaction between these two cell types. This stage of inflammation is associated with congestion, edema, and fibrin exudation. Cellular infiltration occurs in early disease and initially consists mainly of T lymphocytes. As a consequence of inflammation, the synovium becomes hypertrophic from the proliferation of blood vessels and synovial fibroblasts and from multiplication and enlargement of the synovial lining layers. Granulation tissue extends to the cartilage and is known as pannus. The tissue actively invades and destroys the periarticular bone and cartilage at the margin between synovium and bone, known as erosive RA.

The articular manifestations of RA can be placed in two categories: reversible signs and symptoms related to inflammatory synovitis and irreversible structural damage caused by synovitis. This concept is useful not only for staging disease and determining prognosis but also for selecting medical or surgical treatment. Structural damage in the typical patient usually begins sometime between the first and second year of the disease. Van der Heijde, DM, *et al.*, 1982, *Arthritis Rheum* 25:361-365. Although synovitis tends to follow a fluctuating pattern, structural damage progresses as a linear function of the amount of prior synovitis.

The etiology of the early events in RA remains elusive. The possibility of a bacterial or viral infection has been vigorously pursued. All efforts to associate an infectious agent with RA by isolation, electron microscopy, or molecular biology have failed. It is possible that there is no single primary cause of RA and that different mechanisms may lead to the initial tissue injury and precipitate synovial inflammation.

Clinical signs of synovitis may be subtle and are often subjective. Warm, swollen, obviously inflamed joints are usually seen only in the most active phases of inflammatory synovitis. Cartilage loss and erosion of periarticular bone are the characteristic features of

structural damage. The clinical features related to structural damage are marked by
progressive deterioration functionally and anatomically. Structural damage to the joint is
irreversible and additive.

Data from longitudinal clinical and epidemiologic studies provide guidelines for

5   treatment. These studies emphasize 1) the need for early diagnosis, 2) identification of
prognostic factors, and 3) early aggressive treatment. Earlier diagnosis and treatment,
preferably within the first several months after onset of symptoms, may help prevent
irreversible joint damage. The present invention provides such methods and reagents for
the diagnosis, characterization, prognosis, monitoring and treatment of RA.

10   **SUMMARY OF THE INVENTION**

The present invention is directed to the methods of determining or diagnosing
whether patients are afflicted with inflammatory disorders, e.g., joint disorders, i.e.,
rheumatoid arthritis. The present invention also provides methods for determining or
diagnosing whether patients are afflicted with erosive RA. Erosive RA is characterized by

15   erosions or pits in the surface of the bone adjacent to the articular surface. In particular, in
erosive RA, the granulation tissue actively invades and destroys the periarticular bone and
cartilage at the margin between the synovium and the bone. These methods typically
include the step of obtaining a sample of the patient's bodily fluids, determining the level
of expression of one or more markers in these fluids, and identifying whether the patient's

20   fluids include a pattern or profile of expression of a marker set (a pattern or profile of
expression is also referred to herein as the "expression or marker profile" of the marker
set) which correlates with inflammatory disorders, e.g. rheumatoid arthritis.

The present invention therefore provides methods, reagents and kits for diagnosing,
characterizing, prognosing, monitoring, and treating RA, including identifying erosive and

25   non-erosive RA.

In one aspect, the invention relates to various diagnostic, monitoring, test and other
methods related to RA detection and therapy. In one embodiment, the invention provides
a diagnostic method of assessing whether a patient has RA or has higher than normal risk
for developing RA, comprising the steps of comparing the level of expression of a marker

30   of the invention in a patient sample and the normal level of expression of the marker in a
control, *e.g.*, a sample from a patient without RA or the expression level of the marker in a
population-average. A significantly higher level of expression of the marker in the patient
sample as compared to the normal level is an indication that the patient is afflicted with

RA or has higher than normal risk for developing RA. It will be appreciated that the "level of expression" includes a quantitative measurement, *i.e.*, the sample may be analyzed quantitatively, wherein the abundance of one or more of the markers in a sample is determined and compared to the normal abundance of the one or more markers.

5   According to the invention, the marker(s) are selected such that the positive predictive value of the methods of the invention is at least about 10%, preferably about 25%, more preferably about 50% and most preferably about 90%. Also preferred are embodiments of the method wherein the marker is over- or under-expressed by at least two-fold in at least about 20% of fast-progressing RA.

10   In the methods of the present invention, the samples or patient samples may comprise RA-associated body fluids. Such fluids include, for example, blood fluids, (*e.g.*, whole blood, blood serum, plasma, blood having platelets removed therefrom, etc.), urine, saliva, tears, and synovial fluid. The patient samples may also comprise cells, *e.g.*, cells obtained from the patient. The cells may be endothelial cells, white blood cells and

15 synovium cells, osteoclasts, osteoblasts, chondrocytes as well other cells found in joints. In a further embodiment, the patient sample is *in vivo*.

The methods of the present invention are particularly useful for patients with identified inflammatory synovitis or other symptoms associated with RA. The methods of the present invention can also be of particular use with patients having an enhanced risk of

20 developing RA (*e.g.*, patients having a familial history of RA, patients identified as having a RF, patients at least about 40-60 years of age and female patients at least about 40-60 years of age). The methods of the present invention may further be of particular use in monitoring the efficacy of treatment of a RA patient (*e.g.* the efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs

25 (DMARDs)).

In accordance with the methods of the present invention, the level of expression of the marker in a sample can be assessed, for example, by detecting the presence in the sample of:

- a marker protein (*e.g.*, a protein having a sequence selected from the group
30   consisting of SEQ ID NOs:2, 4, 6, 8, and 10), or a fragment of the protein (*e.g.* using a reagent, such as an antibody, an antibody derivative, or an antibody fragment, which binds specifically with the marker protein or a fragment of the protein)

- a metabolite which is produced directly (*i.e.*, catalyzed) or indirectly by a marker protein

- a transcribed polynucleotide (*e.g.* an mRNA or a cDNA, including a polynucleotide selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, and 9), or fragment thereof, having at least a portion with which the marker nucleic acid is substantially homologous (*e.g.* by contacting a mixture of transcribed polynucleotides obtained from the sample with a substrate having one or more of the marker nucleic acids fixed thereto at selected positions)

- a transcribed polynucleotide or fragment thereof, wherein the polynucleotide anneals with the marker nucleic acid under stringent hybridization conditions.

According to the invention, any of the aforementioned methods may be performed using a plurality (*e.g.* 2, 3, 5, or 10 or more) of RA markers, including RA markers known in the art. In such methods, the level of expression in the sample of each of a plurality of markers, at least one of which is a marker of the invention, is compared with the normal level of expression of each of the plurality of markers in samples of the same type obtained from control humans not afflicted with RA. A significantly altered (*i.e.*, increased or decreased as specified in the above-described methods using a single marker) level of expression in the sample of one or more markers of the invention, or some combination thereof, relative to that marker's corresponding normal or control level, is an indication that the patient is afflicted with RA. For all of the aforementioned methods, the marker(s) are preferably selected such that the positive predictive value of the method is at least about 10%.

In a further aspect, the invention provides an antibody, an antibody derivative, or an antibody fragment, which binds specifically with a marker protein or a fragment of the protein. The invention also provides methods for making such antibody, antibody derivative, and antibody fragment. Such methods may comprise immunizing a mammal with a protein or peptide comprising the entirety, or a segment of 10 or more amino acids, of a marker protein, wherein the protein or peptide may be obtained from a cell or by chemical synthesis. The methods of the invention also encompass producing monoclonal and single-chain antibodies, which would further comprise isolating splenocytes from the immunized mammal, fusing the isolated splenocytes with an immortalized cell line to form

hybridomas, and screening individual hybridomas for those that produce an antibody that binds specifically with a marker protein or a fragment of the protein.

In another aspect, the invention relates to various diagnostic and test kits. In one embodiment, the invention provides a kit for assessing whether a patient is afflicted with

5   RA. The kit comprises a reagent for assessing expression of a marker of the invention. In another embodiment, the invention provides a kit for assessing the suitability of a chemical or biologic agent for inhibiting RA in a patient. Such a kit comprises a reagent for assessing expression of a marker of the invention, and may also comprise one or more of such agents. Such kits may comprise an antibody, an antibody derivative, or an antibody

10 fragment, which binds specifically with a marker protein, or a fragment of the protein. Such kits may also comprise a plurality of antibodies, antibody derivatives, or antibody fragments wherein the plurality of such antibody agents binds specifically with a marker protein, or a fragment of the protein. In an additional embodiment, the kit comprises a nucleic acid probe that binds specifically with a marker nucleic acid or a fragment of the

15 nucleic acid. The kit may also comprise a plurality of probes, wherein each of the probes binds specifically with a marker nucleic acid, or a fragment of the nucleic acid.

In a further aspect, the invention relates to methods for treating a patient afflicted with or at risk of developing RA. Such methods may comprise reducing the expression and/or interfering with the biological function of a marker of the invention. In one

20 embodiment, the method comprises providing to the patient an antisense oligonucleotide or polynucleotide complementary to a marker nucleic acid, or a segment thereof. For example, an antisense polynucleotide may be provided to the patient through the delivery of a vector that expresses an anti-sense polynucleotide of a marker nucleic acid or a fragment thereof. In another embodiment, the method comprises providing to the patient

25 an antibody, an antibody derivative, or antibody fragment, which binds specifically with a marker protein or a fragment of the protein.

It will be appreciated that the methods and kits of the present invention may also include known RA markers, *i.e.*, the markers of the present invention may be used alone, in combination, and in combination with known RA markers.

30   **DETAILED DESCRIPTION OF THE INVENTION**

The invention relates to newly discovered markers associated with RA. It has been discovered that a higher than normal level of expression of individual markers and combinations of markers described herein correlates with RA. Methods are provided for

detecting the presence of RA, the absence of RA, the type of RA (*e.g.*, erosive versus non-erosive), and other characteristics of RA that are relevant to prevention, diagnosis, characterization, and therapy of RA.

5   Definitions

As used herein, each of the following terms has the meaning associated with it in this section.

The articles "a" and "an" are used herein to refer to one or to more than one (*i.e.* to at least one) of the grammatical object of the article. By way of example, "an element"

10   means one element or more than one element.

A "marker" is a naturally-occurring polymer corresponding to at least one of the proteins listed in Tables 1-5. Markers further include, without limitation, sense and anti-sense strands of genomic DNA (*i.e.* including any introns occurring therein), RNA generated by transcription of genomic DNA (*i.e.* prior to splicing), RNA generated by

15   splicing of RNA transcribed from genomic DNA, and proteins generated by translation of spliced RNA (*e.g.* including proteins both before and after cleavage of normally cleaved regions such as transmembrane signal sequences). As used herein, "marker" may also include a cDNA made by reverse transcription of an RNA generated by transcription of genomic DNA (including spliced RNA).

20   A "marker set" is a group of more than one marker.

"Proteins of the invention" encompass marker proteins and their fragments; variant marker proteins and their fragments; peptides and polypeptides comprising an at least 15 amino acid segment of a marker or variant marker protein; and fusion proteins comprising a marker or variant marker protein, or an at least 15 amino acid segment of a marker or

25   variant marker protein.

Unless otherwise specified herewithin, the terms "antibody" and "antibodies" broadly encompass naturally-occurring forms of antibodies (*e.g.,* IgG, IgA, IgM, IgE) and recombinant antibodies such as single-chain antibodies, chimeric and humanized antibodies and multi-specific antibodies, as well as fragments and derivatives of all of the

30   foregoing, which fragments and derivatives have at least an antigenic binding site. Antibody derivatives may comprise a protein or chemical moiety conjugated to an antibody.

As used herein a "polynucleotide corresponds to" another (a first) polynucleotide if it is related to the first polynucleotide by any of the following relationships: 1) The second

polynucleotide comprises the first polynucleotide and the second polynucleotide encodes a gene product. 2) The second polynucleotide is 5' or 3' to the first polynucleotide in cDNA, RNA, genomic DNA, or fragment of any of these polynucleotides. For example, a second polynucleotide may be fragment of a gene that includes the first and second

5   polynucleotides. The first and second polynucleotides are related in that they are components of the gene coding for a gene product, such as a protein or antibody. However, it is not necessary that the second polynucleotide comprises or overlaps with the first polynucleotide to be encompassed within the definition of "corresponding to" as used herein. For example, the first polynucleotide may be a fragment of a 3' untranslated region

10   of the second polynucleotide. The first and second polynucleotide may be fragments of a gene coding for a gene product. The second polynucleotide may be an exon of the gene while the first polynucleotide may be an intron of the gene. 3) The second polynucleotide is the complement of the first polynucleotide.

The term "probe" refers to any molecule which is capable of selectively binding to

15   a specifically intended target molecule, for example a marker of the invention. Probes can be either synthesized by one skilled in the art, or derived from appropriate biological preparations. For purposes of detection of the target molecule, probes may be specifically designed to be labeled, as described herein. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic

20   monomers.

An "RA-associated" body fluid or "patient sample" includes, without limitation, blood fluids (*e.g.* whole blood, blood serum, plasma, blood having platelets removed therefrom, etc.), synovial fluid, urine, saliva and tears.

"Expression" refers to the presence or abundance of a marker protein or a fragment

25   of the protein in a sample as well as the presence of a marker nucleic acid, *i.e.*, a transcribed polynucleotide (*e.g.*, an mRNA or a cDNA), or a fragment thereof, in a sample.

"Over-expression" and "under-expression" of a marker refers to expression of the marker in a sample, at a greater or lesser level, respectively, than the normal level of expression of the marker (*e.g.* at least two-fold greater or lesser level). The marker is said

30   to be over-expressed or under-expressed if either the marker protein or marker nucleic acid is present at a greater or lesser level, respectively, than the normal level in a patient sample.

"Erosive RA" is RA characterized by erosions or pits in the surface of the bone adjacent to the articular surface. In particular, in erosive RA, the granulation tissue

actively invades and destroys the periarticular bone and cartilage at the margin between the synorium and the bone.

"Non-erosive RA" is RA that does not exhibit erosive RA characteristics.

As used herein, the term "promoter/regulatory sequence" means a nucleic acid

5   sequence which is required for expression of a gene product operably linked to the promoter/regulatory sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product. The promoter/regulatory sequence may, for example, be one which expresses the gene product

10 in a tissue-specific manner.

A "constitutive" promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a living human cell under most or all physiological conditions of the cell.

An "inducible" promoter is a nucleotide sequence which, when operably linked

15 with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a living human cell substantially only when an inducer, which corresponds to the promoter, is present in the cell.

A "tissue-specific" promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product

20 to be produced in a living human cell substantially only if the cell is a cell of the tissue type corresponding to the promoter.

A "transcribed polynucleotide" is a polynucleotide (*e.g.* an RNA, a cDNA, or an analog of one of an RNA or cDNA) which is complementary to or homologous with all or a portion of a mature RNA made by transcription of a genomic DNA corresponding to a

25 marker of the invention and normal post-transcriptional processing (*e.g.* splicing), if any, of the transcript.

"Complementary" refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of

30 forming specific hydrogen bonds ("base pairing") with a residue of a second nucleic acid region which is antiparallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to a second region of

the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are

5   arranged in an antiparallel fashion, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. More preferably, all nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion.

10   "Homologous" as used herein, refers to nucleotide sequence similarity between two regions of the same nucleic acid strand or between regions of two different nucleic acid strands. When a nucleotide residue position in both regions is occupied by the same nucleotide residue, then the regions are homologous at that position. A first region is homologous to a second region if at least one nucleotide residue position of each region is

15   occupied by the same residue. Homology between two regions is expressed in terms of the proportion of nucleotide residue positions of the two regions that are occupied by the same nucleotide residue. By way of example, a region having the nucleotide sequence 5'-ATTGCC-3' and a region having the nucleotide sequence 5'-TATGGC-3' share 50% homology. Preferably, the first region comprises a first portion and the second region

20   comprises a second portion, whereby, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residue positions of each of the portions are occupied by the same nucleotide residue. More preferably, all nucleotide residue positions of each of the portions are occupied by the same nucleotide residue.

25   A marker is "fixed" to a substrate if it is covalently or non-covalently associated with the substrate such the substrate can be rinsed with a fluid (e.g. standard saline citrate, pH 7.4) without a substantial fraction of the marker dissociating from the substrate.

As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g. encodes a natural

30   protein).

The term "isoform" as used herein refers to variants of a polypeptide that are encoded by the same gene, but that differ in their pI or MW, or both. Such isoforms can differ in their amino acid composition (e.g., as a result of alternative mRNA or premRNA processing, e.g. alternative splicing or limited proteolysis) and in addition, or in the

alternative, may arise from differential post-translational modification (*e.g.*, glycosylation, acylation, phosphorylation).

Expression of a marker in a patient is "significantly" higher or lower than the normal level of expression of a marker if the level of expression of the marker is greater or less, respectively, than the normal level by an amount greater than the standard error of the assay employed to assess expression, and preferably at least twice, and more preferably three, four, five or ten times that amount. Alternately, expression of the marker in the patient can be considered "significantly" higher or lower than the normal level of expression if the level of expression is at least about two, and preferably at least about three, four, or five times, higher or lower, respectively, than the normal level of expression of the marker.

RA is "inhibited" if at least one symptom of the RA is alleviated, terminated, slowed, or prevented. As used herein, RA is "inhibited" if recurrence of RA is reduced, slowed, delayed, or prevented or RA remission is induced or maintained.

A kit is any manufacture (*e.g.* a package or container) comprising at least one reagent, *e.g.* a probe, for specifically detecting a marker of the invention. The manufacture may be promoted, distributed, or sold as a unit for performing the methods of the present invention.

Description

The present invention is based, in part, on newly identified markers which are differently expressed in RA patients as compared to normal individuals (*i.e.*, individuals not afflicted by RA). The markers of the invention correspond to polypeptide and nucleic acid molecules which can be detected in one or both of normal samples and diseased patient samples. The presence, absence, or level of expression of one or more of these markers in patient samples is herein correlated with the rheumatoid arthritic state of the patient.

The present invention also provides markers which are differently expressed in patients with erosive RA. Erosive RA is characterized by erosions or pits in the surface of the bone adjacent to the articular surface. In particular, in erosive RA, the granulation tissue actively invades and destroys the periarticular bone and cartilage at the margin between the synovium and the bone.

The compositions, kits, and methods of the invention have the following uses, among others:

1)   assessing whether a patient is afflicted with RA;

2)   assessing the stage of RA in a patient;

3)   assessing the progressive nature of RA in a patient;

4)   assessing whether a patient has erosive RA;

5)   assessing whether a patient has non-erosive RA;

6)   making an isolated hybridoma which produces an antibody useful for

        assessing whether a patient is afflicted with RA;

7)   assessing the efficacy of one or more test compounds for

         inhibiting RA in a patient;

8)   assessing the efficacy of a therapy for inhibiting RA in a patient;

9)   assessing the efficacy of a therapy for inhibiting erosive RA in a

        patient;

10)   assessing the efficacy of a therapy for inhibiting non-erosive RA

        in a patient;

11)   monitoring the progression of RA in a patient;

12)   selecting a composition or therapy for inhibiting RA in a patient;

13)   selecting a composition or therapy for inhibiting erosive RA in a patient;

14)   selecting a composition or therapy for inhibiting non-erosive RA in a

        patient;

15)   developing agents effective in treating synovitis;

16)   developing agents effective in treating erosive RA;

17)   developing agents effective in treating non-erosive RA;

18)   treating a patient afflicted with RA;

19)   inhibiting RA in a patient;

20)   assessing the rhematoid arthritic progressive potential of a test compound;

        and

21)   inhibiting RA in a patient at risk for developing RA.

The methods of the present invention comprise the step of comparing the level of
expression of a marker in a patient sample, with the normal level of expression of the
marker. A significant difference between the level of expression of the marker in the
patient sample and the normal level is an indication that the patient is afflicted with RA. A
"normal" level of expression refers to the expression level of the marker in the control,
such as in a sample from an individual without RA. Subjects that are not afflicted with RA
can include normal subjects with no known disease or condition, or subjects with joint
diseases or conditions other than RA, including gout, osteoarthritis, or synovitis (*e.g.*,

traumatic synovitis). Alternatively, and particularly as further information becomes available as a result of routine performance of the methods described herein, population-average values for expression of the markers of the invention may be used as the "normal" level of expression. For example, a laboratory may establish reference ranges for the level

5   of the marker for subjects with and without RA, as well as for subjects with erosive and non-erosive forms of RA, as is conventional in the diagnostic art.

As used herein the term "expression" refers to the presence or abundance of a marker protein or a fragment of the protein in a sample as well as the presence of a marker nucleic acid, i.e., a transcribed polynucleotide (e.g., an mRNA or a cDNA), or a fragment

10   thereof, in a sample. In a method of determining the abundance of a marker in a sample compared to a normal or control, i.e., to identify markers that are differentially present, the relative abundance may be determined by normalizing the signal obtained upon detecting the marker in a sample by reference to a suitable background parameter, e.g., to the total protein in the sample being analyzed to an invariant marker, i.e., a marker whose

15   abundance is known to be similar in the sample being compared, or to the total signal detected from all proteins in the sample.

Table 1 lists all of the markers of the invention (and comprises markers listed in Tables 2 – 5), which are over-expressed in patients with RA compared to normal individuals (i.e., individuals who are not afflicted with RA). Table 2 lists markers that are

20   newly-associated with RA and are over-expressed in patients diagnosed with erosive or non-erosive RA. Table 3B lists preferred markers of the present invention. Table 3B lists markers which are over-expressed in serum samples of patients with RA compared to normal individuals (i.e., individuals who are not afflicted with RA). Table 4 lists markers which are especially useful for new detection ("screening") and detection of recurrence of

25   RA. Table 5 lists newly-identified markers (SEQ ID NOs: 1-10) that are over-expressed in patients with RA. All of these tables include a marker identification number ("Marker"), the gene corresponding to the marker ("Gene Name"), the data generated for each synovial fluid sample (E = Erosive and N = Non-Erosive), the corresponding molecular weight ("MW (Da)"), the corresponding GenBank GI Number ("GI number"), and where

30   indicated, the sequence listing identifier of the cDNA sequence of a nucleotide transcript encoded by or corresponding to the marker ("SEQ ID NO (nts)") and the sequence listing identifier of the amino acid sequence of a protein encoded by or corresponding to the marker ("SEQ ID NO (AA)"). Table 6 lists protein concentration of Calgranulin A in a pool of Size Exclusion Chromatography (SEC) fractions 7, 8 and 9 of human serum.

Table 7 lists protein concentration of Calgranulin B in a pool of SEC fractions 7, 8 and 9

of human serum. Tables 8A and 8B list protein concentration of Calgranulin C in a pool

of SEC fractions 7, 8 and 9 of human serum. Table 9 lists the average protein

concentration values in human serum and the significance test results of Serum Amyloid A

5   (SAA) protein.

In a preferred diagnostic method of assessing whether a patient is afflicted with RA

(*e.g.*, new detection ("screening") and detection of recurrence), the method comprises

comparing:

a) the level of expression of a marker of the invention in a patient sample, and

10   b) the normal level of expression of the marker in a control.

A significantly higher level of expression of the marker in the patient sample as compared

to the normal level is an indication that the patient is afflicted with RA. In one

embodiment, the marker is listed in Table 2. In an alternative embodiment, the marker is

listed in Table 4.

15   In a further preferred diagnostic method of assessing whether a patient is afflicted

with erosive RA, the method comprises comparing:

a) the level of expression of a marker of the invention in a patient sample, and

b) the normal level of expression of the marker in a control.

A significantly higher level of expression of the marker in the patient sample as compared

20   to the normal level is an indication that the patient is afflicted with erosive RA. In one

embodiment, the marker is listed in Table 2. In an alternative embodiment, the marker is

listed in Table 3B.

The invention also provides diagnostic methods for assessing the efficacy of a

therapy for inhibiting RA in a patient. Such methods comprise comparing:

25   a) expression of a marker of the invention in a first sample obtained from the

patient prior to providing at least a portion of the therapy to the patient, and

b) expression of the marker in a second sample obtained from the patient

following provision of the portion of the therapy.

A significantly lower level of expression of the marker in the second sample relative to

30   that in the first sample is an indication that the therapy is efficacious for inhibiting RA in

the patient. It will be appreciated that in these methods the "therapy" may be any therapy

for treating RA including, but not limited to, anti-inflammatory drugs, disease-modifying

drugs and gene therapy. Thus, the methods of the invention may be used to evaluate a

patient before, during and after therapy, for example, to evaluate the efficacy of treatment.

In a preferred embodiment, the methods are directed to therapy using a chemical or biologic agent. These methods comprise comparing:

   a) expression of a marker of the invention in a first sample obtained from the patient and maintained in the presence of the chemical or biologic agent, and

5   b) expression of the marker in a second sample obtained from the patient and maintained in the absence of the agent.

A significantly lower level of expression of the marker in the first sample relative to that in the second sample is an indication that the agent is efficacious for inhibiting RA in the patient. In one embodiment, the first and second samples can be portions of a single

10   sample obtained from the patient or portions of pooled samples obtained from the patient.

The invention additionally provides a monitoring method for assessing the progression of RA in a patient, the method comprising:

   a) detecting in a patient sample at a first time point, the expression of a marker of the invention;

15   b) repeating step a) at a subsequent point in time; and

   c) comparing the level of expression detected in steps a) and b), and therefrom monitoring the progression of RA in the patient.

A significantly higher level of expression of the marker in the sample at the subsequent time point from that of the sample at the first time point is an indication that the RA has

20   progressed, whereas a significantly lower level of expression is an indication that the RA has regressed.

The invention moreover provides a test method for selecting a composition for inhibiting RA in a patient. This method comprises the steps of:

   a) obtaining a sample from the patient;

25   b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;

   c) comparing expression of a marker of the invention in each of the aliquots; and

   d) selecting one of the test compositions which significantly reduces the level of expression of the marker in the aliquot containing that test composition, relative to

30   the levels of expression of the marker in the presence of the other test compositions.

In addition, the invention further provides a method of inhibiting RA in a patient. This method comprises the steps of:

   a) obtaining a sample from the patient;

b) separately maintaining aliquots of the sample in the presence of a plurality of compositions;

c) comparing expression of a marker of the invention in each of the aliquots; and

d) administering to the patient at least one of the compositions which significantly

5   lowers the level of expression of the marker in the aliquot containing that composition, relative to the levels of expression of the marker in the presence of the other compositions.

Any marker or combination of markers listed in the tables, as well as any known markers in combination with the markers listed in the tables, may be used in the

10   compositions, kits, and methods of the present invention. In general, it is preferable to use markers for which the difference between the level of expression of the marker in RA patient samples and the level of expression of the same marker in normal samples is as great as possible. Although this difference can be as small as the limit of detection of the method for assessing expression of the marker, it is preferred that the difference be at least

15   greater than the standard error of the assessment method, and preferably a difference of at least 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 100-, 500-, 1000-fold or greater.

It will be appreciated that patient samples containing bodily fluids (*e.g.*, blood fluid, whole blood, serum, blood having platelets removed therefrom etc., and synovial fluid) may be used in the methods of the present invention. In these embodiments, the

20   level of expression of the marker can be assessed by assessing the amount or abundance (*e.g.* absolute amount or concentration) of a marker product (*e.g.*, protein and RNA transcript encoding said protein, fragments of the protein, isoforms of the protein, and RNA transcript) in a sample. The sample can, of course, be subjected to a variety of well-known post-collection preparative and storage techniques (*e.g.* fixation, storage, freezing,

25   lysis, homogenization, DNA or RNA extraction, ultrafiltration, concentration, evaporation, centrifugation, etc.) prior to assessing the amount of the marker in the sample.

Preferred *in vivo* techniques for detection of a marker protein of the invention include introducing into a subject an antibody that specifically binds the protein, isoform of the protein, or protein fragment. In certain embodiments, the antibody can be labeled

30   with a radioactive molecule whose presence and location in a subject can be detected by standard imaging techniques.

Expression of a marker of the invention may be assessed by any of a wide variety of well known methods for detecting expression of a protein or transcribed molecule. Non-limiting examples of such methods include immunological methods for detection of

secreted, cell-surface, cytoplasmic, or nuclear proteins, protein purification methods, protein function or activity assays, nucleic acid hybridization methods, nucleic acid reverse transcription methods, and nucleic acid amplification methods. Such methods may also include physical methods such as liquid and gas chromatography, mass spectroscopy,

5   nuclear magnetic resonance and other imaging technologies.

In a preferred embodiment, expression of a marker protein is assessed using an antibody (e.g. a radio-labeled, chromophore-labeled, fluorophore-labeled, or enzyme-labeled antibody), an antibody derivative (e.g. an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair {e.g. biotin-streptavidin}), or an

10   antibody fragment (e.g. a single-chain antibody, an isolated antibody hypervariable domain, etc.) which binds specifically with a marker protein, isoform of the marker protein, or a fragment of the protein, wherein the protein may have undergone none, all or a portion of its normal post-translational modification and/or proteolysis during the course of its secretion or release from cells.

15   In another preferred embodiment, expression of a marker is assessed by preparing mRNA/cDNA (i.e. a transcribed polynucleotide) from cells in a patient sample, and by hybridizing the mRNA/cDNA with a reference polynucleotide which comprises the marker nucleic acid sequence or its complement, or a fragment of said sequence or complement. cDNA can, optionally, be amplified using any of a variety of polymerase

20   chain reaction methods prior to hybridization with the reference polynucleotide. Expression of one or more marker nucleic acid can likewise be detected using quantitative PCR to assess the level of RNA transcripts encoded by the marker(s).

In a related embodiment, a mixture of transcribed polynucleotides obtained from the sample is contacted with a substrate having fixed thereto a polynucleotide

25   complementary to or homologous with at least a portion (e.g. at least 7, 10, 15, 20, 25, 30, 40, 50, 100, 500, or more nucleotide residues) of a RNA transcript encoded by a marker of the invention. If polynucleotides complementary to or homologous with a RNA transcript encoded by the marker of the invention are differentially detectable on the substrate (e.g. detectable using radioactivity, different chromophores or fluorophores), are fixed to

30   different selected positions, then the levels of expression of a plurality of markers can be assessed simultaneously using a single substrate (e.g. a "gene chip" microarray of polynucleotides fixed at selected positions). When a method of assessing marker expression is used which involves hybridization of one nucleic acid with another, it is preferred that the hybridization be performed under stringent hybridization conditions.

Because the compositions, kits, and methods of the invention rely on detection of a difference in expression levels of one or more markers of the invention, it is preferable that the level of expression of the marker is significantly greater than the minimum detection limit of the method used to assess expression in a normal or control sample.

5   It is understood that by routine screening of additional patient samples for the expression levels of one or more of the markers of the invention, it will be realized that certain of the markers are expressed at varying levels based on the progressiveness of disease. Thus the markers and methods of the present invention may be used to identify a non-progressive to progressive gradient. Such gradient would be especially useful in

10   characterizing, managing and treating RA.

It is recognized that certain markers correspond to proteins which are secreted from patient samples (*i.e.* synovial fluid, endothelial cells, synovium cells, serum, plasma) to the extracellular space surrounding the cells. These markers are preferably used in certain embodiments of the compositions, kits, and methods of the invention, owing to the fact

15   that the protein corresponding to each of these markers can be detected in an RA-associated body fluid sample, which may be easily collected from a human patient. It will be appreciated, however, that intracellular markers are also included within the markers of the present invention and are also useful in the methods of the present invention.

It is a simple matter for the skilled artisan to determine whether any particular

20   marker corresponds to a secreted protein. In order to make this determination, the protein corresponding to a marker is expressed in a test cell, extracellular fluid is collected, and the presence or absence of the protein in the extracellular fluid is assessed (*e.g.* using a labeled antibody which binds specifically with the protein).

The compositions, kits, and methods of the invention can also be used to detect

25   expression of markers corresponding to proteins having at least one portion which is displayed on the surface of cells which express it. It is a simple matter for the skilled artisan to determine whether the protein corresponding to any particular marker comprises a cell-surface protein. For example, immunological methods may be used to detect such proteins on whole cells, or well known computer-based sequence analysis methods (*e.g.*

30   the SIGNALP program; Nielsen *et al.*, 1997, *Protein Engineering* 10:1-6) may be used to predict the presence of at least one extracellular domain (*i.e.* including both secreted proteins and proteins having at least one cell-surface domain). Expression of a marker corresponding to a protein having at least one portion which is displayed on the surface of

a cell which expresses it may be detected without necessarily lysing the cell (*e.g.* using a labeled antibody which binds specifically with a cell-surface domain of the protein).

When a plurality of markers of the invention are used in the compositions, kits, and methods of the invention, the level of expression of each marker in a patient sample can be

5   compared with the normal level of expression of each of the plurality of markers in RA samples of the same type, either in a single reaction mixture (*i.e.* using reagents, such as different fluorescent probes, for each marker) or in individual reaction mixtures corresponding to one or more of the markers. In one embodiment, a significantly enhanced level of expression of more than one of the plurality of markers in the sample,

10 relative to the corresponding normal levels, is an indication that the patient is afflicted with RA. When a plurality of markers is used, it is preferred that 2, 3, 4, 5, 8, 10, 12, 15, 20, 30, or 50 or more individual markers be used, wherein fewer markers are preferred.

Prior to the present invention, only a limited number of markers were known to be associated with RA (*e.g.*, RF, complement factor B, and C-reactive protein). These

15 markers may be used together with one or more markers of the invention in a panel of markers. For example, a sample may be assayed to determine the presence and/or expression levels of known markers in combination with the markers of the present invention. The presence, over- and/or under-expression of markers, such as RF in combination with the presence, over- and/or underexpression of the markers of the present

20 invention, may be used to further characterize RA.

It is recognized that the compositions, kits, and methods of the invention will be of particular utility to patients having an enhanced risk of developing RA and their medical advisors. Patients recognized as having an enhanced risk of developing RA include, for example, patients having a familial history of RA, patients identified as having a RF,

25 patients of advancing age and women of advancing age (*i.e.* between 40 and 60 years).

The level of expression of a marker in normal (*i.e.* an individual who is not afflicted with RA) individuals or a control can be assessed in a variety of ways. As further information becomes available as a result of routine performance of the methods described herein, population-average values for expression of the markers of the invention may be

30 used. In other embodiments, the 'normal' level of expression of a marker may be determined by assessing expression of the marker in a patient sample obtained from a non-RA-afflicted patient, from a patient sample obtained from a patient before the suspected onset of RA in the patient, from archived patient samples, and the like.

The invention includes compositions, kits, and methods for assessing the presence of RA in a sample (*e.g.* an archived tissue sample or a sample obtained from a patient). These compositions, kits, and methods are substantially the same as those described above, except that, where necessary, the compositions, kits, and methods are adapted for use with

5   samples other than patient samples. For example, when the sample to be used is a parafinized, archived human tissue sample, it can be necessary to adjust the ratio of compounds in the compositions of the invention, in the kits of the invention, or the methods used to assess levels of marker expression in the sample. Such methods are well known in the art and within the skill of the ordinary artisan.

10   The invention includes a kit for assessing the presence of RA (*e.g.* in a sample such as a patient sample). The kit comprises a plurality of reagents, each of which is capable of binding specifically with a nucleic acid or polypeptide corresponding to a marker of the invention. Suitable reagents for binding with a polypeptide corresponding to a marker of the invention include antibodies, antibody derivatives, antibody fragments, and the like.

15   Suitable reagents for binding with a nucleic acid (*e.g.* a genomic DNA, an mRNA, a spliced mRNA, a cDNA, or the like) include complementary nucleic acids. For example, the nucleic acid reagents may include oligonucleotides (labeled or non-labeled) fixed to a substrate, labeled oligonucleotides not bound with a substrate, pairs of PCR primers, molecular beacon probes, and the like.

20   The kit of the invention may optionally comprise additional components useful for performing the methods of the invention. By way of example, the kit may comprise fluids (*e.g.* SSC buffer) suitable for annealing complementary nucleic acids or for binding an antibody with a protein with which it specifically binds, one or more sample compartments, an instructional material which describes performance of a method of the

25   invention, a sample from a normal individual, a sample from a RA patient, and the like.

The invention also includes a method of making an isolated hybridoma which produces an antibody useful for assessing whether patient is afflicted with RA. In this method, a marker protein of the invention is isolated (*e.g.* by purification from a cell in which it is expressed or by transcription and translation of a nucleic acid encoding the

30   protein *in vivo* or *in vitro* using known methods). A vertebrate, preferably a mammal such as a mouse, rat, rabbit, or sheep, is immunized using the isolated protein or protein fragment. The vertebrate may optionally (and preferably) be immunized at least one additional time with the isolated protein or protein fragment, so that the vertebrate exhibits a robust immune response to the protein or protein fragment. Splenocytes are isolated

from the immunized vertebrate and fused with an immortalized cell line to form

hybridomas, using any of a variety of methods well known in the art. Hybridomas formed

in this manner are then screened using standard methods to identify one or more

hybridomas which produce an antibody which specifically binds with the protein or

5   protein fragment. The invention also includes hybridomas made by this method and

antibodies made using such hybridomas.

The invention also includes a method of assessing the efficacy of a test compound

for inhibiting RA. As described above, differences in the level of expression of the

markers of the invention correlate with the rheumatoid arthritic state of the patient.

10   Although it is recognized that changes in the levels of expression of certain of the markers

of the invention likely result from the rheumatoid arthritic state of patient, it is likewise

recognized that changes in the levels of expression of other of the markers of the invention

induce, maintain, and promote the rheumatoid arthritic state of those patients. Thus,

compounds which inhibit RA in a patient will cause the level of expression of one or more

15   of the markers of the invention to change to a level nearer the normal level of expression

for that marker (*i.e.* the level of expression for the marker in RA patients).

This method thus comprises comparing expression of a marker in a first patient

sample and maintained in the presence of the test compound and expression of the marker

in a second patient sample and maintained in the absence of the test compound. A

20   significant decrease in the level of expression of a marker may be an indication that the

test compound inhibits RA. The patient samples may, for example, be aliquots of a single

sample obtained from a patient, pooled normal samples obtained an individual, cells of a

normal individual, aliquots of a single sample obtained from a RA patient, pooled samples

from a RA patient, cells of a RA patient, or the like. In one embodiment, the samples from

25   a RA patient and a plurality of compounds known to be effective for inhibiting RA are

tested in order to identify the compound which is likely to best inhibit the RA in the

patient.

This method may likewise be used to assess the efficacy of a therapy for inhibiting

RA in a patient. In this method, the level of expression of one or more markers of the

30   invention in a pair of samples (one subjected to the therapy, the other not subjected to the

therapy) is assessed. As with the method of assessing the efficacy of test compounds, if

the therapy induces a significant decrease in the level of expression of a marker, or blocks

induction of a marker, then the therapy may be efficacious for inhibiting RA. As above, if

samples from a selected patient are used in this method, then alternative therapies can be

assessed *in vitro* in order to select a therapy most likely to be efficacious for inhibiting RA in the patient.

The present invention further provides methods for identifying the presence of erosive and non-erosive RA by detecting expression of a marker listed in Tables 3A-5,

5   wherein over-expression of one or a plurality of the markers is correlated with erosive RA. By identifying whether a patient sample is afflicted with erosive or non-erosive RA, therapy may be customized to better treat the specific type of RA.

Expression of a marker can be inhibited in a number of ways generally known in the art. For example, an antisense oligonucleotide can be provided to the patient samples

10   in order to inhibit transcription, translation, or both, of the marker(s). Alternately, a polynucleotide encoding an antibody, an antibody derivative, or an antibody fragment, and operably linked with an appropriate promoter/regulator region, can be provided to the patient sample in order to generate intracellular antibodies which will inhibit the function or activity of the protein. Using the methods described herein, a variety of molecules,

15   particularly including molecules sufficiently small that they are able to cross the cell membrane, can be screened in order to identify molecules which inhibit expression of the marker(s). The compound so identified can be provided to the patient in order to inhibit expression of the marker(s) in the patient.

Expression of a marker can be enhanced in a number of ways generally known in

20   the art. For example, a polynucleotide encoding the marker and operably linked with an appropriate promoter/regulator region can be provided to patient samples in order to induce enhanced expression of the protein (and mRNA) corresponding to the marker therein. Alternatively, if the protein is capable of crossing the cell membrane, inserting itself in the cell membrane, or is normally a secreted protein, then expression of the protein

25   can be enhanced by providing the protein (*e.g.* directly or by way of the bloodstream) to the patient sample.

As described above, the rheumatoid arthritic state of the patient is correlated with changes in the levels of expression of the markers of the invention. The invention thus includes a method for assessing the RA promoting or progression potential of a test

30   compound. This method comprises maintaining separate aliquots of patient samples in the presence and absence of the test compound. Expression of a marker of the invention in each of the aliquots is compared. A significant increase in the level of expression of a marker in the aliquot maintained in the presence of the test compound (relative to the aliquot maintained in the absence of the test compound) may be an indication that the test

compound possesses RA promoting or progression potential. The relative RA promoting or progression potentials of various test compounds can be assessed by comparing the degree of enhancement or inhibition of the level of expression of the relevant markers, by comparing the number of markers for which the level of expression is enhanced or

5   inhibited, or by comparing both.

Various aspects of the invention are described in further detail in the following subsections.

I. Isolated Proteins and Antibodies

10   One aspect of the invention pertains to marker proteins which are isolated proteins biologically active portions thereof, isoforms, as well as polypeptide fragments suitable for use as immunogens to raise antibodies directed against a polypeptide of the invention. In one embodiment, the native polypeptide corresponding to a marker can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein

15   purification techniques. In another embodiment, polypeptides corresponding to a marker of the invention are produced by recombinant DNA techniques. Alternative to recombinant expression, a polypeptide corresponding to a marker of the invention can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is

20   substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus,

25   protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein"). When the protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of

30   the protein preparation. When the protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of the protein have less than about 30%, 20%,

10%, 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.

Biologically active portions of a polypeptide corresponding to a marker of the invention include polypeptides comprising amino acid sequences sufficiently identical to

5   or derived from the amino acid sequence of the protein corresponding to the marker, which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the corresponding protein. A biologically active portion of a protein of the invention can be a polypeptide which is, for example, 10,

10   25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of the native form of a polypeptide of the invention.

Preferred polypeptides have amino acid sequences encoded by the nucleic acid

15   sequences described herein. Other useful proteins are substantially identical (*e.g.*, at least about 40%, preferably 50%, 60%, 70%, 80%, 90%, 95%, or 99%) to one of these sequences and retain the functional activity of the protein of the corresponding naturally-occurring protein yet differ in amino acid sequence due to natural allelic variation or mutagenesis.

20   To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then

25   compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % identity = # of identical positions/total # of positions (*e.g.*, overlapping positions) x100). In one

30   embodiment the two sequences are the same length.

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-2268, modified as in Karlin and

Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is

incorporated into the NBLAST and XBLAST programs of Altschul, *et al.* (1990) *J. Mol.*

Biol. 215:403-410. BLAST nucleotide searches can be performed with the NBLAST

program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a

5   nucleic acid molecules of the invention. BLAST protein searches can be performed with

the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences

homologous to a protein molecules of the invention. To obtain gapped alignments for

comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*

(1997) *Nucleic Acids Res.* 25:3389-3402. Alternatively, PSI-Blast can be used to perform

10   an iterated search which detects distant relationships between molecules. When utilizing

BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective

programs (*e.g.*, XBLAST and NBLAST) can be used. Another preferred, non-limiting

example of a mathematical algorithm utilized for the comparison of sequences is the

algorithm of Myers and Miller, (1988) *CABIOS* 4:11-17. Such an algorithm is

15   incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence

alignment software package. When utilizing the ALIGN program for comparing amino

acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap

penalty of 4 can be used. Yet another useful algorithm for identifying regions of local

sequence similarity and alignment is the FASTA algorithm as described in Pearson and

20   Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85:2444-2448. When using the FASTA

algorithm for comparing nucleotide or amino acid sequences, a PAM120 weight residue

table can, for example, be used with a *k*-tuple value of 2.

The percent identity between two sequences can be determined using techniques

similar to those described above, with or without allowing gaps. In calculating percent

25   identity, only exact matches are counted.

The invention also provides chimeric or fusion proteins corresponding to a marker

of the invention. As used herein, a "chimeric protein" or "fusion protein" comprises all or

part (preferably a biologically active part) of a polypeptide corresponding to a marker of

the invention operably linked to a heterologous polypeptide (*i.e.*, a polypeptide other than

30   the polypeptide corresponding to the marker). Within the fusion protein, the term

"operably linked" is intended to indicate that the polypeptide of the invention and the

heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide

can be fused to the amino-terminus or the carboxyl-terminus of the polypeptide of the

invention.

One useful fusion protein is a GST fusion protein in which a polypeptide corresponding to a marker of the invention is fused to the carboxyl terminus of GST sequences. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.

5   In another embodiment, the fusion protein contains a heterologous signal sequence at its amino terminus. For example, the native signal sequence of a polypeptide corresponding to a marker of the invention can be removed and replaced with a signal sequence from another protein. For example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (Ausubel *et*

10   *al.*, ed., *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook *et al.,* *supra*) and the protein A secretory signal (Pharmacia

15   Biotech; Piscataway, New Jersey).

In yet another embodiment, the fusion protein is an immunoglobulin fusion protein in which all or part of a polypeptide corresponding to a marker of the invention is fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical

20   compositions and administered to a subject to inhibit an interaction between a ligand (soluble or membrane-bound) and a protein on the surface of a cell (receptor), to thereby suppress signal transduction *in vivo*. The immunoglobulin fusion protein can be used to affect the bioavailability of a cognate ligand of a polypeptide of the invention. Inhibition of ligand/receptor interaction can be useful therapeutically, both for treating proliferative

25   and differentiative disorders and for modulating (*e.g.* promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed against a polypeptide of the invention in a subject, to purify ligands and in screening assays to identify molecules which inhibit the interaction of receptors with ligands.

30   Chimeric and fusion proteins of the invention can be produced by standard recombinant DNA techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can

subsequently be annealed and re-amplified to generate a chimeric gene sequence (see, *e.g.*, Ausubel *et al., supra*). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the

5   fusion moiety is linked in-frame to the polypeptide of the invention.

A signal sequence can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites

10   that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. Thus, the invention pertains to the described polypeptides having a signal sequence, as well as to polypeptides from which the signal sequence has been proteolytically cleaved (*i.e.*, the cleavage products). In one embodiment, a nucleic acid sequence encoding a signal sequence can be operably linked in an expression vector to a

15   protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be

20   linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.

It will be appreciated that as an alternative to recombinant expression, the marker proteins of the present invention may be chemically synthesized using standard peptide synthesis techniques.

25   The present invention also pertains to variants of the polypeptides corresponding to individual markers of the invention. Such variants have an altered amino acid sequence, *e.g.*, amino acid substitutions or insertions can be made using naturally occurring or non-naturally occurring amino acids, including L- and D-amino acids. Such variants can function as either agonists (mimetics) or as antagonists. Variants can be generated by

30   mutagenesis, *e.g.*, discrete point mutation or truncation. An agonist can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the protein. An antagonist of a protein can inhibit one or more of the activities of the naturally occurring form of the protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the

protein of interest. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the protein.

5   Variants of a protein of the invention which function as either agonists (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the protein of the invention for agonist or antagonist activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of

10   variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display). There are a variety of methods which can be used to produce libraries of potential variants of the polypeptides of the invention from a

15   degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, 1983, *Tetrahedron* 39:3; Itakura *et al.*, 1984, *Annu. Rev. Biochem.* 53:323; Itakura *et al.*, 1984, *Science* 198:1056; Ike *et al.*, 1983 *Nucleic Acid Res.* 11:477).

          In addition, libraries of fragments of the coding sequence of a polypeptide

20   corresponding to a marker of the invention can be used to generate a variegated population of polypeptides for screening and subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA,

25   renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes amino terminal and internal fragments of various sizes of the protein of interest.

30   Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming

appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries,

5 can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan, 1992, *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave *et al.,* 1993, *Protein Engineering* 6(3):327- 331).

The present invention also pertains to human orthologs for any non-human nucleic acid or amino acid sequences. The identification of such human orthologs may be

10 determined through conventional Molecular Biology techniques known to someone of ordinary skill in the art, such as blast analysis or library screening, as discussed throughout.

An isolated polypeptide corresponding to a marker of the invention, or a fragment thereof, can be used as an immunogen to generate antibodies using standard techniques for

15 polyclonal and monoclonal antibody preparation. The full-length polypeptide or protein can be used or, alternatively, the invention provides antigenic peptide fragments for use as immunogens. The antigenic peptide of a protein of the invention comprises at least 8 (preferably 10, 15, 20, or 30 or more) amino acid residues of the amino acid sequence of one of the polypeptides of the invention, and encompasses an epitope of the protein such

20 that an antibody raised against the peptide forms a specific immune complex with a marker of the invention to which the protein corresponds. Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, *e.g.*, hydrophilic regions. Hydrophobicity sequence analysis, hydrophilicity sequence analysis, or similar analyses can be used to identify hydrophilic regions.

25 An immunogen typically is used to prepare antibodies by immunizing a suitable (*i.e.* immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate. An appropriate immunogenic preparation can contain, for example, recombinantly-expressed or chemically-synthesized polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar

30 immunostimulatory agent.

Accordingly, another aspect of the invention pertains to antibodies directed against a polypeptide of the invention. The terms "antibody" and "antibody substance" as used interchangeably herein refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site

which specifically binds an antigen, such as a polypeptide of the invention, *e.g.*, an epitope
of a polypeptide of the invention. A molecule which specifically binds to a given
polypeptide of the invention is a molecule which binds the polypeptide, but does not
substantially bind other molecules in a sample, *e.g.*, a biological sample, which naturally

5   contains the polypeptide. Examples of immunologically active portions of
immunoglobulin molecules include F(ab) and F(ab')$_2$ fragments which can be generated by
treating the antibody with an enzyme such as pepsin. The invention provides polyclonal
and monoclonal antibodies. The term "monoclonal antibody" or "monoclonal antibody
composition", as used herein, refers to a population of antibody molecules that contain

10   only one species of an antigen binding site capable of immunoreacting with a particular
epitope.

Polyclonal antibodies can be prepared as described above by immunizing a suitable
subject with a polypeptide of the invention as an immunogen. Preferred polyclonal
antibody compositions are ones that have been selected for antibodies directed against a

15   polypeptide or polypeptides of the invention. Particularly preferred polyclonal antibody
preparations are ones that contain only antibodies directed against a polypeptide or
polypeptides of the invention. Particularly preferred immunogen compositions are those
that contain no other human proteins such as, for example, immunogen compositions made
using a non-human host cell for recombinant expression of a polypeptide of the invention.

20   In such a manner, the only human epitope or epitopes recognized by the resulting antibody
compositions raised against this immunogen will be present as part of a polypeptide or
polypeptides of the invention.

The antibody titer in the immunized subject can be monitored over time by
standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using

25   immobilized polypeptide. If desired, the antibody molecules can be harvested or isolated
from the subject (*e.g.*, from the blood, plasma, or serum of the subject) and further purified
by well-known techniques, such as protein A chromatography to obtain the IgG fraction.
Alternatively, antibodies specific for a protein or polypeptide of the invention can be
selected or (*e.g.*, partially purified) or purified by, *e.g.*, affinity chromatography. For

30   example, a recombinantly expressed and purified (or partially purified) protein of the
invention is produced as described herein, and covalently or non-covalently coupled to a
solid support such as, for example, a chromatography column. The column can then be
used to affinity purify antibodies specific for the proteins of the invention from a sample
containing antibodies directed against a large number of different epitopes, thereby

generating a substantially purified antibody composition, *i.e.,* one that is substantially free of contaminating antibodies. By a substantially purified antibody composition is meant, in this context, that the antibody sample contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those of the desired protein

5   or polypeptide of the invention, and preferably at most 20%, yet more preferably at most 10%, and most preferably at most 5% (by dry weight) of the sample is contaminating antibodies. A purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein or polypeptide of the invention.

At an appropriate time after immunization, *e.g.,* when the specific antibody titers

10   are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497, the human B cell hybridoma technique (see Kozbor *et al.,* 1983, *Immunol. Today* 4:72), the EBV-hybridoma technique (see Cole *et al.,* pp. 77-96 In *Monoclonal Antibodies and Cancer Therapy,* Alan

15   R. Liss, Inc., 1985) or trioma techniques. The technology for producing hybridomas is well known (see generally *Current Protocols in Immunology,* Coligan *et al.* ed., John Wiley & Sons, New York, 1994). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, *e.g.,* using a standard ELISA assay.

20   Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody directed against a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (*e.g.,* an antibody phage display library) with the polypeptide of interest. Kits for generating and screening phage display libraries are commercially available (*e.g.,* the Pharmacia *Recombinant Phage*

25   *Antibody System,* Catalog No. 27-9400-01; and the Stratagene *SurfZAP Phage Display Kit,* Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO

30   92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275- 1281; Griffiths *et al.* (1993) *EMBO J.* 12:725-734.

Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. A chimeric antibody is a molecule in which different portions are derived from different animal

5   species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. (See, *e.g.,* Cabilly *et al.,* U.S. Patent No. 4,816,567; and Boss *et al.,* U.S. Patent No. 4,816,397, which are incorporated herein by reference in their entirety.) Humanized antibodies are antibody molecules from non-human species having one or more complementarily determining regions (CDRs) from the non-human species

10   and a framework region from a human immunoglobulin molecule. (See, *e.g.,* Queen, U.S. Patent No. 5,585,089, which is incorporated herein by reference in its entirety.) Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application

15   171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Patent No. 4,816,567; European Patent Application 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.* (1987) *J. Immunol.* 139:3521- 3526; Sun *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura *et al.* (1987) *Cancer Res.* 47:999-1005; Wood *et al.* (1985) *Nature*

20   314:446-449; and Shaw *et al.* (1988) *J. Natl. Cancer Inst.* 80:1553-1559); Morrison (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *Bio/Techniques* 4:214; U.S. Patent 5,225,539; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeyan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J. Immunol.* 141:4053-4060.

Antibodies of the invention may be used as therapeutic agents in treating RA. In a

25   preferred embodiment, completely human antibodies of the invention are used for therapeutic treatment of human RA patients, particularly those having erosive and non-erosive RA. Such antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. The transgenic mice are

30   immunized in the normal fashion with a selected antigen, *e.g.,* all or a portion of a polypeptide corresponding to a marker of the invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus,

using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995) *Int. Rev. Immunol.* 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and

5   protocols for producing such antibodies, see, *e.g.*, U.S. Patent 5,625,126; U.S. Patent 5,633,425; U.S. Patent 5,569,825; U.S. Patent 5,661,016; and U.S. Patent 5,545,806. In addition, companies such as Abgenix, Inc. (Freemont, CA), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

10   Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, *e.g.*, a murine antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers *et al.*, 1994, *Bio/technology* 12:899-903).

15   An antibody directed against a polypeptide corresponding to a marker of the invention (*e.g.*, a monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to detect the marker (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the level and pattern of expression of the marker. The antibodies can also

20   be used diagnostically to monitor protein levels in tissues or body fluids (*e.g.* in an ovary-associated body fluid) as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials,

25   bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine

30   fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I, ^{131}I, ^{35}S or ^{3}H.

Further, an antibody (or fragment thereof) can be conjugated to a therapeutic
moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or
cytotoxic agent includes any agent that is detrimental to cells. Examples include,
cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide,

5   tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy
anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone,
glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or
homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites
(*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil

10   decarbazine), alkylating agents (*e.g.*, mechlorethamine, thioepa chlorambucil, melphalan,
carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan,
dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II)
(DDP) cisplatin), anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and
doxorubicin), antibiotics *(e.g.*, dactinomycin (formerly actinomycin), bleomycin,

15   mithramycin, and anthramycin (AMC)), and anti-mitotic agents (*e.g.*, vincristine and
vinblastine).

The conjugates of the invention can be used for modifying a given biological
response, the drug moiety is not to be construed as limited to classical chemical therapeutic
agents. For example, the drug moiety may be a protein or polypeptide possessing a desired

20   biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A,
pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,
.alpha.-interferon, .beta.-interferon, nerve growth factor, platelet derived growth factor,
tissue plasminogen activator; or, biological response modifiers such as, for example,
lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

25   granulocyte macrophase colony stimulating factor ("GM-CSF"), granulocyte colony
stimulating factor ("G-CSF"), or other growth factors.

Techniques for conjugating such therapeutic moiety to antibodies are well known,
see, *e.g.*, Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer
Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld *et al.* (eds.), pp.

30   243-56 (Alan R. Liss, Inc. 1985); Hellstrom *et al.*, "Antibodies For Drug Delivery", in
Controlled Drug Delivery (2nd Ed.), Robinson *et al.* (eds.), pp. 623-53 (Marcel Dekker,
Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A
Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera *et
al.* (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The

Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal

Antibodies For Cancer Detection And Therapy, Baldwin *et al.* (eds.), pp. 303-16

(Academic Press 1985), and Thorpe *et al.*, "The Preparation And Cytotoxic Properties Of

Antibody-Toxin Conjugates", Immunol. Rev., 62:119-58 (1982).

5   Alternatively, an antibody can be conjugated to a second antibody to form an

antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

Accordingly, in one aspect, the invention provides substantially purified antibodies or

fragments thereof, and non-human antibodies or fragments thereof, which antibodies or

fragments specifically bind to a polypeptide comprising an amino acid sequence selected

10   from the group consisting of the amino acid sequences of the present invention, an amino

acid sequence encoded by the cDNA of the present invention, a fragment of at least 15

amino acid residues of an amino acid sequence of the present invention, an amino acid

sequence which is at least 95% identical to the amino acid sequence of the present

invention (wherein the percent identity is determined using the ALIGN program of the

15   GCG software package with a PAM120 weight residue table, a gap length penalty of 12,

and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid

molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid

molecules of the present invention, or a complement thereof, under conditions of

hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C. In

20   various embodiments, the substantially purified antibodies of the invention, or fragments

thereof, can be human, non-human, chimeric and/or humanized antibodies.

         In another aspect, the invention provides non-human antibodies or fragments

thereof, which antibodies or fragments specifically bind to a polypeptide comprising an

amino acid sequence selected from the group consisting of: the amino acid sequence of

25   the present invention, an amino acid sequence encoded by the cDNA of the present

invention, a fragment of at least 15 amino acid residues of the amino acid sequence of the

present invention, an amino acid sequence which is at least 95% identical to the amino

acid sequence of the present invention (wherein the percent identity is determined using

the ALIGN program of the GCG software package with a PAM120 weight residue table, a

30   gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is

encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting

of the nucleic acid molecules of the present invention, or a complement thereof, under

conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at

65°C. Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat

antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the non-human antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.

5   In still a further aspect, the invention provides monoclonal antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of the present invention, an amino acid sequence encoded by the cDNA of the present invention, a fragment of at least 15 amino acid residues of an amino acid sequence of the present invention, an amino acid sequence which is at least 95% identical to an amino acid

10 sequence of the present invention (wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions

15 of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C. The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.

         The substantially purified antibodies or fragments thereof may specifically bind to a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain or cytoplasmic membrane of a polypeptide of the invention. In a

20 particularly preferred embodiment, the substantially purified antibodies or fragments thereof, the non-human antibodies or fragments thereof, and/or the monoclonal antibodies or fragments thereof, of the invention specifically bind to a secreted sequence or an extracellular domain of the amino acid sequences of the present invention.

         Any of the antibodies of the invention can be conjugated to a therapeutic moiety or to a

25 detectable substance. Non-limiting examples of detectable substances that can be conjugated to the antibodies of the invention are an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

         The invention also provides a kit containing an antibody of the invention

30 conjugated to a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody of the invention and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition contains an antibody of the invention, a therapeutic moiety, and a pharmaceutically acceptable carrier.

Still another aspect of the invention is a method of making an antibody that specifically recognizes a polypeptide of the present invention, the method comprising immunizing a mammal with a polypeptide. The polypeptide used as an immunogen comprises an amino acid sequence selected from the group consisting of the amino acid

5   sequence of the present invention, an amino acid sequence encoded by the cDNA of the nucleic acid molecules of the present invention, a fragment of at least 15 amino acid residues of the amino acid sequence of the present invention, an amino acid sequence which is at least 95% identical to the amino acid sequence of the present invention (wherein the percent identity is determined using the ALIGN program of the GCG

10   software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C.

15   After immunization, a sample is collected from the mammal that contains an antibody that specifically recognizes the polypeptide. Preferably, the polypeptide is recombinantly produced using a non-human host cell. Optionally, the antibodies can be further purified from the sample using techniques well known to those of skill in the art. The method can further comprise producing a monoclonal antibody- producing cell from the cells of the

20   mammal. Optionally, antibodies are collected from the antibody-producing cell.

II. Isolated Nucleic Acid Molecules

Another aspect of the invention pertains to isolated nucleic acid molecules that correspond to a marker of the invention, including nucleic acids which encode a marker

25   protein of the invention or a portion of such a polypeptide. Isolated nucleic acids of the invention also include nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules that correspond to a marker of the invention, including nucleic acids which encode a polypeptide corresponding to a marker of the invention, and fragments of such nucleic acid molecules, e.g., those suitable for use as PCR primers for

30   the amplification or mutation of nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Preferably, an "isolated" nucleic acid molecule is free of sequences (preferably protein-encoding sequences) which naturally flank the nucleic acid (*i.e.*, sequences located at the 5'

5   and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kB, 4 kB, 3 kB, 2 kB, 1 kB, 0.5 kB or 0.1 kB of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid

10   molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid encoding a marker protein can be isolated using standard molecular biology techniques and the

15   sequence information in the database records described herein. Using all or a portion of such nucleic acid sequences, nucleic acid molecules of the invention can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook *et al.*, ed., *Molecular Cloning: A Laboratory Manual, 2nd ed.,* Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

20   A process for identifying the full-length coding sequence of a marker of the present invention is thus also provided. Any conventional recombinant DNA techniques applicable for isolating polynucleotides may also be employed. One such method involves the 5'-RACE-PCR technique, in which the poly-A mRNA that contains the coding sequence of particular interest is first reverse transcribed with a 3'-primer comprising a

25   sequence disclosed herein. The newly synthesized cDNA strand is then tagged with an anchor primer with a known sequence, which preferably contains a convenient cloning restriction site attached at the 5'end. The tagged cDNA is then amplified with the 3'-primer (or a nested primer sharing sequence homology to the internal sequences of the coding region) and the 5'-anchor primer. The amplification may be conducted under

30   conditions of various levels of stringency to optimize the amplification specificity. 5'-RACE-PCR can be readily performed using commercial kits (available from, *e.g.*, BRL Life Technologies Inc., Clontech) according to the manufacturer's instructions.

Isolating the complete coding sequence of a gene can also be carried out in a hybridization assay using a suitable probe. The probe preferably comprises at least 10

nucleotides, and more preferably exhibits sequence homology to the polynucleotides of the markers of the present invention. Other high throughput screens for cDNAs, such as those involving gene chip technology, can also be employed in obtaining the complete cDNA sequence.

5   In addition, databases exist that reduce the complexity of ESTs by assembling contiguous EST sequences into tentative genes. For example, TIGR has assembled human ESTs into a datable called THC for tentative human consensus sequences. The THC database allows for a more definitive assignment compared to ESTs alone. Software programs exist (TIGR assembler and TIGEM EST assembly machine and contig assembly

10   program (see Huang, X., 1996, *Genomes* 33:21-23)) that allow for assembling ESTs into contiguous sequences from any organism.

      Alternatively, mRNA from a sample preparation is used to construct cDNA library in the ZAP Express vector following the procedure described in Velculescu *et al.*, 1997, *Science* 270:484. The ZAP Express cDNA synthesis kit (Stratagene) is used accordingly

15   to the manufacturer's protocol. Plates containing 250 to 2000 plaques are hybridized as described in Rupert *et al.*, 1988, *Mol. Cell. Bio.* 8:3104 to oligonucleotide probes with the same conditions previously described for standard probes except that the hybridization temperature is reduced to a room temperature. Washes are performed in 6X standard-saline-citrate 0.1% SDS for 30 minutes at room temperature. The probes are labeled with

20   ^{32}P-ATP trough use of T4 polynucleotide kinase.

      A partial cDNA (3' fragment) can be isolated by 3' directed PCR reaction. This procedure is a modification of the protocol described in Polyak *et al.*, 1997, *Nature* 389:300. Briefly, the procedure uses SAGE tags in PCR reaction such that the resultant PCR product contains the SAGE tag of interest as well as additional cDNA, the length of

25   which is defined by the position of the tag with respect to the 3' end of the cDNA. The cDNA product derived from such a transcript driven PCR reaction can be used for many applications.

      RNA from a source to express the cDNA corresponding to a given tag is first converted to double-stranded cDNA using any standard cDNA protocol. Similar

30   conditions used to generate cDNA for SAGE library construction can be employed except that a modified oligo-dT primer is used to derive the first strand synthesis. For example, the oligonucleotide of composition 5'-B-TCC GGC GCG CCG TTT TCC CAG TCA' CGA(30)- 3', contains a poly-T stretch at the 3' end for hybridization and priming from poly-A tails, an M13 priming site for use in subsequent PCR steps, a 5' Biotin label (B) for

capture to strepavidin-coated magnetic beads, and an AscI restriction endonuclease site for releasing the cDNA from the strepavidin-coated magnetic beads. Theoretically, any sufficiently-sized DNA region capable of hybridizing to a PCR primer can be used as well as any other 8 base pair recognizing endonuclease.

5   cDNA constructed utilizing this or similar modified oligo-dT primer is then processed exactly as described in U.S. Patent No. 5,695,937 up until adapter ligation where only one adapter is ligated to the cDNA pool. After Adapter ligation, the cDNA is released from the streptavidin-coated magnetic beads and is then used as a template for cDNA amplification.

10   Various PCR protocols can be employed using PCR priming sites within the 3' modified oligo-dT primer and the SAGE tag. The SAGE tag-derived PCR primer employed can be of varying length dictated by 5' extension of the tag into the adaptor sequence. cDNA products are now available for a variety of applications.

          This technique can be further modified by: (1) altering the length and/or content of

15   the modified oligo-dT primer; (2) ligating adaptors other than that previously employed within the SAGE protocol; (3) performing PCR from template retained on the streptavidin-coated magnetic beads; and (4) priming first strand cDNA synthesis with non-oligo-dT based primers.

          Gene trapper technology can also be used. The reagents and manufacturer's

20   instructions for this technology are commercially available from Life Technologies, Inc., Gaithsburg, Maryland. Briefly, a complex population of single-stranded phagemid DNA containing directional cDNA inserts is enriched for the target sequence by hybridization in solution to a biotinylated oligonucleotide probe complementary to the target sequence. The hybrids are captured on streptavidin-coated paramagnetic beads. A magnet retrieves

25   the paramagnetic beads from the solution, leaving nonhybridized single-stranded DNAs behind. Subsequently, the captured single-stranded DNA target is released from the biotinylated oligonucleotide. After release, the cDNA clone is further enriched by using a nonbiotinylated target oligonucleotide to specifically prime conversion of the single-stranded DNA. Following transformation and plating, typically 20% to 100% of the

30   colonies represent the cDNA clone of interest. To identify the desired cDNA clone, the colonies may be screened by colony hybridization using the ^{32}P-labeled oligonucleotide as described above for solution hybridization, or alternatively by DNA sequencing and alignment of all sequences obtained from numerous clones to determine a consensus sequence.

A nucleic acid molecule of the invention can be amplified using cDNA, mRNA, or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore,

5   oligonucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which has a nucleotide sequence

10   complementary to the nucleotide sequence of a nucleic acid corresponding to a marker of the invention or to the nucleotide sequence of a nucleic acid encoding a protein which corresponds to a marker of the invention. A nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence

15   thereby forming a stable duplex.

Moreover, a nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence, wherein the full length nucleic acid sequence comprises a marker of the invention or which encodes a polypeptide corresponding to a marker of the invention. Such nucleic acids can be used, for example, as a probe or primer. The

20   probe/primer typically is used as one or more substantially purified oligonucleotides. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 7, preferably about 15, more preferably about 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 or more consecutive nucleotides of a nucleic acid of the invention.

25   Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences corresponding to one or more markers of the invention. The probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which mis-express the protein,

30   such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.

The invention further encompasses nucleic acid molecules that differ, due to degeneracy of the genetic code, from the nucleotide sequence of nucleic acids encoding a protein which corresponds to a marker of the invention, and thus encode the same protein.

In addition to the nucleotide sequences described herein, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus. In addition, it will be appreciated that DNA polymorphisms that affect RNA expression levels can also exist that may affect the overall expression level of that gene (e.g., by affecting regulation or degradation).

As used herein, the phrase "allelic variant" refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence.

As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide corresponding to a marker of the invention. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.

In another embodiment, an isolated nucleic acid molecule of the invention is at least 7, 15, 20, 25, 30, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or more nucleotides in length and hybridizes under stringent conditions to a nucleic acid corresponding to a marker of the invention or to a nucleic acid encoding a protein corresponding to a marker of the invention. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 75% (80%, 85%, preferably 90%) identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in sections 6.3.1-6.3.6 of *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989). A preferred, non-limiting example of stringent hybridization conditions for annealing two single-stranded DNA each of which

is at least about 100 bases in length and/or for annealing a single-stranded DNA and a single-stranded RNA each of which is at least about 100 bases in length, are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50-65°C. Further preferred hybridization conditions are

5   taught in Lockhart, *et al.,* Nature Biotechnology, Volume 14, 1996 August:1675-1680; Breslauer, *et al.,* Proc. Natl. Acad. Sci. USA, Volume 83, 1986 June: 3746-3750; Van Ness, *et al.,* Nucleic Acids Research, Volume 19, No. 19, 1991 September: 5143-5151; McGraw, *et al.,* BioTechniques, Volume 8, No. 6 1990: 674-678; and Milner, *et al.,* Nature Biotechnology, Volume 15, 1997 June: 537-541, all expressly incorporated by

10   reference.

In addition to naturally-occurring allelic variants of a nucleic acid molecule of the invention that can exist in the population, the skilled artisan will further appreciate that sequence changes can be introduced by mutation thereby leading to changes in the amino acid sequence of the encoded protein, without altering the biological activity of the protein

15   encoded thereby. For example, one can make nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are not conserved or only semi-conserved

20   among homologs of various species may be non-essential for activity and thus would be likely targets for alteration. Alternatively, amino acid residues that are conserved among the homologs of various species (*e.g.,* murine and human) may be essential for activity and thus would not be likely targets for alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules

25   encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from the naturally-occurring proteins which correspond to the markers of the invention, yet retain biological activity. In one embodiment, such a protein has an amino acid sequence that is at least about 40% identical, 50%, 60%, 70%, 80%, 90%, 95%, or 98% identical to the

30   amino acid sequence of one of the proteins which correspond to the markers of the invention.

An isolated nucleic acid molecule encoding a variant protein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of nucleic acids of the invention, such that one or more amino acid residue

substitutions, additions, or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid

5   substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine,

10   tyrosine, cysteine), non-polar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for

15   biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

The present invention encompasses antisense nucleic acid molecules, *i.e.*, molecules which are complementary to a sense nucleic acid of the invention, *e.g.*,

20   complementary to the coding strand of a double-stranded cDNA molecule corresponding to a marker of the invention or complementary to an mRNA sequence corresponding to a marker of the invention. Accordingly, an antisense nucleic acid of the invention can hydrogen bond to (*i.e.* anneal with) a sense nucleic acid of the invention. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof,

25   *e.g.*, all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can also be antisense to all or part of a non-coding region of the coding strand of a nucleotide sequence encoding a polypeptide of the invention. The non-coding regions ("5' and 3' untranslated regions") are the 5' and 3' sequences which flank the coding region and are not translated into amino acids.

30   An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or

variously modified nucleotides designed to increase the biological stability of the
molecules or to increase the physical stability of the duplex formed between the antisense
and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted
nucleotides can be used. Examples of modified nucleotides which can be used to generate

5   the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-
iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-
carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil,
dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-
methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2- methyladenine, 2-

10   methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-
methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-
mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-
isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-
thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-

15   oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-
3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense
nucleic acid can be produced biologically using an expression vector into which a nucleic
acid has been sub-cloned in an antisense orientation (*i.e.*, RNA transcribed from the
inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest,

20   described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to
a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA
and/or genomic DNA encoding a polypeptide corresponding to a selected marker of the
invention to thereby inhibit expression of the marker, *e.g.*, by inhibiting transcription

25   and/or translation. The hybridization can be by conventional nucleotide complementarity
to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule
which binds to DNA duplexes, through specific interactions in the major groove of the
double helix. Examples of a route of administration of antisense nucleic acid molecules of
the invention includes direct injection at a tissue site or infusion of the antisense nucleic

30   acid into an RA-associated body fluid. Alternatively, antisense nucleic acid molecules can
be modified to target selected cells and then administered systemically. For example, for
systemic administration, antisense molecules can be modified such that they specifically
bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the
antisense nucleic acid molecules to peptides or antibodies which bind to cell surface

receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

5   An antisense nucleic acid molecule of the invention can be an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual α-units, the strands run parallel to each other (Gaultier *et al.*, 1987, *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et*

10   *al.*, 1987, *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.*, 1987, *FEBS Lett.* 215:327-330).

The invention also encompasses ribozymes. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus,

15   ribozymes (*e.g.*, hammerhead ribozymes as described in Haselhoff and Gerlach, 1988, *Nature* 334:585-591) can be used to catalytically cleave mRNA transcripts to thereby inhibit translation of the protein encoded by the mRNA. A ribozyme having specificity for a nucleic acid molecule encoding a polypeptide corresponding to a marker of the invention can be designed based upon the nucleotide sequence of a cDNA corresponding to the

20   marker. For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved (see Cech *et al.* U.S. Patent No. 4,987,071; and Cech *et al.* U.S. Patent No. 5,116,742). Alternatively, an mRNA encoding a polypeptide of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of

25   RNA molecules (see, *e.g.*, Bartel and Szostak, 1993, *Science* 261:1411-1418).

The invention also encompasses nucleic acid molecules which form triple helical structures. For example, expression of a polypeptide of the invention can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the gene encoding the polypeptide (*e.g.*, the promoter and/or enhancer) to form triple helical

30   structures that prevent transcription of the gene in target cells. See generally Helene (1991) *Anticancer Drug Des.* 6(6):569-84; Helene (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher (1992) *Bioassays* 14(12):807-15.

In various embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the

stability, hybridization, or solubility of the molecule. For example, the deoxyribose

phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids

(see Hyrup *et al.*, 1996, *Bioorganic & Medicinal Chemistry* 4(1): 5-23). As used herein,

the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA

5   mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide

backbone and only the four natural nucleobases are retained. The neutral backbone of

PNAs has been shown to allow for specific hybridization to DNA and RNA under

conditions of low ionic strength. The synthesis of PNA oligomers can be performed using

standard solid phase peptide synthesis protocols as described in Hyrup *et al.* (1996), *supra*;

10   Perry-O'Keefe *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:14670-675.

PNAs can be used in therapeutic and diagnostic applications. For example, PNAs

can be used as antisense or antigene agents for sequence-specific modulation of gene

expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication.

PNAs can also be used, *e.g.*, in the analysis of single base pair mutations in a gene by, *e.g.*,

15   PNA directed PCR clamping; as artificial restriction enzymes when used in combination

with other enzymes, *e.g.*, S1 nucleases (Hyrup (1996), *supra*; or as probes or primers for

DNA sequence and hybridization (Hyrup, 1996, *supra*; Perry-O'Keefe *et al.*, 1996, *Proc.*

Natl. Acad. Sci. USA 93:14670-675).

In another embodiment, PNAs can be modified, *e.g.*, to enhance their stability or

20   cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of

PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery

known in the art. For example, PNA-DNA chimeras can be generated which can combine

the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition

enzymes, *e.g.*, RNASE H and DNA polymerases, to interact with the DNA portion while

25   the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras

can be linked using linkers of appropriate lengths selected in terms of base stacking,

number of bonds between the nucleobases, and orientation (Hyrup, 1996, *supra*). The

synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), *supra*,

and Finn *et al.* (1996) *Nucleic Acids Res.* 24(17):3357-63. For example, a DNA chain can

30   be synthesized on a solid support using standard phosphoramidite coupling chemistry and

modified nucleoside analogs. Compounds such as 5'-(4-methoxytrityl)amino-5'-deoxy-

thymidine phosphoramidite can be used as a link between the PNA and the 5' end of DNA

(Mag *et al.*, 1989, *Nucleic Acids Res.* 17:5973-88). PNA monomers are then coupled in a

step-wise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA

segment (Finn *et al.*, 1996, *Nucleic Acids Res.* 24(17):3357-63). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser *et al.*, 1975, *Bioorganic Med. Chem. Lett.* 5:1119-11124).

In other embodiments, the oligonucleotide can include other appended groups such

5   as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered

10   cleavage agents (see, *e.g.*, Krol *et al.*, 1988, *Bio/Techniques* 6:958-976) or intercalating agents (see, *e.g.*, Zon, 1988, *Pharm. Res.* 5:539-549). To this end, the oligonucleotide can be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The invention also includes molecular beacon nucleic acids having at least one

15   region which is complementary to a nucleic acid of the invention, such that the molecular beacon is useful for quantitating the presence of the nucleic acid of the invention in a sample. A "molecular beacon" nucleic acid is a nucleic acid comprising a pair of complementary regions and having a fluorophore and a fluorescent quencher associated therewith. The fluorophore and quencher are associated with different portions of the

20   nucleic acid in such an orientation that when the complementary regions are annealed with one another, fluorescence of the fluorophore is quenched by the quencher. When the complementary regions of the nucleic acid are not annealed with one another, fluorescence of the fluorophore is quenched to a lesser degree. Molecular beacon nucleic acids are described, for example, in U.S. Patent 5,876,930.

25

III.   Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a polypeptide corresponding to a marker of the invention (or a portion of such a polypeptide). As used herein, the term "vector" refers to a

30   nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced

(*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, namely expression vectors, are capable

5   of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

10   The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector,

15 "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation

20 signals). Such regulatory sequences are described, for example, in Goeddel, *Methods in Enzymology: Gene Expression Technology* vol.185, Academic Press, San Diego, CA (1991). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences).

25 It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.

30   The recombinant expression vectors of the invention can be designed for expression of a polypeptide corresponding to a marker of the invention in prokaryotic (*e.g.*, *E. coli*) or eukaryotic cells (*e.g.*, insect cells {using baculovirus expression vectors}, yeast cells or mammalian cells). Suitable host cells are discussed further in Goeddel,

supra. Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either

5 fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion

10 expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and

15 Johnson, 1988, *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, 1988, *Gene* 69:301-315) and pET 11d (Studier *et al.*, p. 60-89, In *Gene*

20 *Expression Technology: Methods in Enzymology* vol.185, Academic Press, San Diego, CA, 1991). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host

25 strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, p. 119-128, In *Gene Expression Technology: Methods in*

30 *Enzymology* vol. 185, Academic Press, San Diego, CA, 1990. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, 1992, *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the expression vector is a yeast expression vector.
Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari *et al.*,
1987, *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz, 1982, *Cell* 30:933-943),
pJRY88 (Schultz *et al.*, 1987, *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San
5   Diego, CA), and pPicZ (Invitrogen Corp, San Diego, CA).

       In another embodiment, the methods of the present invention include the
generation of markers of the invention by direct chemical synthesis, rather than by
production from DNA, using the protein synthetic machinery of living organisms or cell
extracts containing such machinery.

10   Alternatively, the expression vector is a baculovirus expression vector.
Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, Sf 9
cells) include the pAc series (Smith *et al.*, 1983, *Mol. Cell Biol.* 3:2156-2165) and the pVL
series (Lucklow and Summers, 1989, *Virology* 170:31-39).

       In yet another embodiment, a nucleic acid of the invention is expressed in
15   mammalian cells using a mammalian expression vector. Examples of mammalian
expression vectors include pCDM8 (Seed, 1987, *Nature* 329:840) and pMT2PC (Kaufman
et al., 1987, *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's
control functions are often provided by viral regulatory elements. For example, commonly
used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian
20   Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells
see chapters 16 and 17 of Sambrook *et al.*, *supra*.

       In another embodiment, the recombinant mammalian expression vector is capable
of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*,
tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific
25   regulatory elements are known in the art. Non-limiting examples of suitable tissue-
specific promoters include the albumin promoter (liver-specific; Pinkert *et al.*, 1987,
Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton, 1988, *Adv.*
Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore,
1989, *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.*, 1983, *Cell* 33:729-740;
30   Queen and Baltimore, 1983, *Cell* 33:741-748), neuron-specific promoters (*e.g.*, the
neurofilament promoter; Byrne and Ruddle, 1989, *Proc. Natl. Acad. Sci. USA* 86:5473-
5477), pancreas-specific promoters (Edlund *et al.*, 1985, *Science* 230:912-916), and
mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Patent No. 4,873,316
and European Application Publication No. 264,166). Developmentally-regulated

promoters are also encompassed, for example the murine hox promoters (Kessel and

Gruss, 1990, *Science* 249:374-379) and the α-fetoprotein promoter (Camper and

Tilghman, 1989, *Genes Dev.* 3:537-546).

5   The invention further provides a recombinant expression vector comprising a DNA

molecule of the invention cloned into the expression vector in an antisense orientation.

That is, the DNA molecule is operably linked to a regulatory sequence in a manner which

allows for expression (by transcription of the DNA molecule) of an RNA molecule which

is antisense to the mRNA encoding a polypeptide of the invention. Regulatory sequences

operably linked to a nucleic acid cloned in the antisense orientation can be chosen which

10   direct the continuous expression of the antisense RNA molecule in a variety of cell types,

for instance viral promoters and/or enhancers, or regulatory sequences can be chosen

which direct constitutive, tissue-specific or cell type specific expression of antisense RNA.

The antisense·expression vector can be in the form of a recombinant plasmid, phagemid, or

attenuated virus in which antisense nucleic acids are produced under the control of a high

15   efficiency regulatory region, the activity of which can be determined by the cell type into

which the vector is introduced. For a discussion of the regulation of gene expression using

antisense genes see Weintraub *et al.,* 1986, *Trends in Genetics,* Vol. 1(1).

       Another aspect of the invention pertains to host cells into which a recombinant

expression vector of the invention has been introduced. The terms "host cell" and

20   "recombinant host cell" are used interchangeably herein. It is understood that such terms

refer not only to the particular subject cell but to the progeny or potential progeny of such

a cell. Because certain modifications may occur in succeeding generations due to either

mutation or environmental influences, such progeny may not, in fact, be identical to the

parent cell, but are still included within the scope of the term as used herein.

25   A host cell can be any prokaryotic (*e.g., E. coli*) or eukaryotic cell (*e.g.,* insect

cells, yeast or mammalian cells).

       Vector DNA can be introduced into prokaryotic or eukaryotic cells via

conventional transformation or transfection techniques. As used herein, the terms

"transformation" and "transfection" are intended to refer to a variety of art-recognized

30   techniques for introducing foreign nucleic acid into a host cell, including calcium

phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection,

lipofection, or electroporation. Suitable methods for transforming or transfecting host cells

can be found in Sambrook, *et al.* (*supra*), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, for resistance to antibiotics) is

5   generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

10   A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce a polypeptide corresponding to a marker of the invention. Accordingly, the invention further provides methods for producing a polypeptide corresponding to a marker of the invention using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a

15   recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the marker is produced. In another embodiment, the method further comprises isolating the marker polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman transgenic

20   animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a sequences encoding a polypeptide corresponding to a marker of the invention have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous sequences encoding a marker of the invention have been introduced into their genome or homologous

25   recombinant animals in which endogenous gene(s) encoding a polypeptide corresponding to a marker of the invention sequences have been altered. Such animals are useful for studying the function and/or activity of the polypeptide corresponding to the marker and for identifying and/or evaluating modulators of polypeptide activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a

30   rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an

encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, an "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA

5   molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing a nucleic acid encoding a polypeptide corresponding to a marker of the invention into the male pronuclei of a fertilized oocyte, *e.g.*, by microinjection, retroviral infection, and allowing the oocyte

10   to develop in a pseudopregnant female foster animal. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the polypeptide of the invention to particular cells. Methods for generating transgenic animals via embryo manipulation and

15   microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191 and in Hogan, *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the

20   presence of the transgene in its genome and/or expression of mRNA encoding the transgene in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying the transgene can further be bred to other transgenic animals carrying other transgenes.

To create an homologous recombinant animal, a vector is prepared which contains

25   at least a portion of a gene encoding a polypeptide corresponding to a marker of the invention into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the gene. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out"

30   vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous protein). In the homologous recombination vector, the altered portion of the gene is flanked at its 5' and 3' ends by additional nucleic acid of the

gene to allow for homologous recombination to occur between the exogenous gene carried by the vector and an endogenous gene in an embryonic stem cell. The additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'

5   and 3' ends) are included in the vector (see, e.g., Thomas and Capecchi, 1987, *Cell* 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous gene are selected (see, e.g., Li et al., 1992, *Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (e.g.,

10   a mouse) to form aggregation chimeras (see, e.g., Bradley, *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, Robertson, Ed., IRL, Oxford, 1987, pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which

15   all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Current Opinion in Bio/Technology* 2:823-829 and in PCT Publication NOS. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.

20   In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:6232-6236. Another example of a recombinase system is the FLP

25   recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al., 1991, *Science* 251:1351-1355). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a

30   transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

           Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997) *Nature* 385:810-813 and PCT Publication NOS. WO 97/07668 and WO 97/07669.

IV. Pharmaceutical Compositions

The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as "active compounds") corresponding to a marker of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically

5   comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically

10   active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The invention includes methods for preparing pharmaceutical compositions for

15   modulating the expression or activity of a polypeptide or nucleic acid corresponding to a marker of the invention. Such methods comprise formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid corresponding to a marker of the invention. Such compositions can further include additional active agents. Thus, the invention further includes methods for

20   preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid corresponding to a marker of the invention and one or more additional active compounds.

The invention also provides methods (also referred to herein as "screening assays")

25   for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, peptoids, small molecules or other drugs) which (a) bind to the marker, or (b) have a modulatory (e.g., stimulatory or inhibitory) effect on the activity of the marker or, more specifically, (c) have a modulatory effect on the interactions of the marker with one or more of its natural substrates (e.g., peptide, protein, hormone, co-factor, or

30   nucleic acid), or (d) have a modulatory effect on the expression of the marker. Such assays typically comprise a reaction between the marker and one or more assay components. The other components may be either the test compound itself, or a combination of test compound and a natural binding partner of the marker.

The test compounds of the present invention may be obtained from any available source, including systematic libraries of natural and/or synthetic compounds. Test compounds may also be obtained by any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries

5   of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive; see, *e.g.,* Zuckermann *et al.,* 1994, *J. Med. Chem.* 37:2678-85); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic

10   library methods using affinity chromatography selection. The biological library and peptoid library approaches are limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, 1997, *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the

15   art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994). *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

20   Libraries of compounds may be presented in solution (*e.g.,* Houghten, 1992, *Biotechniques* 13:412-421), or on beads (Lam, 1991, *Nature* 354:82-84), chips (Fodor, 1993, *Nature* 364:555-556), bacteria and/or spores, (Ladner, USP 5,223,409), plasmids (Cull *et al,* 1992, *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith, 1990, *Science* 249:386-390; Devlin, 1990, *Science* 249:404-406; Cwirla *et al,* 1990, *Proc.*

25   *Natl. Acad. Sci.* 87:6378-6382; Felici, 1991, *J. Mol. Biol.* 222:301-310; Ladner, *supra.*).

In one embodiment, the invention provides assays for screening candidate or test compounds which are substrates of a marker or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to a marker or biologically active portion thereof. Determining the

30   ability of the test compound to directly bind to a marker can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic label such that binding of the compound to the marker can be determined by detecting the labeled marker compound in a complex. For example, compounds (*e.g.,* marker substrates) can be labeled with ^{125}I, ^{35}S, ^{14}C, or ^{3}H, either directly or indirectly, and the radioisotope detected by

direct counting of radioemission or by scintillation counting. Alternatively, assay
components can be enzymatically labeled with, for example, horseradish peroxidase,
alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of
conversion of an appropriate substrate to product.

5   In another embodiment, the invention provides assays for screening candidate or
test compounds which modulate the activity of a marker or a biologically active portion
thereof. In all likelihood, the marker can, *in vivo*, interact with one or more molecules,
such as but not limited to, peptides, proteins, hormones, cofactors and nucleic acids. For
the purposes of this discussion, such cellular and extracellular molecules are referred to
10   herein as "binding partners" or marker "substrate".

           One necessary embodiment of the invention in order to facilitate such screening is
the use of the marker to identify its natural *in vivo* binding partners. There are many ways
to accomplish this which are known to one skilled in the art. One example is the use of the
marker as "bait protein" in a two-hybrid assay or three-hybrid assay (see, *e.g.*, U.S. Patent
15   No. 5,283,317; Zervos *et al*, 1993, *Cell* 72:223-232; Madura *et al*, 1993, *J. Biol. Chem.*
268:12046-12054; Bartel *et al* ,1993, *Biotechniques* 14:920-924; Iwabuchi *et al*, 1993
Oncogene 8:1693-1696; Brent WO94/10300) in order to identify other proteins which bind
to or interact with the marker (binding partners) and, therefore, are possibly involved in
the natural function of the marker. Such marker binding partners are also likely to be
20   involved in the propagation of signals by the marker or downstream elements of a marker-
mediated signaling pathway. Alternatively, such marker binding partners may also be
found to be inhibitors of the marker.

           The two-hybrid system is based on the modular nature of most transcription
factors, which consist of separable DNA-binding and activation domains. Briefly, the
25   assay utilizes two different DNA constructs. In one construct, the gene that encodes a
marker fused to a gene encoding the DNA binding domain of a known transcription factor
(*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences,
that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for
the activation domain of the known transcription factor. If the "bait" and the "prey"
30   proteins are able to interact, *in vivo*, forming a marker-dependent complex, the DNA-
binding and activation domains of the transcription factor are brought into close proximity.
This proximity allows transcription of a reporter gene (*e.g.*, LacZ) which is operably
linked to a transcriptional regulatory site responsive to the transcription factor. Expression
of the reporter gene can be readily detected and cell colonies containing the functional

transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the marker.

In a further embodiment, assays may be devised through the use of the invention for the purpose of identifying compounds which modulate (*e.g.*, affect either positively or

5   negatively) interactions between a marker and its substrates and/or binding partners. Such compounds can include, but are not limited to, molecules such as antibodies, peptides, hormones, oligonucleotides, nucleic acids, and analogs thereof. Such compounds may also be obtained from any available source, including systematic libraries of natural and/or synthetic compounds. The preferred assay components for use in this embodiment is an

10   RA marker identified herein, the known binding partner and/or substrate of same, and the test compound. Test compounds can be supplied from any source.

The basic principle of the assay systems used to identify compounds that interfere with the interaction between the marker and its binding partner involves preparing a reaction mixture containing the marker and its binding partner under conditions and for a

15   time sufficient to allow the two products to interact and bind, thus forming a complex. In order to test an agent for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test compound can be initially included in the reaction mixture, or can be added at a time subsequent to the addition of the marker and its binding partner. Control reaction mixtures are incubated without the test

20   compound or with a placebo. The formation of any complexes between the marker and its binding partner is then detected. The formation of a complex in the control reaction, but less or no such formation in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the marker and its binding partner. Conversely, the formation of more complex in the presence of compound than in the

25   control reaction indicates that the compound may enhance interaction of the marker and its binding partner.

The assay for compounds that interfere with the interaction of the marker with its binding partner may be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the marker or its binding partner onto a

30   solid phase and detecting complexes anchored to the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the markers and the binding partners (*e.g.*, by competition) can be

identified by conducting the reaction in the presence of the test substance, *i.e.,* by adding the test substance to the reaction mixture prior to or simultaneously with the marker and its interactive binding partner. Alternatively, test compounds that disrupt preformed complexes, *e.g.,* compounds with higher binding constants that displace one of the

5   components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are briefly described below.

In a heterogeneous assay system, either the marker or its binding partner is anchored onto a solid surface or matrix, while the other corresponding non-anchored

10 component may be labeled, either directly or indirectly. In practice, microtitre plates are often utilized for this approach. The anchored species can be immobilized by a number of methods, either non-covalent or covalent, that are typically well known to one who practices the art. Non-covalent attachment can often be accomplished simply by coating the solid surface with a solution of the marker or its binding partner and drying.

15 Alternatively, an immobilized antibody specific for the assay component to be anchored can be used for this purpose. Such surfaces can often be prepared in advance and stored.

In related embodiments, a fusion protein can be provided which adds a domain that allows one or both of the assay components to be anchored to a matrix. For example, glutathione-S-transferase/marker fusion proteins or glutathione-S-transferase/binding

20 partner can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and either the non-adsorbed marker or its binding partner, and the mixture incubated under conditions conducive to complex formation (*e.g.,* physiological conditions). Following incubation, the beads or microtiter plate wells are

25 washed to remove any unbound assay components, the immobilized complex assessed either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of marker binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the

30 screening assays of the invention. For example, either a marker or a marker binding partner can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated marker or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (*e.g.,* biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In

certain embodiments, the protein-immobilized surfaces can be prepared in advance and stored.

In order to conduct the assay, the corresponding partner of the immobilized assay component is exposed to the coated surface with or without the test compound. After the

5   reaction is complete, unreacted assay components are removed (*e.g.,* by washing) and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized component is

10   not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; *e.g.,* using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, can be directly labeled or indirectly labeled with, *e.g.,* a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which modulate (inhibit or enhance) complex formation or which disrupt preformed

15   complexes can be detected.

In an alternate embodiment of the invention, a homogeneous assay may be used. This is typically a reaction, analogous to those mentioned above, which is conducted in a liquid phase in the presence or absence of the test compound. The formed complexes are then separated from unreacted components, and the amount of complex formed is

20   determined. As mentioned for heterogeneous assay systems, the order of addition of reactants to the liquid phase can yield information about which test compounds modulate (inhibit or enhance) complex formation and which disrupt preformed complexes.

In such a homogeneous assay, the reaction products may be separated from unreacted assay components by any of a number of standard techniques, including but not

25   limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation. In differential centrifugation, complexes of molecules may be separated from uncomplexed molecules through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A.P., *Trends Biochem Sci* 1993 Aug;18(8):284-

30   7). Standard chromatographic techniques may also be utilized to separate complexed molecules from uncomplexed ones. For example, gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex may be separated from the relatively smaller uncomplexed components. Similarly, the relatively different charge

properties of the complex as compared to the uncomplexed molecules may be exploited to differentially separate the complex from the remaining individual reactants, for example through the use of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, e.g., Heegaard, 1998, *J Mol.*

5   *Recognit.* 11:141-148; Hage and Tweed, 1997, *J. Chromatogr. B. Biomed. Sci. Appl.,* 699:499-525). Gel electrophoresis may also be employed to separate complexed molecules from unbound species (see, *e.g.,* Ausubel *et al* (eds.), In: Current Protocols in Molecular Biology, J. Wiley & Sons, New York. 1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In order to maintain the

10   binding interaction during the electrophoretic process, non-denaturing gels in the absence of reducing agent are typically preferred, but conditions appropriate to the particular interactants will be well known to one skilled in the art. Immunoprecipitation is another common technique utilized for the isolation of a protein-protein complex from solution (see, *e.g.,* Ausubel *et al* (eds.), In: Current Protocols in Molecular Biology, J. Wiley &

15   Sons, New York. 1999). In this technique, all proteins binding to an antibody specific to one of the binding molecules are precipitated from solution by conjugating the antibody to a polymer bead that may be readily collected by centrifugation. The bound assay components are released from the beads (through a specific proteolysis event or other technique well known in the art which will not disturb the protein-protein interaction in the

20   complex), and a second immunoprecipitation step is performed, this time utilizing antibodies specific for the correspondingly different interacting assay component. In this manner, only formed complexes should remain attached to the beads. Variations in complex formation in both the presence and the absence of a test compound can be compared, thus offering information about the ability of the compound to modulate

25   interactions between the marker and its binding partner.

Also within the scope of the present invention are methods for direct detection of interactions between the marker and its natural binding partner and/or a test compound in a homogeneous or heterogeneous assay system without further sample manipulation. For example, the technique of fluorescence energy transfer may be utilized (see, *e.g.,*

30   Lakowicz *et al,* U.S. Patent No. 5,631,169; Stavrianopoulos *et al,* U.S. Patent No. 4,868,103). Generally, this technique involves the addition of a fluorophore label on a first 'donor' molecule (*e.g.,* marker or test compound) such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, 'acceptor' molecule (*e.g.,* marker or test compound), which in turn is able to fluoresce due to the absorbed energy. Alternately,

the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the

5   molecules, spatial relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter). A test substance which either enhances or hinders

10   participation of one of the species in the preformed complex will result in the generation of a signal variant to that of background. In this way, test substances that modulate interactions between a marker and its binding partner can be identified in controlled assays.

In another embodiment, modulators of marker expression are identified in a

15   method wherein a cell is contacted with a candidate compound and the expression of mRNA or protein, corresponding to a marker in the cell, is determined. The level of expression of mRNA or protein in the presence of the candidate compound is compared to the level of expression of mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of marker expression based

20   on this comparison. For example, when expression of marker mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of marker mRNA or protein expression. Conversely, when expression of marker mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the

25   candidate compound is identified as an inhibitor of marker mRNA or protein expression. The level of marker mRNA or protein expression in the cells can be determined by methods described herein for detecting marker mRNA or protein.

In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-

30   based or a cell free assay, and the ability of the agent to modulate the activity of a marker can be further confirmed in vivo, e.g., in a whole animal model for cellular transformation.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an

agent identified as described herein (*e.g.*, an marker modulating agent, an antisense marker nucleic acid molecule, an marker-specific antibody, or an marker-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in

5   an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

It is understood that appropriate doses of small molecule agents and protein or polypeptide agents depends upon a number of factors within the knowledge of the

10   ordinarily skilled physician, veterinarian, or researcher. The dose(s) of these agents will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the agent to have upon the nucleic acid or polypeptide of the invention. Exemplary doses of a small

15   molecule include milligram or microgram amounts per kilogram of subject or sample weight (*e.g.* about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram). Exemplary doses of a protein or polypeptide include gram, milligram or microgram amounts per kilogram of subject or

20   sample weight (*e.g.* about 1 microgram per kilogram to about 5 grams per kilogram, about 100 micrograms per kilogram to about 500 milligrams per kilogram, or about 1 milligram per kilogram to about 50 milligrams per kilogram). It is furthermore understood that appropriate doses of one of these agents depend upon the potency of the agent with respect to the expression or activity to be modulated. Such appropriate doses can be determined

25   using the assays described herein. When one or more of these agents is to be administered to an animal (*e.g.* a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher can, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level

30   for any particular animal subject will depend upon a variety of factors including the activity of the specific agent employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for

5   parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as

10   acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

       Pharmaceutical compositions suitable for injectable use include sterile aqueous

15   solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable

20   under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a

25   coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol,

30   sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

       Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, a polypeptide or antibody) in the required amount in an appropriate solvent with one

or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium, and then incorporating the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides,

5   polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes having monoclonal antibodies incorporated therein or thereon) can also be used as pharmaceutically acceptable carriers. These can be prepared

10   according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be

15   treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding

20   such an active compound for the treatment of individuals.

For antibodies, the preferred dosage is 0.1 mg/kg to 100 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other

25   antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration. A method for lipidation of antibodies is described by Cruikshank *et al.* (1997) *J. Acquired Immune Deficiency Syndromes and Human Retrovirology* 14:193.

The nucleic acid molecules corresponding to a marker of the invention can be

30   inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Patent 5,328,470), or by stereotactic injection (see, *e.g.*, Chen *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow

release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.* retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

5   The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

V. Monitoring the Effectiveness of an Anti-RA Agent

As discussed above, the markers of the present invention can be used to assess
10   whether RA has become refractory to an ongoing treatment (*e.g.*, a therapeutic treatment). This embodiment of the present invention relies on comparing two or more samples obtained from a patient undergoing anti-RA treatment. In general, it is preferable to obtain a first sample from the patient prior to beginning therapy and one or more samples during treatment. In such a use, a baseline of expression prior to therapy is determined and then
15   changes in the baseline state of expression is monitored during the course of therapy. Alternatively, two or more successive samples obtained during treatment can be used without the need of a pre-treatment baseline sample. In such a use, the first sample obtained from the subject is used as a baseline for determining whether the expression of a particular gene is increasing or decreasing.

20   In general, when monitoring the effectiveness of a therapeutic treatment, two or more samples from the patient are examined. Preferably, three or more successively obtained samples are used, including at least one pretreatment sample.

VI. Electronic Apparatus Readable Media and Arrays

25   Electronic apparatus readable media comprising a marker of the present invention is also provided. As uFsed herein, "electronic apparatus readable media" refers to any suitable medium for storing, holding or containing data or information that can be read and accessed directly by an electronic apparatus. Such media can include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic
30   tape; optical storage media such as compact disc; electronic storage media such as RAM, ROM, EPROM, EEPROM and the like; general hard disks and hybrids of these categories such as magnetic/optical storage media. The medium is adapted or configured for having recorded thereon a marker of the present invention.

As used herein, the term "electronic apparatus" is intended to include any suitable computing or processing apparatus or other device configured or adapted for storing data or information. Examples of electronic apparatus suitable for use with the present invention include stand-alone computing apparatus; networks, including a local area

5   network (LAN), a wide area network (WAN) Internet, Intranet, and Extranet; electronic appliances such as a personal digital assistants (PDAs), cellular phone, pager and the like; and local and distributed processing systems.

As used herein, "recorded" refers to a process for storing or encoding information on the electronic apparatus readable medium. Those skilled in the art can readily adopt

10   any of the presently known methods for recording information on known media to generate manufactures comprising the markers of the present invention.

A variety of software programs and formats can be used to store the marker information of the present invention on the electronic apparatus readable medium. For example, the nucleic acid sequence corresponding to the markers can be represented in a

15   word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like, as well as in other forms. Any number of dataprocessor structuring formats (*e.g.*, text file or database) may be employed in order to obtain or create a medium having recorded thereon the markers of the

20   present invention.

By providing the markers of the invention in readable form, one can routinely access the marker sequence information for a variety of purposes. For example, one skilled in the art can use the nucleotide or amino acid sequences of the present invention in readable form to compare a target sequence or target structural motif with the sequence

25   information stored within the data storage means. Search means are used to identify fragments or regions of the sequences of the invention which match a particular target sequence or target motif.

The present invention therefore provides a medium for holding instructions for performing a method for determining whether a subject has RA or a pre-disposition to RA,

30   wherein the method comprises the steps of determining the presence or absence of a RA marker and based on the presence or absence of the RA marker, determining whether the subject has RA or a pre-disposition to RA and/or recommending a particular treatment for the RA or pre-RA condition.

The present invention further provides in an electronic system and/or in a network, a method for determining whether a subject has RA or a pre-disposition to RA associated with a RA marker wherein the method comprises the steps of determining the presence or absence of the RA marker, and based on the presence or absence of the RA marker,

5   determining whether the subject has RA or a pre-disposition to RA, and/or recommending a particular treatment for the RA or pre-RA condition. The method may further comprise the step of receiving phenotypic information associated with the subject and/or acquiring from a network phenotypic information associated with the subject.

The present invention also provides in a network, a method for determining

10   whether a subject has RA or a pre-disposition to RA associated with a RA marker, said method comprising the steps of receiving information associated with the RA marker receiving phenotypic information associated with the subject, acquiring information from the network corresponding to the RA marker and/or RA, and based on one or more of the phenotypic information, the RA marker, and the acquired information, determining

15   whether the subject has RA or a pre-disposition to RA. The method may further comprise the step of recommending a particular treatment for the RA or pre- RA condition

The present invention also provides a business method for determining whether a subject has RA or a pre-disposition to RA, said method comprising the steps of receiving information associated with the RA marker, receiving phenotypic information associated

20   with the subject, acquiring information from the network corresponding to the RA marker and/or RA, and based on one or more of the phenotypic information, the RA marker, and the acquired information, determining whether the subject has RA or a pre-disposition to RA. The method may further comprise the step of recommending a particular treatment for the RA or pre-RA condition.

25   The invention also includes gene and protein arrays comprising a RA marker of the present invention. The arrays can be used to assay expression of one or more genes or to assay expression of one or more proteins in the arrays. In one embodiment, the gene arrays can be used to assay gene expression in a tissue to ascertain tissue specificity of genes in the array. In another embodiment, the protein arrays can be used to assay protein

30   expression in a tissue to ascertain tissue specificity of proteins in the array. In this manner, several thousands of genes or proteins can be simultaneously assayed for expression. This allows a profile to be developed showing a battery of genes or proteins specifically expressed in one or more tissues.

In addition to such qualitative determination, the invention allows the quantitation of gene or protein expression. Thus, not only tissue specificity, but also the level of expression of a battery of genes or proteins in the tissue is ascertainable. Thus, genes or proteins can be grouped on the basis of their tissue expression *per se* and level of

5   expression in that tissue. This is useful, for example, in ascertaining the relationship of gene or protein expression between or among tissues. Thus, one tissue can be perturbed and the effect on gene or protein expression in a second tissue can be determined. In this context, the effect of one cell type on another cell type in response to a biological stimulus can be determined. Such a determination is useful, for example, to know the effect of cell-

10   cell interaction at the level of gene or protein expression. If an agent is administered therapeutically to treat one cell type but has an undesirable effect on another cell type, the invention provides an assay to determine the molecular basis of the undesirable effect and thus provides the opportunity to co-administer a counteracting agent or otherwise treat the undesired effect. Similarly, even within a single cell type, undesirable biological effects

15   can be determined at the molecular level. Thus, the effects of an agent on expression of other than the target gene can be ascertained and counteracted.

In another embodiment, the arrays can be used to monitor the time course of expression of one or more genes or proteins in the array. This can occur in various biological contexts, as disclosed herein, for example development of RA, progression of

20   RA, and processes, such a cellular transformation associated with RA.

The arrays are also useful for ascertaining the effect of the expression of a gene or protein on the expression of other genes or proteins in the same cell or in different cells. This provides, for example, for a selection of alternate molecular targets for therapeutic intervention if the ultimate or downstream target cannot be regulated.

25   The arrays are also useful for ascertaining differential expression patterns of one or more genes or proteins in normal and abnormal cells. This provides a battery of genes or proteins that could serve as a molecular target for diagnosis or therapeutic intervention.

VII. Predictive Medicine

30   The present invention pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trails are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining the level of expression of polypeptides or nucleic acids corresponding to one

or more markers of the invention, in order to determine whether an individual is at risk of developing RA. Such assays can be used for prognostic or predictive purposes to thereby prophylactically treat an individual prior to the onset of the RA.

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs or other compounds administered either to inhibit RA or to treat or prevent any other disorder {*i.e.* in order to understand any RA progressive effects that such treatment may have}) on the expression or activity of a marker of the invention in clinical trials. These and other agents are described in further detail in the following sections.

A. Diagnostic Assays

An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid corresponding to a marker of the invention in a biological sample involves obtaining a biological sample (*e.g.* a RA-associated body fluid) from a test subject and contacting the biological sample with a compound or an agent capable of detecting the polypeptide or nucleic acid (*e.g.*, mRNA, genomic DNA, or cDNA). The detection methods of the invention can thus be used to detect mRNA, protein, cDNA, or genomic DNA, for example, in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of a polypeptide corresponding to a marker of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence, liquid and gas chromatography, mass spectroscopy, and nuclear magnetic resonance, as well as other imaging technologies. *In vitro* techniques for detection of genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of a polypeptide corresponding to a marker of the invention include introducing into a subject a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

A general principle of such diagnostic and prognostic assays involves preparing a sample or reaction mixture that may contain a marker, and a probe, under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways.

For example, one method to conduct such an assay would involve anchoring the marker or probe onto a solid phase support, also referred to as a substrate, and detecting target marker/probe complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, a sample from a subject, which is to be assayed for

5   presence and/or concentration of marker, can be anchored onto a carrier or solid phase support. In another embodiment, the reverse situation is possible, in which the probe can be anchored to a solid phase and a sample from a subject can be allowed to react as an unanchored component of the assay.

There are many established methods for anchoring assay components to a solid

10   phase. These include, without limitation, marker or probe molecules which are immobilized through conjugation of biotin and streptavidin. Such biotinylated assay components can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In certain

15   embodiments, the surfaces with immobilized assay components can be prepared in advance and stored.

Other suitable carriers or solid phase supports for such assays include any material capable of binding the class of molecule to which the marker or probe belongs. Well-known supports or carriers include, but are not limited to, glass, polystyrene, nylon,

20   polypropylene, nylon, polyethylene, dextran, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

In order to conduct assays with the above mentioned approaches, the non-immobilized component is added to the solid phase upon which the second component is anchored. After the reaction is complete, uncomplexed components may be removed (*e.g.*,

25   by washing) under conditions such that any complexes formed will remain immobilized upon the solid phase. The detection of marker/probe complexes anchored to the solid phase can be accomplished in a number of methods outlined herein.

In a preferred embodiment, the probe, when it is the unanchored assay component, can be labeled for the purpose of detection and readout of the assay, either directly or

30   indirectly, with detectable labels discussed herein and which are well-known to one skilled in the art.

It is also possible to directly detect marker/probe complex formation without further manipulation or labeling of either component (marker or probe), for example by utilizing the technique of fluorescence energy transfer (see, for example, Lakowicz *et al.*,

U.S. Patent No. 5,631,169; Stavrianopoulos, *et al.*, U.S. Patent No. 4,868,103). A fluorophore label on the first, 'donor' molecule is selected such that, upon excitation with incident light of appropriate wavelength, its emitted fluorescent energy will be absorbed by a fluorescent label on a second 'acceptor' molecule, which in turn is able to fluoresce

5   due to the absorbed energy. Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial relationships between the

10   molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (*e.g.*, using a fluorimeter).

In another embodiment, determination of the ability of a probe to recognize a

15   marker can be accomplished without labeling either assay component (probe or marker) by utilizing a technology such as real-time Biomolecular Interaction Analysis (BIA) (see, *e.g.*, Sjolander, S. and Urbaniczky, C., 1991, *Anal. Chem.* 63:2338-2345 and Szabo *et al.*, 1995, *Curr. Opin. Struct. Biol.* 5:699-705). As used herein, "BIA" or "surface plasmon resonance" is a technology for studying biospecific interactions in real time, without

20   labeling any of the interactants (*e.g.*, BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

25   Alternatively, in another embodiment, analogous diagnostic and prognostic assays can be conducted with marker and probe as solutes in a liquid phase. In such an assay, the complexed marker and probe are separated from uncomplexed components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation. In differential centrifugation,

30   marker/probe complexes may be separated from uncomplexed assay components through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A.P., 1993, *Trends Biochem Sci.* 18(8):284-7). Standard chromatographic techniques may also be utilized to separate complexed molecules from uncomplexed ones. For example, gel

filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex may be separated from the relatively smaller uncomplexed components. Similarly, the relatively different charge properties of the marker/probe complex as

5   compared to the uncomplexed components may be exploited to differentiate the complex from uncomplexed components, for example through the utilization of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, *e.g.*, Heegaard, N.H., 1998, *J. Mol. Recognit.* Winter 11(1-6):141-8; Hage, D.S., and Tweed, S.A. *J Chromatogr B Biomed Sci Appl* 1997 Oct

10   10;699(1-2):499-525). Gel electrophoresis may also be employed to separate complexed assay components from unbound components (see, *e.g.*, Ausubel *et al.*, ed., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1987-1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In order to maintain the binding interaction during the electrophoretic process,

15   non-denaturing gel matrix materials and conditions in the absence of reducing agent are typically preferred. Appropriate conditions to the particular assay and components thereof will be well known to one skilled in the art.

In a particular embodiment, the level of mRNA corresponding to the marker can be determined both by *in situ* and by *in vitro* formats in a biological sample using methods

20   known in the art. The term "biological sample" is intended to include tissues, cells, biological fluids and isolates thereof, isolated from a subject, as well as tissues, cells and fluids present within a subject. Many expression detection methods use isolated RNA. For *in vitro* methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from RA-associated body fluids (see,

25   *e.g.*, Ausubel *et al.*, ed., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York 1987-1999). Additionally, large numbers of tissue samples can readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Patent No. 4,843,155).

The isolated mRNA can be used in hybridization or amplification assays that

30   include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays. One preferred diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected. The nucleic acid probe can be, for example, a full-length cDNA, or a portion thereof, such as an oligonucleotide

of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a marker of the present invention. Other suitable probes for use in the diagnostic assays of the invention are described herein. Hybridization of an mRNA with the probe indicates that

5   the marker in question is being expressed.

In one format, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s),

10   for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the markers of the present invention.

An alternative method for determining the level of mRNA corresponding to a marker of the present invention in a sample involves the process of nucleic acid

15   amplification, *e.g.*, by rtPCR (the experimental embodiment set forth in Mullis, 1987, U.S. Patent No. 4,683,202), ligase chain reaction (Barany, 1991, *Proc. Natl. Acad. Sci. USA*, 88:189-193), self sustained sequence replication (Guatelli *et al.*, 1990, *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.*, 1988,

20   *Bio/Technology* 6:1197), rolling circle replication (Lizardi *et al.*, U.S. Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. As used herein, amplification primers are

25   defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a

30   nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

For *in situ* methods, mRNA does not need to be isolated from the patient sample prior to detection. In such methods, a cell or tissue sample is prepared/processed using known histological methods. The sample is then immobilized on a support, typically a

glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the marker.

As an alternative to making determinations based on the absolute expression level of the marker, determinations may be based on the normalized expression level of the marker. Expression levels are normalized by correcting the absolute expression level of a marker by comparing its expression to the expression of a gene that is not a marker, *e.g.*, a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin gene, or epithelial cell-specific genes. This normalization allows the comparison of the expression level in one sample, *e.g.*, a patient sample, to another sample, *e.g.*, a non-RA sample, or between samples from different sources.

In a method of determining the abundance of a marker in a sample compared to the normal or control, *i.e.*, to identify markers that are differentially present, the relative abundance may be determined by normalizing the signal obtained upon detecting the marker in a sample by reference to a suitable background parameter, *e.g.*, to the total protein in the sample being analyzed to an invariant marker, *i.e.*, a marker whose abundance is known to be similar in the sample being compared, or to the total signal detected from all proteins in the sample.

Alternatively, the expression level can be provided as a relative expression level. To determine a relative expression level of a marker, the level of expression of the marker is determined for 10 or more samples of normal versus RA patient sample isolates, preferably 50 or more samples, prior to the determination of the expression level for the sample in question. The mean expression level of each of the genes assayed in the larger number of samples is determined and this is used as a baseline expression level for the marker. The expression level of the marker determined for the test sample (absolute level of expression) is then divided by the mean expression value obtained for that marker. This provides a relative expression level.

Preferably, the samples used in the baseline determination will be from RA or from non-RA patient samples. The choice of the cell source is dependent on the use of the relative expression level. Using expression found in normal tissues as a mean expression score aids in validating whether the marker assayed is RA specific (versus normal cells). In addition, as more data is accumulated, the mean expression value can be revised, providing improved relative expression values based on accumulated data. Expression data from RA patient samples provides a means for grading the severity of the RA state.

In another embodiment of the present invention, a polypeptide corresponding to a marker is detected. A preferred agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide corresponding to a marker of the invention, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more

5   preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')$_2$) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect

10   labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

Proteins from patient samples can be isolated using techniques that are well known to those of skill in the art. The protein isolation methods employed can, for example, be

15   such as those described in Harlow and Lane (Harlow and Lane, 1988, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

A variety of formats can be employed to determine whether a sample contains a protein that binds to a given antibody. Examples of such formats include, but are not

20   limited to, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis, protein arrays, antibody arrays, enzyme linked immunoabsorbant assay (ELISA), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays and protein A

25   immunoassays. A skilled artisan can readily adapt known protein/antibody detection methods for use in determining whether a patient sample expresses a marker of the present invention.

In one format, antibodies, or antibody fragments, can be used in methods such as Western blots, antibody arrays or immunofluorescence techniques to detect the expressed

30   proteins. In such uses, it is generally preferable to immobilize either the antibody or proteins on a solid support. Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and

modified celluloses, polyacrylamides, gabbros, and magnetite. For protein and antibody arrays see, *e.g.* US 6,365,418, US 6,329,209, US 6,406,921, US 6,475,808 and US 6,475,809.

One skilled in the art will know many other suitable carriers for binding antibody or antigen, and will be able to adapt such support for use with the present invention. For example, protein isolated from a patient sample can be run on a polyacrylamide gel electrophoresis and immobilized onto a solid phase support such as nitrocellulose. The support can then be washed with suitable buffers followed by treatment with the detectably labeled antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means.

The invention also encompasses kits for detecting the presence of a polypeptide or nucleic acid corresponding to a marker of the invention in a biological sample (*e.g.* an RA-associated body fluid). Such kits can be used to determine if a subject is suffering from or is at increased risk of developing RA. For example, the kit can comprise a labeled compound or agent capable of detecting a polypeptide or an mRNA encoding a polypeptide corresponding to a marker of the invention in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (*e.g.*, an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for interpreting the results obtained using the kit.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (*e.g.*, attached to a solid support) which binds to a polypeptide corresponding to a marker of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable label.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, *e.g.*, a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide corresponding to a marker of the invention or (2) a pair of primers useful for amplifying a nucleic acid molecule corresponding to a marker of the invention. The kit can also comprise, *e.g.*, a buffering agent, a preservative, or a protein stabilizing agent. The kit can further comprise components necessary for detecting the detectable label (*e.g.*, an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample. Each component of the kit can be enclosed within an individual container and all

of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit.

B. Pharmacogenomics

Agents or modulators which have a stimulatory or inhibitory effect on expression of a marker of the invention can be administered to individuals to treat (prophylactically or therapeutically) RA in the patient. In conjunction with such treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the level of expression of a marker of the invention in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, *e.g.*, Linder (1997) *Clin. Chem.* 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body are referred to as "altered drug action." Genetic conditions transmitted as single factors altering the way the body acts on drugs are referred to as "altered drug metabolism". These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These

polymorphisms are expressed in two phenotypes in the population, the extensive

metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among

different populations. For example, the gene coding for CYP2D6 is highly polymorphic

and several mutations have been identified in PM, which all lead to the absence of

5   functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently

experience exaggerated drug response and side effects when they receive standard doses.

If a metabolite is the active therapeutic moiety, a PM will show no therapeutic response, as

demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed

metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do

10   not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has

been identified to be due to CYP2D6 gene amplification.

Thus, the level of expression of a marker of the invention in an individual can be

determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment

of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of

15   polymorphic alleles encoding drug-metabolizing enzymes to the identification of an

individual's drug responsiveness phenotype. This knowledge, when applied to dosing or

drug selection, can avoid adverse reactions or therapeutic failure and thus enhance

therapeutic or prophylactic efficiency when treating a subject with a modulator of

expression of a marker of the invention.

20   This invention also provides a process for preparing a database comprising at least

one of the markers. For example, the polynucleotide sequences are stored in a digital

storage medium such that a data processing system for standardized representation of the

genes that identify a RA cell is compiled. The data processing system is useful to analyze

gene expression between two cells by first selecting a cell suspected of being of a

25   neoplastic phenotype or genotype and then isolating polynucleotides from the cell. The

isolated polynucleotides are sequenced. The sequences from the sample are compared

with the sequence(s) present in the database using homology search techniques. Greater

than 90%, more preferably greater than 95% and more preferably, greater than or equal to

97% sequence identity between the test sequence and the polynucleotides of the present

30   invention is a positive indication that the polynucleotide has been isolated from a RA cell

as defined above.

In an alternative embodiment, the polynucleotides of this invention are sequenced

and the information regarding sequence and in some embodiments, relative expression, is

stored in any functionally relevant program, e.g., in Compare Report using the SAGE

software (available though Dr. Ken Kinzler at John Hopkins University). The Compare Report provides a tabulation of the polynucleotide sequences and their abundance for the samples normalized to a defined number of polynucleotides per library (say 25,000). This is then imported into MS-ACCESS either directly or via copying the data into an Excel

5   spreadsheet first and then from there into MS-ACCESS for additional manipulations. Other programs such as SYBASE or Oracle that permit the comparison of polynucleotide numbers could be used as alternatives to MS-ACCESS. Enhancements to the software can be designed to incorporate these additional functions. These functions consist in standard Boolean, algebraic, and text search operations, applied in various combinations to reduce a

10   large input set of polynucleotides to a manageable subset of a polynucleotide of specifically defined interest.

C. Monitoring Clinical Trials

Monitoring the influence of agents (*e.g.*, drug compounds) on the level of

15   expression of a marker of the invention can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent to affect marker expression can be monitored in clinical trials of subjects receiving treatment for RA. In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist,

20   peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of one or more selected markers of the invention in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression of the

25   marker(s) in the post-administration samples; (v) comparing the level of expression of the marker(s) in the pre-administration sample with the level of expression of the marker(s) in the post-administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent can be desirable to increase expression of the marker(s) to higher levels than detected, *i.e.*, to

30   increase the effectiveness of the agent. Alternatively, decreased administration of the agent can be desirable to decrease expression of the marker(s) to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

D. Surrogate Markers

The markers of the invention may serve as surrogate markers for one or more disorders or disease states or for conditions leading up to disease states, and in particular, RA. As used herein, a "surrogate marker" is an objective biochemical marker which
5   correlates with the absence or presence of a disease or disorder, or with the progression of a disease or disorder (*e.g.*, with the presence or absence of RA symptoms). While the presence or quantity of such markers is independent of the disease, changes in the absence or presence or quantity of the marker serve as a reflection of the disease or its treatment. Therefore, these markers may serve to indicate whether a particular course of treatment is
10 effective in lessening a disease state or disorder. Surrogate markers are of particular use when the presence or extent of a disease state or disorder is difficult to assess through standard methodologies (*e.g.*, early stage RA), or when an assessment of disease progression is desired before a potentially dangerous clinical endpoint is reached (*e.g.*, an assessment of cardiovascular disease may be made using cholesterol levels as a surrogate
15 marker, and an analysis of HIV infection may be made using HIV RNA levels as a surrogate marker, well in advance of the undesirable clinical outcomes of myocardial infarction or fully-developed AIDS). Examples of the use of surrogate markers in the art include: Koomen *et al.* (2000) *J. Mass. Spectrom.* 35: 258-264; and James (1994) *AIDS Treatment News Archive* 209.

20 The markers of the invention are also useful as pharmacodynamic markers. As used herein, a "pharmacodynamic marker" is an objective biochemical marker which correlates specifically with drug effects. The presence or quantity of a pharmacodynamic marker is not related to the disease state or disorder for which the drug is being administered; therefore, the presence or quantity of the marker is indicative of the presence
25 or activity of the drug in a subject. For example, a pharmacodynamic marker may be indicative of the concentration of the drug in a biological tissue, in that the marker is either expressed or transcribed or not expressed or transcribed in that tissue in relationship to the level of the drug. In this fashion, the distribution or uptake of the drug may be monitored by the pharmacodynamic marker. Similarly, the presence or quantity of the
30 pharmacodynamic marker may be related to the presence or quantity of the metabolic product of a drug, such that the presence or quantity of the marker is indicative of the relative breakdown rate of the drug *in vivo*. Pharmacodynamic markers are of particular use in increasing the sensitivity of detection of drug effects, particularly when the drug is administered in low doses. Since even a small amount of a drug may be sufficient to

activate multiple rounds of marker transcription or expression, the amplified marker may be in a quantity which is more readily detectable than the drug itself. Also, the marker may be more easily detected due to the nature of the marker itself; for example, using the methods described herein, antibodies may be employed in an immune-based detection

5 system for a protein marker, or marker-specific radiolabeled probes may be used to detect a mRNA marker. Furthermore, the use of a pharmacodynamic marker may offer mechanism-based prediction of risk due to drug treatment beyond the range of possible direct observations. Examples of the use of pharmacodynamic markers in the art include: Matsuda *et al.* US 6,033,862; Hattis *et al.* (1991) *Env. Health Perspect.* 90: 229-238;

10 Schentag (1999) *Am. J. Health-Syst. Pharm.* 56 Suppl. 3: S21-S24; and Nicolau (1999) *Am, J. Health-Syst. Pharm.* 56 Suppl. 3: S16-S20.

The markers of the invention are also useful as pharmacogenomic markers. As used herein, a "pharmacogenomic marker" is an objective biochemical marker which correlates with a specific clinical drug response or susceptibility in a subject (see, *e.g.*,

15 McLeod *et al.* (1999) *Eur. J. Cancer* 35(12): 1650-1652). The presence or quantity of the pharmacogenomic marker is related to the predicted response of the subject to a specific drug or class of drugs prior to administration of the drug. By assessing the presence or quantity of one or more pharmacogenomic markers in a subject, a drug therapy which is most appropriate for the subject, or which is predicted to have a greater degree of success,

20 may be selected. For example, based on the presence or quantity of RNA or protein for specific RA markers in a subject, a drug or course of treatment may be selected that is optimized for the treatment of the specific RA likely to be present in the subject. Similarly, the presence or absence of a specific sequence mutation in marker DNA may correlate with drug response. The use of pharmacogenomic markers therefore permits the

25 application of the most appropriate treatment for each subject without having to administer the therapy.

EXPERIMENTAL PROTOCOL

In normal human joints, a thin film of synovial fluid covers the surfaces of synovium and cartilage within the joint space. Only in disease or injury does the volume

30 of this fluid increase to produce a clinically apparent effusion that may be aspirated easily for study. For this reason, most knowledge of human synovial fluid comes not from normal subjects, but from patients with joint disease or injury.

The intrasynovial concentration of any protein represents the net contributions of plasma concentration, synovial blood flow, microvascular permeability, and lymphatic removal. In addition, specific proteins may be produced or consumed within the joint space. For example, lubricin is normally synthesized within synovial cells and released

5   into synovial fluid where it facitilates boundary layer lubrication of the cartilage-on-cartilage bearing. In disease, additional proteins may be synthesized (*e.g.*, IgG rheumatoid factor in RA) or released from inflammatory cells or articular tissues. Simkin, PA, *et al.*, 1995, *Curr Opin Rheumatol.* 7:346-351. In contrast, intra-articular proteins may be depleted by local consumption, as are complement components in rheumatoid disease.

10   The markers of the present invention were thus initially identified in the synovial fluid of human patients who have been diagnosed with either erosive or non-erosive RA. The markers were identified by mass spectrometry after synovial fluid samples were subjected to digestion of hyaluronic acid followed by a series of protein depletion and fractionation steps to enrich subsets of proteins from the original synovial fluid samples.

15   Some of these identified markers were then validated in serum of patients who have been diagnosed with either erosive or non-erosive RA. The following materials and methods describe the fundamental technologies/methodologies that were used in the marker discovery process.

20   **Patients**

The synovial fluid and serum samples of patients were sorted into erosive and non-erosive samples by the following inclusion criteria: 1) diagnosis of RA via the accepted American College of Rheumatology criteria, and 2) the age of onset of symptoms between 25-50. The exclusion criteria consisted of 1) a history or evidence (X-ray) of osteo

25   arthritis, 2) systemic lupus erythematosus (SLE), 3) psoriasis or psoriatic arthritis, and 4) JRA, except in those cases with elevated rheumatoid factor.

The study design involved synovial fluid and serum samples from subjects with erosive RA that had "late" disease, wherein the onset of the symptoms was five years or more. Likewise, the study design also included subjects with non-erosive RA with "new"

30   disease, wherein the onset of the symptoms was less than five years, and subjects with non-erosive RA with "late" disease, wherein the onset of the symptoms was five years or more.

I. Synovial Fluid Studies

Methods

Erosive and non-erosive synovial fluid patient samples were digested with a fungal hyaluronidase enzyme, which allowed for nearly complete digestion of hyaluronic acid

5 · present in the synovial fluid samples. Then, in order to reduce the complexity of the protein mixture, predominant protein species, or highly abundant proteins, such as albumin and immunoglobulins, were removed from the samples. This depletion step involved running the synovial fluid samples over protein G and Cibacron blue resins, respectively. To further increase the number of total detectable proteins by mass spectrometry, the

10 depleted samples were then also treated with Protein L to remove kappa light chain containing antibodies that were present in the protein mixture. The depleted synovial fluid samples were introduced into 8M urea, then reduced and alkylated to reduce endogenous protein aggregates. The samples were then subsequently subjected to sizing exchange chromatography (SEC) to fractionate the samples by size. Fractionated protein samples

15 were then subjected to trypsin digestion and prepared for online reverse phase liquid chromatography prior to introduction into the ion trap mass spectrometer by nanospray electrospray ionization. For the more complex protein fractions, 20-centimeter columns and 3-hour gradients were run in conjunction with two-dimensional chromatography with salt step elutions prior to reverse phase separation introduction of the eluted sample

20 peptides into the mass spectrometer. For the less complex fractions, 10-centimeter columns and a 2-hour gradient with single-dimension chromatography was used to introduce sample into the mass spectrometer.

Protein Identification

25 The raw output of mass spectra was processed using software proprietary to Millennium Pharmaceuticals Inc., called SpectrumMill. The output obtained from SpectrumMill provides an analysis of proteins present in individual SEC fractions of the original SF samples. Spectra were searched against a non-redundant NCBI mammals database. Validation of peptides was performed by either using SpectrumMill's

30 "Automatic Validation of MS-Tag Results", by validating spectra manually or by running 1D SDS PAGE gels on depleted synovial fluid samples. In all, a total of 490 proteins (Table 1) were identified in all 10 synovial fluid samples, namely five erosive synovial fluid samples and 5 non-erosive samples.

Discovery of newly-identified markers (Table 5) from the Millennium EST contig database. Novel Millennium EST's and public EST's from the dbEST data base were clustered and assembled into contigs using tools supplied by DoubleTwist, Inc. Each contig was translated into all six reading frames. Protein sequences were removed if they

5   did not represent open reading frames (ORF's) of sufficient length. Spectra that had not produced valid tags to known proteins in the non-redundant mammals protein database were searched against the translated contig database using the SpectrumMill software. Entries were selected if they showed differential expression between the erosive and non-erosive sample sets. Entries were removed if 1) they showed 98% identity to known

10   proteins in the non-redundant mammals protein database by BLAST analysis and 2) if the identified peptides were represented in Table 1. If the entry was not highly identical to a known protein in the non-redundant mammals protein database but was identified only by peptides that were represented in proteins that were listed in Table 1, the entry was also removed. The annotations of the remaining entries were created from dbEST and GenPept

15   entries or inferred from BLAST results.

II. Serum Studies (S100 Proteins)

Materials

The triple quadrupole mass spectrometer (API-3000 equipped with Analyst

20   software version 1.1, Applied Biosystems, Foster City, CA) has nearly a 100% duty cycle and greater sensitivity than ion trap mass spectrometers when used for high throughput peptide analysis in multiple reaction monitoring (MRM) experiments. In order to use the triple quadrupole mass spectrometer to detect the endogenous/native tryptic peptides that represent peptide fragments of the calgranulin proteins of interest, it is necessary to create

25   a set of "tune files" in the triple quadrupole mass spectrometer. These files serve to identify the mass/charge ratios and other physical parameters, including e.g. optimized voltages that allow an operator to identify the best fragment/transition ions that are unique to the tryptic peptides one seeks to identify in serum. In order to create tune files to a specific tryptic peptide, one prepares a synthetic version of that peptide and uses that

30   synthetic peptide to select a set of optimized parameters that are unique to the molecule. These optimized parameters are then programmed into the triple quad mass spectrometer where they serve as reference standards for the identification of matching endogenous tryptic peptides in samples of processed serum. It is this set of physical parameters

including the mass to charge ration of the parent ion or starting tryptic peptide and the fragment ions that are produced by collision associated dissociation that are measured by the triple quad mass spectrometer.

In this application, the mass spectrometer was tuned using synthetic peptides based
5   on the selected theoretical tryptic cleavage sites of candidate proteins. The following tryptic peptide sequences were used for Calgranulin A (S100 A8 / M44), Calgranulin B (S100 A9 / M31) and Calgranulin C (S100A12 / M60):

Calgranulin A = S100 A8: Tryptic fragment LLETECPQYIR

Calgranulin B = S100 A9; Tryptic fragment LGHPDTLNQGEFK

10   Calgranulin C = S100 A12; Tryptic fragments ELANTIK and GHFDTLSK

For peptides containing leucine(s) within their amino acid sequences, a corresponding synthetic peptide with a uniformly labeled [^{13}C (U)]-leucine was synthesized. This stable heavy isotope-labeled peptide was used as the internal standard for quantification as shown below. The instrument equipped with a nanospray source
15   (James A. Hill Instrument Services, Arlington, MA) was tuned to each synthetic peptide for a set of selected transition ions. This was accomplished by infusing a mixture of pure synthetic peptides that were diluted to a final concentration of 500fmol/μL in acetonitrile: 0.1% formic acid (3:7) with a syringe pump (Harvard Apparatus, Holliston, MA) set to 0.2μL/min. The mass to charge ratios (m/z) of these transition ions observed from ^{12}C
20   synthetic and ^{13}C isotope-labeled peptides and their optimized voltages were transcribed respectively into a 110 minute liquid chromatography synchronized method (LCsync) in the Analyst 1.1 software. A reverse phase liquid chromatography (RPLC) method was programmed into the coupled Agilent 1100 HPLC system (Agilent Technologies, Waldbronn, Germany). This system consisted of a binary pump and micro-well plate
25   sampler. Verification of the system, selection of the best-ionizing peptides, and the limit of detection (LOD) was determined by injecting various levels (0 to 500fmol/μL) of the heavy and light synthetic peptides onto a 150mm x 0.075mm PicoFrit column (New Objective, Inc., Woburn, MA) packed with either Magic C$_{18}$ media, 5μm particles (200Å pore size) (Michrom Bioresources, Inc., Auburn, CA) or Vydac C$_{18}$ media, 10μm particles
30   (300Å pore size) (Vydac, Hesperia, CA). Peptides were eluted from the column using an acetonitrile gradient (5% to 50% in 0.1% formic acid) run over 50 minutes at a final flow rate, post capillary splitter, of 200nl/min.

Methods

Pooled serum samples (5 individuals/pool, 0.25mL/individual) from healthy individuals and patients diagnosed with non-erosive or erosive rheumatoid arthritis (RA), were depleted of three abundant serum proteins using three types of affinity
5   chromatography columns: a hemoglobin column for haptoglobin; HiTrap protein G columns for IgG removal; and Hitrap cibacron blue columns for removal of human serum albumin. After depletion of abundant proteins, samples were fractionated using size-exclusion chromatography (SEC).

10   *Preparation of Hemoglobin Column*

40 mg of hemoglobin (Sigma, cat# H0267) was dissolved in 1.5 mL of coupling buffer (0.2 M $NaHCO_3$, 0.5 M NaCl, pH 8.3). The solution was then desalted using a HiTrap Desalting column (Amersham Biosciences, cat# 17-1408-01) with the coupling buffer as the running buffer. The volume was adjusted to a concentration of 20 mg/mL of
15   hemoglobin. A 1 mL HiTrap NHS-activated HP column (Amersham Biosciences, cat#17-0716-01) was washed with 5 mL of ice-cold 1 mM HCl, then immediately injected with 0.5 mL of the hemoglobin solution and incubated at room temperature (RT) for a minimum of 30 minutes. The column was washed with 5 mL of deactivation buffer (0.5 M ethanolamine, 0.5 M NaCl, pH 8.3) and incubated at RT for another 30 minutes.
20   Finally the column was washed with 10 mL of depletion buffer (200 mM NH_4HCO_3, pH 7.8).

Depletion of Serum Samples

The three affinity columns were assembled in tandem in the following order: a
25   hemoglobin column (1 ml) prepared as above; three protein G columns (1 mL each) (Amersham Biosciences, cat# 17-0404-01); and one 5 mL Cibacron Blue column (Amersham Biosciences, cat# 17-0413-01). The columns were washed with 90 mL of depletion buffer (200 mM NH_4HCO_3, pH 7.8).

1.25 mL of serum was diluted with the depletion buffer to a final volume of 3 mL,
30   which was then loaded onto the assembled columns and washed with the depletion buffer (200 mM NH_4HCO_3, pH 7.8) at the flow rate of 1 mL/min. The flow-through was collected until A_{280} returned to the baseline. The flow-through was freeze-dried for 48 hours, and the dry powder was stored at -20 °C for the next step.

SEC Fractionation of the Depleted Serum Samples

The lyophilized samples were dissolved in 2.0 mL of 8M urea, 200 mM ammonium bicarbonate. Six mgs of DTT was added (20mM final concentration) and the mixture was incubated for 60 minutes at 60°C. After cooling to RT, 18.5 mg of

5   iodoacetamide (final concentration 50 mM) was added to alkylate peptides. After 30 minutes of incubation in the dark at RT, the alkylated sample was immediately loaded onto the SEC column.

The column (Superdex 200 16/60, Amersham Biosciences, cat# 17-1069-01) was pre-equilibrated with 240 mL of the running buffer (200 mM NH_4HCO_3, 8 M urea). With

10 a flowrate of 0.5 mL/min, 5 mL fractions were collected 76 minutes after injection. Proteins with molecular weights below 40 kDa were collected in fractions #5 to #12.

The fractions were concentrated and diluted with water to final volumes of approximately 100 µL, with final buffer composition of 50 mM NH_4HCO_3 and 2 M urea. Centriplus YM-3 and CentriconYM-3 (Millipore, cat# 4420 and 4203) were used for

15 concentrating the fraction.

Preparation of Samples for Multiple Reaction Monitoring

Tubes containing fractionated proteins that spanned the native molecular weight range of candidate proteins of interest (fractions 7, 8 & 9) were pooled and subjected to

20 trypsin digestion. After digestion by trypsin, a ^{13}C-signature synthetic peptide representing selected known tryptic cleavage fragments of the candidate markers was added to the mixture at a final concentration of 500 fmol/µl. The addition of this "standard" and its detection by MRM can be used to establish a semi-quantitative measure of the levels of tryptic peptides derived from endogenous candidate proteins in patient serum samples.

25 The proteins S100 A8, -A9, -A12 have molecular weights within the 10,400 to 13,200 dalton range. Based upon the SEC chromatography of protein standards, pooling of SEC fractions 7, 8, and 9 facilitated the collection of these S100 proteins into one analyzed pool. A one microliter aliquot of each SEC pool was injected sequentially in triplicate with blank and standard samples onto the same microcapillary C_{18} column. The

30 extracted ion chromatogram (XIC) and total ion chromatogram (TIC) were analyzed for the tryptic peptides native to the serum samples (designated ^{12}C) and ^{13}C-labeled internal standard peptide of each target protein. The ratio of the TIC for the native peptide and the ^{13}C labeled peptide, the protein molecular weight, and fraction volumes were used

according to the following equation to calculate the target protein concentration per milliliter of serum: $((^{12}C\ TIC/^{13}C\ TIC)(500)(\text{fraction volume } (\mu L))(\text{protein MW}))/1,000,000 = ng/mL$.

5   **Results**

'As described above, pooled SEC fractions (7, 8 & 9) taken from healthy individuals, patients with erosive rheumatoid arthritis or non-erosive arthritis, were analyzed in the triple quadrupole mass spectrometer for the presence of tryptic peptides representing fragments of the endogenous proteins calgranulin A, -B and -C.

10   Three separate measurements were taken for each candidate peptide and the average ng/ml values were calculated.

Calgranulin A = S100 A8 (M44)

It was determined that the concentration of S100 A8 was 3 to 4-fold higher in pooled

15   serum samples taken from erosive RA patients as compared to pooled serum from healthy individuals or patients diagnosed with non-erosive RA (refer to Table 6).

Calgranulin B = S100 A9 (M31)

The concentration of S100 A9 was on average 14-fold higher in pooled serum samples

20   taken from patients with erosive RA as compared to pooled serum samples taken from healthy individuals. S100 A9 concentration was also higher in samples of patients with erosive RA as compared to pooled serum samples taken from patients with non-erosive RA (refer to Table 7).

25   Calgranulin C = S100 A12 (M60)

Two different peptides were measured to determine the concentration of S100 A12. The concentrations of S100A12 were determined to be 15-fold or higher in pooled serum samples taken from patients with erosive RA versus pooled serum samples taken from healthy individuals (refer to Table 8A). S100A12 was determined to be 8 to 9-fold higher

30   in pooled serum samples taken from patients with erosive RA versus pooled serum samples taken from patients with non-erosive RA (refer to Tables 8A and 8B).

Thus, three members of the S100 protein family, S100 A8, S100 A9, and S100 A12, are significantly elevated in the pooled serum of rheumatoid arthritis patients as

compared to the pooled serum of healthy patients.   Also, each of these proteins appears to be present in higher concentrations in patients with erosive RA versus non-erosive RA.

III. Serum Studies (SAA protein)

5   Serum amyloid A is an acute phase protein and it is known to be elevated in different diseases including rheumatoid arthritis. During the discovery phase of research, levels of this protein were identified as being increased in the synovial fluid of patients with erosive disease. For the determination of serum amyloid A (SAA) the N-Latex SAA assay from Dade Behring (Id.No. OQMP G11) was used and measured on the Behring

10   Nephelometer II (Dade Behring) according to the package insert.

Briefly, this is a homogeneous immunoassay using polystyrene particles coated with antibodies raised against human SAA. Serum or synovial fluid samples are automatically diluted 1:400 with N Diluent (Dade Behring) by the instrument and the specific reagents are added automatically. After mixing of the samples with the

15   polystyrene particles, agglutination takes place and the intensity of the scattered light is measured. The scattered light intensity is dependent on the concentration of the analyte in the sample and consequently its concentration can be determined by comparison with dilutions of a standard of known concentration. The sensitivity of the assay is 3 mg/l SAA.

20   **Results**

The results of this immunoassay analysis demonstrated that SAA is significantly increased in the serum of patients with rheumatoid arthritis versus healthy individuals and a small set of disease controls (osteoarthritis (6), chondrocalcinosis (3 patients), or psoriatic arthritis (1 patient). Tables 9A, 9B, and 9C list the average protein concentration

25   values in human serum and the significance test results of the serum amyloid A (SAA) protein. Table 9A lists the average SAA concentration (mg/L) and the number of patient samples analyzed. The one-tail t-test values in table 9B are provided to demonstrate that the SAA concentration between erosive and non-erosive serum samples and the disease and healthy controls are significantly different, accounting for assay variability. Table 9C

30   shows that the significance test comparison of SAA concentration values between erosive and non-erosive patient serum samples are also significantly from different populations when assay variability is considered.

Summary of the Data

Tables 1-5 list the markers obtained using the foregoing protocol. These Tables list the markers designated with a name ("Marker"), the name the gene is commonly known by, if applicable ("Gene Name"), the data generated for each synovial fluid sample (E =

5   Erosive and N = Non-Erosive), the corresponding molecular weight ("MW (Da)"), the corresponding GenBank GI Number ("GI number"), the sequence listing identifier of the cDNA sequence of a nucleotide transcript encoded by or corresponding to the marker ("SEQ ID NO (nts)") and the sequence listing identifier of the amino acid sequence of a protein encoded by or corresponding to the marker ("SEQ ID NO (AA)"). Tables 6-9 list

10   the results obtained in serum samples for four of the markers initially identified in synovial fluids. Tables 6, 7, 8A and 8B list the "Sample Type", the protein concentration after the "1st Injection", "2nd Injection" and "3rd Injection", the "Average" of the three injections, as well as the Standard Deviation "% RSD". Table 9A, 9B and 9C list the average concentration of SAA protein in samples of healthy, disease control, non-erosive and

15   erosive human serum, one tail t-tests comparison of the SAA concentrations of erosive and non-erosive samples to healthy and disease controls, and the one tail t-test comparison of SAA concentrations in erosive and non-erosive serum samples.

Table 1 lists all of the markers of the invention (and comprises markers listed in Tables 2 - 5), which are over-expressed in patients with RA compared to normal

20   individuals (*i.e.*, individuals who are not afflicted with RA). Table 2 lists markers that are newly-associated with RA and are over-expressed in patients diagnosed with erosive or non-erosive RA. Table 3B lists preferred markers of the present invention. Table 3B lists markers which are over-expressed in serum samples of patients with RA compared to normal individuals (*i.e.*, individuals who are not afflicted with RA). Table 4 lists markers

25   which are especially useful for new detection ("screening") and detection of recurrence of RA. Table 5 lists newly-identified markers that are over-expressed in patients with RA. Table 6 lists protein concentration of Calgranulin A in a pool of SEC fractions 7, 8 and 9 of human serum. Table 7 lists protein concentration of Calgranulin B in a pool of SEC fractions 7, 8 and 9 of human serum. Tables 8A and 8B list protein concentration of

30   Calgranulin C in a pool of SEC fractions 7, 8 and 9 of human serum. Table 9 lists the average protein concentration values in human serum and the significance test results of the serum amyloid A (SAA) protein.

Other Embodiments

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following 5 claims.

The contents of all references, patents, published patent applications, and database records cited throughout this application are hereby incorporated by reference.

10^{10} and above +++
10^8 to 10^{10} ++
10^6 to 10^8 +
0 -

Table 1

Marker	Gene Name	E_51 Br38	E_59 Br26	E_63 Br35	E_67 Br42	E_70 Br43	N_52 Br29	N_54 Br28	N_58 Br34	N_65 Br36	N_66 Br39	MW (Da)	GI number	SEQ ID NO (nts)	SEQ ID NO (AA)
M1	HAPTOGLOBIN-2 PRECURSOR	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	45205.6	4826762		
M2	SEROTRANSFERRIN PRECURSOR (SIDEROPHILIN) (BETA-1-METAL BINDING GLOBULIN)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	77050.4	4557871		
M3	SERUM ALBUMIN PRECURSOR	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	69367.1	4502027		
M4	COMPLEMENT C3 PRECURSOR [CONTAINS: C3A ANAPHYLATOXIN]	++	+++	+++	+++	+++	+++	+++	+++	+++	+++	187165	4557385		
M5	proapolipoprotein	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	28961.7	178775		
M6	ALPHA-1-ANTITRYPSIN PRECURSOR (ALPHA-1 PROTEASE INHIBITOR) (ALPHA-1-ANTIPROTEINASE)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	46736.8	1703025		
M7	FIBRINOGEN ALPHA/ALPHA-E CHAIN PRECURSOR	+++	+++	+++	+++	+++	+++	+++	+++	++	+++	94973.5	4503689		
M8	FIBRINOGEN BETA CHAIN PRECURSOR	+++	++	+++	+++	+++	+++	+++	+++	++	++	55928.5	399492		
M9	vitamin D-binding protein	+++	+++	+++	+++	+++	+++	+++	+++	++	+++	52950	2119656		
M10	TRANSTHYRETIN PRECURSOR (PREALBUMIN) (TBPA) (TTR) (ATTR)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	15887.1	4507725		
	TRANSTHYRETIN PRECURSOR (PREALBUMIN) (TTR) (ATTR)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++		4507725		

M11	CERULOPLASMIN PRECURSOR (FERROXIDASE)	++	+++	+++	+++	+++	+++	++	+++	++	+++	122206	4557485
M12	apolipoprotein A-IV precursor	++	++	+++	+++	+++	+++	+++	+++	++	++	43384.7	178779
M13	alpha 1-acid glycoprotein	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	23366.1	1197209
M14	hemopexin	+++	+++	+++	+++	+++	+++	+++	+++	+++	++	49295.7	1335098
M15	macroglobulin alpha2	++	+++	++	+++	++	++	++	++	++	++	160807	224053
M16	alpha-2-glycoprotein 1, zinc	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	37720.3	184848
M17	IgG rearranged gamma chain	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	38194.4	14749011
M18	Ig lambda chain	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	24489.4	106653
M19	immunoglobulin alpha-1 heavy chain constant region	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	37583.8	184749
M20	HEMOGLOBIN BETA CHAIN	+++	+++	+++	+++	++	++	++	+++	-	+++	15998.5	4504349
M21	ANTITHROMBIN-III PRECURSOR (ATIII)	++	++	+++	+++	++	++	+	+++	++	++	52602.7	4502261
M22	AMBP PROTEIN PRECURSOR [CONTAINS: ALPHA-1-MICROGLOBULIN (PROTEIN HC) (COMPLEX-FORMING GLYCOPROTEIN HETEROGENEOUS IN CHARGE)	++	+++	+++	+++	+++	+++	++	+++	+++	+++	38999.7	4502067
M23	PROTHROMBIN PRECURSOR (COAGULATION FACTOR II)	++	+++	+++	+++	+++	++	++	+++	++	++	70037.3	4503635
M24	ALPHA-2-HS-GLYCOPROTEIN PRECURSOR (FETUIN-A) (ALPHA-2-Z-GLOBULIN) (BA-ALPHA-2-GLYCOPROTEIN)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	39324.9	4502005
M25	actin beta	++	+++	+++	++	+++	++	++	-	++	++	41737	4501885

M26	CLUSTERIN PRECURSOR (COMPLEMENT-ASSOCIATED PROTEIN SP-40,40) (COMPLEMENT CYTOLYSIS INHIBITOR) (CLI) (NA1 AND NA2) (APOLIPOPROTEIN J) (APO-J) (TRPM-2)	+++	++	++	++	++	++	+++	+++	+++	+++	++	52494.9	4502905
M27	bA120D12.1 (CD5 antigen-like (scavenger receptor cysteine rich family))	++	++	++	+++	++	+++	+++	+++	+++	++	38088.1	5174411
M28	fibrinogen gamma-B chain precursor	+++	++	+++	+++	++	+++	+++	++	+++	++	51511.9	71828
M29	polyubiquitin 4	++	++	+++	++	+	++	++	++	+	-	30303.9	2118964
M30	KININOGEN PRECURSOR (ALPHA-2-THIOL PROTEINASE INHIBITOR) [CONTAINS: BRADYKININ]	++	-	-	-	-	++	++	-	-	-	71945.7	125507
M31	CALGRANULIN B (MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 14) (MRP-14) (P14) (LEUKOCYTE L1 COMPLEX HEAVY CHAIN) (S100 CALCIUM-BINDING PROTEIN A9)	+++	+++	+++	+++	+++	+++	+++	++	++	++	13242.1	4506773
M32	PLASMA RETINOL-BINDING PROTEIN PRECURSOR (PRBP) (RBP)	+++	++	++	+++	+++	+++	+++	+++	+++	+++	22868	5803139
M33	Ig mu chain precursor, membrane-bound (clone 201)	++	+++	++	+++	++	+++	++	++	++	++	68510.5	87919
M34	APOLIPOPROTEIN A-II PRECURSOR (APO-AII)	++	+++	+++	+++	+++	+++	+++	+++	+++	+++	11175.1	4502149
M35	LEUCINE-RICH ALPHA-2-GLYCOPROTEIN (LRG)	++	+++	++	+++	+++	+++	++	+++	++	++	34346.6	112908

	Protein											
M36	dJ34F7.4 (complement component 4A)	++	-	++	++	++	+	-	++	++	192753	7671645
M37	similar to phosphoglycerate mutase 1 (brain)	++	++	++	++	++	-	-	+	++	28850.2	15301114
M38	alpha-1-antichymotrypsin precursor	-	++	+++	++	++	+	-	-	++	45482.4	177933
M39	ALPHA-1B-GLYCOPROTEIN	++	++	++	++	++	+++	++	++	++	51941	112892
M40	HEMOGLOBIN ALPHA CHAIN	++	+++	+++	++	++	+++	+++	-	+++	152257.6	4504345
M41	lipoprotein CIII	++	++	++	+++	++	+++	+++	+++	++	8764.7	224917
M42	TETRANECTIN PRECURSOR (TN) (PLASMINOGEN-KRINGLE 4 BINDING PROTEIN)	++	++	+++	+++	+++	++	+++	+++	+++	22567	4507557
M43	amyloid related serum protein SAA	++	++	+++	+++	+++	++	-	++	+	11682.8	4506777
M44	CALGRANULIN A (MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 8) (MRP-8) (CYSTIC FIBROSIS ANTIGEN) (CFAG) (P8) (LEUKOCYTE L1 COMPLEX LIGHT CHAIN) (S100 CALCIUM-BINDING PROTEIN A8)	+++	++	+++	+++	+++	+++	+++	++	+	10834.6	14729628
M45	C-REACTIVE PROTEIN PRECURSOR	-	+++	++	+++	+++	+	-	++	++	25038.7	14728083
M46	RHO GDP-DISSOCIATION INHIBITOR 2 (RHO GDI2) (RHO-GDI BETA) (LY-GDI)	++	++	+++	++	++	++	++	+	++	22988.1	10835002
M47	PROFILIN I	+++	+++	+++	+++	++	++	++	++	++	15054.3	4826898
M48	IMMUNOGLOBULIN J CHAIN	+++	++	++	+++	+++	+++	+++	+++	+++	15594.6	400044
M49	APOLIPOPROTEIN D PRECURSOR	++	-	++	-	+++	++	+++	+++	++	21275.7	4502163
M50	inter-alpha-trypsin inhibitor family heavy chain-related protein	++	++	++	++	+++	+	++	++	-	103373	4096840

- 98 -

ID	Protein													
M51	14-3-3 PROTEIN BETA/ALPHA (PROTEIN KINASE C INHIBITOR PROTEIN-1) (KCIP-1) (PROTEIN 1054)	++	++	++	++	++	-	+	-	++	+	++	28082.5	4507949
M52	Ig G1 H Nie	+	++	++	-	-	-	-	-	-	-	-	49207.8	229601
M53	OSTEOPONTIN PRECURSOR (BONE SIALOPROTEIN 1) (URINARY STONE PROTEIN) (SECRETED PHOSPHOPROTEIN 1) (SPP-1) (NEPHROPONTIN) (UROPONTIN)	-	++	++	++	++	-	++	-	-	++	-	354422.9	14724978
M54	AFAMIN PRECURSOR (ALPHA-ALBUMIN) (ALPHA-ALB)	++	-	++	-	++	++	++	-	++	+	++	69069.6	4501987
M55	TRIOSEPHOSPHATE ISOMERASE (TIM)	++	++	-	-	++	++	-	-	-	++	++	26669.6	4507645
M56	pre-serum amyloid P component	++	-	-	-	++	+++	-	-	-	-	-	25397.3	337758
M57	COMP_HUMAN	++	++	++	-	+	++	++	++	-	-	-	89149	2623750
M58	prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)	-	++	++	-	-	++	++	-	++	++	-	50307.8	15298143
M59	VITRONECTIN PRECURSOR (SERUM SPREADING FACTOR) (S-PROTEIN) [CONTAINS: SOMATOMEDIN B]	++	++	++	++	++	++	++	++	+++	++	++	54305.9	14774022
M60	CALGRANULIN C (S100 A12 protein)	++	+++	++	++	++	++	++	-	-	-	-	10443.9	2146972
M61	cofilin 1 (non-muscle)	++	++	++	++	++	++	-	++	++	+++	+++	16811.7	14784011
M62	cathepsin B	++	++	++	++	++	-	-	-	-	-	-	37821.8	4503139
M63	plasmin (EC 3.4.21.7) precursor [validated]	+	+	-	++	+	++	+	+	++	+	+	90568.6	625234
M64	PLASMA GLUTATHIONE PEROXIDASE PRECURSOR (GSHPX-P)	++	++	++	+++	++	+++	++	++	+++	++	++	25505.6	121672
M65	lumican	-	++	++	++	++	-	+++	++	+++	++	++	38429.2	4505047

M66	apolipoprotein C-II	++	+	-	-	-	-	-	-	-	10183.5	2134777
M67	calmodulin 2 (phosphorylase kinase, delta)	++	++	++	++	+++	++	++	+++	++	16836.7	14250065
M68	THYMOSIN BETA-4	++	+	++	++	++	+	++	-	-	5062.7	14730886
M69	uracil DNA glycosylase	++	+	++	-	++	-	-	-	-	35492.9	35053
M70	defensin alpha-3 precursor, neutrophil-specific [validated]	+++	+++	+++	+++	++	-	++	-	-	10245	4885179
M71	CD14 antigen	-	-	++	++	++	-	++	-	-	40076.4	4557417
M72	peptidylprolyl isomerase (EC 5.2.1.8) A	++	++	++	++	++	-	-	++	++	19008.7	12804335
M73	similar to transgelin 2	++	++	++	++	++	+	-	-	++	24454	14728128
M74	BETA-2-GLYCOPROTEIN I PRECURSOR (APOLIPOPROTEIN H) (APO-H) (B2GPI) (BETA(2)GPI)	++	-	-	++	+++	++	++	++	-	38298.4	14711355
	(ACTIVATED PROTEIN C-BINDING PROTEIN) (APC INHIBITOR)											
M75	complement 9	-	-	-	-	-	++	+	-	-	60398.5	2258128
M76	alpha2 plasmin inhibitor	++	++	++	++	++	+	++	-	-	54596.1	11386143
M77	FICOLIN 3 PRECURSOR (COLLAGEN/FIBRINOGEN DOMAIN-CONTAINING PROTEIN 3) (COLLAGEN/FIBRINOGEN DOMAIN-CONTAINING LECTIN 3 P35) (HAKATA ANTIGEN)	-	-	++	-	-	++	++	-	-	32889.1	4504331
M78	glutathione transferase	++	++	++	-	-	++	-	-	-	23463.2	14766346
M79	Ig kappa chain	++	++	++	+++	+++	+++	++	++	++	10963.4	106717
M80	TRYPSIN PRECURSOR	++	++	++	++	++	++	++	++	++	24409.6	136429
M81	complement factor B	++	++	++	++	++	+++	++	-	-	85505.3	4502397
M82	CALGIZZARIN (S100C PROTEIN) (MLN 70)	++	++	++	++	++	-	+	-	-	11740.5	5032057

ID	Protein												
M83	BETA-2-MICROGLOBULIN PRECURSOR	++	+++	+++	+++	+++	+++	++	++	+++	++	13714.6	4757826
M84	CYSTEINE-RICH SECRETORY PROTEIN-3 PRECURSOR (CRISP-3) (SGP28 PROTEIN)	+	-	++	++	-	++	++	-	++	-	27630.5	5174675
M85	rearranged Ig kappa-chain	+	++	++	++	++	+++	-	-	++	++	12301	973416
M86	megakaryocyte stimulating factor	++	++	++	++	-	+++	++	++	++	++	151092	5031925
M87	inter-alpha-trypsin inhibitor heavy chain H1 precursor	+	-	+	++	++	+	+	+	++	++	101388	478685
M88	keratin 9, cytoskeletal	-	-	+	-	-	+	+	+	-	+	62129.7	1082558
M89	FERRITIN HEAVY CHAIN (FERRITIN H SUBUNIT)	-	++	++	-	-	+	+	+	-	+	21225.8	1484648
M90	HISTONE H1.1	+	++	++	-	+	++	++	-	-	+	21734.2	356168
M91	keratin 1	-	-	-	-	++	++	+	+	-	+	66067	11935049
M92	ferritin light subunit	-	++	++	++	-	+	+	-	-	-	16394.7	182516
M93	PROTEASOME SUBUNIT ALPHA TYPE 2 (PROTEASOME COMPONENT C3)	+	++	++	-	-	-	-	-	-	-	25153.9	12804095
M94	CARBONIC ANHYDRASE I (CARBONATE DEHYDRATASE I) (CA-I)	-	++	++	-	-	-	-	-	-	++	28870.3	4502517
M95	LYMPHOCYTE-SPECIFIC PROTEIN LSP1 (PP52 PROTEIN) (52 KDA PHOSPHOPROTEIN) (LYMPHOCYTE-SPECIFIC ANTIGEN WP34)	-	-	++	-	-	-	-	-	-	-	37191.8	10880979
M96	apolipoprotein F	++	-	++	-	++	++	++	-	++	-	35399.7	4502165
M97	immunoglobulin lambda chain variable region	-	++	++	-	-	-	-	-	-	-	13394.7	587410

ID	Protein										Acc1	Acc2
M98	OSTEOINDUCTIVE FACTOR PRECURSOR (OIF) (OSTEOGLYCIN) (MIMECAN)	-	-	++	-	-	-	-	++	++	33922.4	7661704
M99	APOLIPOPROTEIN E PRECURSOR (APO-E)	-	++	-	+	-	++	++	-	-	36154.3	4557325
M100	PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN (PEBP) (NEUROPOLYPEPTIDE H3) (HIPPOCAMPAL CHOLINERGIC NEUROSTIMULATING PEPTIDE) (HCNP) (RAF KINASE INHIBITOR PROTEIN) (RKIP)	++	+	++	+	-	++	-	++	+	21056.9	4505621
M101	SUPEROXIDE DISMUTASE [CU-ZN]	++	-	+	+	+	++	-	++	++	15935.8	4507149
M102	HISTONE H1A (H1.1)	+	++	++	-	+	-	+	-	-	22178.7	121916
M103	neutrophil lipocalin	++	-	++	-	-	-	-	-	-	20547.6	4261868
M104	serum paraoxonase/arylesterase 1	-	-	-	++	++	-	-	-	++	39731.5	14752059
M105	CYTIDINE DEAMINASE (CYTIDINE AMINOHYDROLASE)	++	++	++	-	-	-	-	-	-	16184.8	11386157
M106	CYSTATIN B (LIVER THIOL PROTEINASE INHIBITOR) (CPI-B) (STEFIN B)	++	++	++	++	++	++	-	-	+	11139.6	4503117
M107	immunoglobulin kappa light chain variable region	-	-	-	++	++	+	+	-	-	11799.3	6492203
M108	angiotensinogen (serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 8)	-	-	-	++	++	++	++	++	++	53114.4	15079348
M109	COLLAGEN ALPHA 3(VI) CHAIN PRECURSOR	-	-	++	++	-	-	-	++	++	343554	4758028
M110	beta galactoside binding lectin	-	++	-	++	-	-	++	-	-	14584.6	227920
M111	SH3BGRL3-like protein	++	++	++	++	-	-	-	-	-	10437.8	13775198

M112	proteoglycan link protein 2	-	-	-	+	-	-	-	-	++	-	-	40165.8	4503053
M113	LYSOZYME C PRECURSOR (1,4-BETA-N-ACETYLMURAMIDASE C)	++	++	++	++	-	-	-	-	-	-	-	16537.1	45578894
M114	cysteine-rich secreted A12-alpha-like protein 2	-	+	++	++	-	-	-	-	-	-	-	11419.5	9966777
M115	LEUKOCYTE ELASTASE INHIBITOR (LEI) (MONOCYTE/NEUTROPHIL ELASTASE INHIBITOR) (M/NEI) (EI)	-	++	+	++	-	-	-	-	-	-	-	42742	13489087
M116	INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 PRECURSOR (IGFBP-4) (IBP-4) (IGF-BINDING PROTEIN 4)	+	+	-	++	++	++	-	+	++	-	+	27934.2	136539470
M117	LOW AFFINITY IMMUNOGLOBULIN GAMMA FC REGION RECEPTOR III-A PRECURSOR (IGG FC RECEPTOR III-2) (FC-GAMMA RIII-ALPHA) (FC-GAMMA RIIIA) (FCRIIIA) (FC-GAMMA RIII) (FCRIII) (CD16-A) (FCR-10)	++	++	++	++	++	-	-	++	-	-	++	29089.3	12056967
M118	sex hormone-binding globulin	-	-	+	++	-	+	+	+	-	-	+	37488	14770624
M119	Annexin I (Lipocortin I) (Calpactin II) (Chromobindin 9) (P35) (Phospholipase A2 Inhibitory Protein)	-	+	++	++	-	-	-	++	-	-	-	38714.5	4502101
M120	MnSOD precursor	-	-	++	-	+	+	-	-	-	-	+	24721.2	34711
M121	EPIDIDYMAL SECRETORY PROTEIN E1 PRECURSOR (NIEMANN-PICK DISEASE TYPE C2 PROTEIN) (EPI-1) (HE1) (EPIDIDYMAL SECRETORY PROTEIN 14.6) (ESP14.6)	++	++	++	++	-	-	-	++	-	-	-	16570.3	5453678

M122	monoclonal antibody HW1 immunoglobulin light chain variable region	-	-	-	++	++	-	-	-	++	++	11556	2995691
M123	METASTATIN	++	++	++	-	++	++	-	++	-	-	11846.7	4506765
M124	inter-alpha (globulin) inhibitor, H2 polypeptide	-	-	-	-	-	++	+	-	-	-	106464	14742977
M125	alpha-1 type I collagen	-	++	+	++	-	-	-	++	++	++	55060.9	179594
M126	GELSOLIN PRECURSOR, PLASMA (ACTIN-DEPOLYMERIZING FACTOR) (ADF) (BREVIN) (AGEL)	-	++	-	-	-	-	-	++	-	++	85697.9	4504165
M127	PROTEASOME SUBUNIT ALPHA TYPE 4 (PROTEASOME COMPONENT C9) (MACROPAIN SUBUNIT C9) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT C9) (PROTEASOME SUBUNIT L)	-	++	++	-	-	-	-	-	-	-	29484	4506185
M128	SIMILAR TO COACTOSIN-LIKE PROTEIN	-	++	++	++	-	+	-	-	-	-	15945.1	1196417
M129	THIOREDOXIN (ATL-DERIVED FACTOR) (ADF) (SURFACE ASSOCIATED SULPHYDRYL PROTEIN) (SASP)	++	++	++	-	-	++	+	-	-	-	11737.6	14740403
M130	KI2 PROTEIN PRECURSOR	-	++	-	++	-	-	-	++	++	-	27039.2	4506869
M131	VITAMIN-K DEPENDENT PROTEIN C PRECURSOR (AUTOPROTHROMBIN IIA) (ANTICOAGULANT PROTEIN C) (BLOOD COAGULATION FACTOR XIV)	-	-	-	-	-	++	+	-	-	-	52071.6	4506115
M132	titin, cardiac muscle [validated]	-	-	-	-	-	-	-	-	++	++	29935535	2136280
M133	MBL-associated protein MAp19	-	-	-	++	-	++	-	++	++	-	20629.3	14726286

M134	EOSINOPHIL CATIONIC PROTEIN PRECURSOR (ECP) (RIBONUCLEASE 3) (RNASE 3)	-	++	++	++	+	++	-	-	++	18440.5	4506551
M135	This CDS feature is included to show the translation of the corresponding V_region. Presently translation qualifiers on V_region features are illegal	-	.	++	-	-	++	-	-	++	11577.6	886295
M136	enhancer protein	-	++	++	-	-	-	-	-	-	22127.5	2135068
M137	cysteine-rich protein 1	-	++	-	++	++	-	++	++	+	8532.9	45030047
M138	anti-Gd cold agglutinin monoclonal IgMK light chain variable region	-	++	-	++	++	++	++	++	+	10365.6	545723
M139	CYSTATIN A (STEFIN A) (CYSTATIN AS)	+	-	-	++	++	++	-	-	-	11006.5	4885165
M140	ANNEXIN II (LIPOCORTIN II) (CALPACTIN I HEAVY CHAIN) (CHROMOBINDIN 8) (P36) (PROTEIN I) (PLACENTAL ANTICOAGULANT PROTEIN IV) (PAP-IV)	-	++	++	-	-	-	-	-	-	38604.2	4757756
M141	diazepam binding inhibitor	-	++	++	+	-	-	-	-	-	11793.4	10140853
M142	bA139H14.1 (lymphocyte cytosolic protein 1 (L-plastin))	-	-	++	-	-	-	-	+	-	70288.8	8217500
M143	heparan sulfate proteoglycan 2 (perlecan)	-	-	-	++	-	-	++	-	++	122673	147333263
M144	cathepsin C	-	-	+	+	-	-	-	-	-	51854.1	13631727
M145	MYELOBLASTIN PRECURSOR (LEUKOCYTE PROTEINASE 3) (PR-3) (PR3) (AGP7) (WEGENER'S AUTOANTIGEN) (P29) (C-ANCA ANTIGEN)	+	-	-	-	++	+	-	-	-	27807.2	14765501
M146	glutaredoxin	-	+	++	-	++	-	-	-	-	11761.8	643695

ID	Description											
M147	TRANSLATIONALLY CONTROLLED TUMOR PROTEIN (TCTP)	++	++	-	-	-	-	-	-	+	19595.5	4507669
M148	PROTEASOME COMPONENT C13 PRECURSOR (MACROPAIN SUBUNIT C13) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT C13)	-	-	-	-	-	++	-	-	-	30354.5	1172602
M149	ENDOTHELIAL PROTEIN C RECEPTOR PRECURSOR (ENDOTHELIAL CELL PROTEIN C RECEPTOR) (ACTIVATED PROTEIN C RECEPTOR) (APC RECEPTOR)	-	++	++	-	-	-	-	-	+	26671.6	11420547
M150	Ig superfamily protein	-	-	++	++	-	-	-	++	-	43987.3	6005958
M151	D-DOPACHROME TAUTOMERASE (PHENYLPYRUVATE TAUTOMERASE II)	++	+	++	-	+	-	-	-	-	12711.8	4503291
M152	p80 protein	-	++	-	-	-	-	-	-	++	75356.7	1483131
M153	COLLAGEN ALPHA 1(V) CHAIN PRECURSOR	-	-	++	-	-	-	-	++	++	183619	4502957
M154	immunoglobulin light chain variable region	-	-	++	-	++	++	-	-	-	11837.5	882304
M155	rho GDP dissociation inhibitor (GDI)	-	-	++	-	-	-	-	-	++	23193.2	36038
M156	FIBRONECTIN PRECURSOR (FN) (COLD-INSOLUBLE GLOBULIN) (CIG)	-	-	++	-	-	+	-	-	+	262608	25068872
M157	FK506-BINDING PROTEIN (FKBP-12) (PEPTIDYL-PROLYL CIS-TRANS ISOMERASE) (PPIASE) (ROTAMASE) (IMMUNOPHILIN FKBP12)	++	++	-	-	-	-	-	-	-	11950.8	4503725

M158	IG KAPPA CHAIN V REGION GOM	++	-	-	++	++	++	-	-	++	-	12199.7	10636525
M159	similar to osteoclast stimulating factor 1 (H. sapiens)	++	-	-	-	-	-	-	-	-	-	23786.9	147383380
M160	Ig heavy chain V-III region (TIL-Vr)	+	-	++	-	-	-	++	++	++	-	10853.2	87860
M161	PEROXIREDOXIN 2 (THIOREDOXIN PEROXIDASE 1) (THIOREDOXIN-DEPENDENT PEROXIDE REDUCTASE 1) (THIOL-SPECIFIC ANTIOXIDANT PROTEIN) (TSA) (PRP) (NATURAL KILLER CELL ENHANCING FACTOR B) (NKEF-B)	++	-	+	-	-	-	-	-	-	++	21892	13631440
M162	myosin catalytic light chain LC17b	++	++	-	-	-	-	-	-	-	-	16931.1	10440556
M163	protein SPY75	+	+	-	-	-	-	-	-	-	-	53998.3	4885405
M164	2-phosphopyruvate-hydratase alpha-enolase	-	++	-	-	++	-	-	-	-	-	47109.1	693933
M165	IG LAMBDA CHAIN V-V REGION DEL	-	++	++	-	-	-	-	-	-	++	11342.6	126571
M166	pancreatic secretory trypsin inhibitor	-	+	-	++	+	-	-	-	-	+	6247.1	671743
M167	GLIA MATURATION FACTOR GAMMA (GMF-GAMMA)	++	-	+	++	-	-	-	-	-	-	16801.4	4758440
M168	CALCYCLIN (LUNG 10 KDA PROTEIN)	-	+	++	-	-	+	-	-	-	-	10153.8	1173337
M169	SH3 DOMAIN-BINDING GLUTAMIC ACID-RICH-LIKE PROTEIN	-	++	+	-	-	-	-	-	-	-	12774.3	4506925
M170	CHYMOTRYPSINOGEN A	-	-	-	-	-	++	-	-	-	-	25666.3	117615
M171	DJ-1 protein	++	-	++	-	++	+	-	-	-	-	19847.1	6005749
M172	phosphoprotein enriched in astrocytes 15	-	-	+	-	-	-	-	-	-	-	15040.2	4505705

	Protein													
M173	EGF-CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 1 PRECURSOR (FIBULIN-3) (FIBL-3) (T16 PROTEIN)	-	-	-	++	-	+	-	-	-	+	54641	9665262
M174	superoxide dismutase 3, extracellular	+	-	-	-	-	++	-	-	-	-	25851.1	14733169
M175	CLARA CELL PHOSPHOLIPID-BINDING PROTEIN PRECURSOR (CCPBP) (CLARA CELLS 10 KDA SECRETORY PROTEIN) (CC10) (UTEROGLOBIN) (URINE PROTEIN 1) (UP1)	-	+	+	++	-	-	-	-	++	-	9993.8	4507809
M176	Similar to LIM and SH3 protein 1	+	-	++	-	-	-	-	-	-	-	29658.3	15214662
M177	PROSTAGLANDIN-H2 D-ISOMERASE PRECURSOR (PROSTAGLANDIN-D SYNTHASE) (GLUTATHIONE-INDEPENDENT PGD SYNTHETASE) (PROSTAGLANDIN D2 SYNTHASE) (PGD2 SYNTHASE) (PGDS) (PGDS2) (PGDS) (BETA-TRACE PROTEIN)	+	-	++	++	-	-	++	++	-	++	21028.9	4506251
M178	mannose 6-phosphate/insulin-like growth factor II receptor	-	++	-	-	-	-	-	-	-	-	273400	6981078
M179	OXYGEN-REGULATED PROTEIN 1 (RETINITIS PIGMENTOSA RP1 PROTEIN) (RETINITIS PIGMENTOSA 1 PROTEIN)	-	++	-	-	-	-	-	-	-	-	240663	54454016
M180	SERUM AMYLOID A PROTEIN (SAA) [CONTAINS: AMYLOID PROTEIN A (AMYLOID FIBRIL PROTEIN AA)]	-	-	++	+	+	-	-	-	-	-	12289.5	7531274

ID	CARGO SELECTION												
M181	CARGO SELECTION PROTEIN TIP47 (47 KDA MANNOSE 6-PHOSPHATE RECEPTOR-BINDING PROTEIN) (47 KDA MPR-BINDING PROTEIN) (PLACENTAL PROTEIN 17)	-	-	++	-	-	-	-	-	-	-	47033.1	5032183
M182	adenylyl cyclase-associated protein	-	-	++	-	-	++	-	-	-	-	51749.4	15296533
M183	aldolase C	-	++	-	-	-	-	-	-	-	-	39456.1	4885063
M184	similar to PROTEASOME SUBUNIT ALPHA TYPE 6 (PROTEASOME IOTA CHAIN) (MACROPAIN IOTA CHAIN) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX IOTA CHAIN) (27 KDA PROSOMAL PROTEIN) (PROS-27) (P27K) (H. sapiens)	-	++	++	-	-	-	-	-	-	-	27330.7	14719929
M185	immunoglobulin light chain variable region	-	-	-	-	-	++	-	-	-	++	12160.7	5419711
M186	FOLLISTATIN-RELATED PROTEIN 1 PRECURSOR	-	-	+	++	++	++	-	-	-	-	34985.7	5901956
M187	GAMMA-INTERFERON INDUCIBLE LYSOSOMAL THIOL REDUCTASE PRECURSOR (GAMMA-INTERFERON-INDUCIBLE PROTEIN IP-30)	-	++	++	-	-	++	-	-	-	-	29149.1	12643406
M188	F-ACTIN CAPPING PROTEIN BETA SUBUNIT (CAPZ BETA)	++	++	++	-	-	++	++	-	-	-	31350.7	13124696
M189	coagulation factor X	++	-	-	-	-	-	++	-	+	-	52535.2	180336
M190	histone H3	-	-	-	-	++	-	-	-	-	-	15328	4504279
M191	adiponectin	-	-	-	-	-	-	-	-	-	++	26413.8	4757760
M192	16G2	-	+	+	-	-	-	-	++	-	-	42055.2	14738192
M193	Ig kappa chain precursor V region (A10)	++	-	-	-	-	-	-	-	-	-	12430.1	87866

ID	Protein												
M194	immunoglobulin lambda light chain variable region	-	-	+	-	-	++	-	-	-	-	9483.3	109945949
M195	S-100P PROTEIN	++	+	-	-	+	-	-	-	-	-	10400	5174663
M196	INTERCELLULAR ADHESION MOLECULE-2 PRECURSOR (ICAM-2) (CD102)	-	+	-	++	-	-	-	++	-	+	30653.5	4504557
M197	MANNOSYL-OLIGOSACCHARIDE ALPHA-1,2-MANNOSIDASE (MAN(9)-ALPHA-MANNOSIDASE)	-	-	-	++	-	-	-	-	-	-	70821.3	51745721
M198	NAD+-isocitrate dehydrogenase, alpha subunit	-	-	++	-	-	++	-	++	++	++	39592	5031777
M199	CONNECTIVE TISSUE GROWTH FACTOR PRECURSOR (HYPERTROPHIC CHONDROCYTE-SPECIFIC PROTEIN 24)	-	-	-	-	-	-	-	++	-	-	38069.8	4503123
M200	complement factor H-related protein FHR-2	++	-	-	-	-	-	-	-	-	-	277868.8	21349940
M201	RIBONUCLEASE, SEMINAL PRECURSOR (SEMINAL RNASE) (S-RNASE) (RIBONUCLEASE BS-1)	-	-	-	-	-	++	-	-	-	-	16377.3	133237
M202	immunoglobulin kappa chain	-	-	-	-	++	+	-	-	-	-	10661.9	722612
M203	putative	+	-	-	-	-	+	-	-	-	-	12859.9	12832737
M204	SERUM AMYLOID A-4 PROTEIN PRECURSOR (CONSTITUTIVELY EXPRESSED SERUM AMYLOID A PROTEIN) (C-SAA)	-	-	-	-	-	++	-	-	-	-	14806.8	10835095
M205	HP1-BF74	-	-	-	-	-	-	+	-	-	+	61207.3	11424882
M206	myristoylated alanine-rich C-kinase substrate	-	-	-	-	-	+	-	-	-	-	3276.6	187385

ID	Protein										MW	Accession
M207	CORTICOSTEROID-BINDING GLOBULIN PRECURSOR (CBG) (TRANSCORTIN)	-	++	-	-	-	+	-	+	-	45141.1	4502595
M208	mannose-binding lectin	++	-	+	-	-	-	-	-	-	26090.6	5911809
M209	APOLIPOPROTEIN L PRECURSOR (APO-L)	-	-	-	-	-	+	-	++	+	42383.5	14916953
M210	GLUTATHIONE TRANSFERASE OMEGA 1 (GSTO 1-1)	++	++	-	-	-	-	-	-	-	27566	47758484
M211	Somatomedin A	-	-	+	-	-	-	-	-	-	7578.8	224061
M212	ganglioside M2 activator protein	-	++	-	-	-	-	-	+	-	17623.5	106058
M213	Ig heavy chain V region (174.2E10)	+	-	-	++	-	++	-	+	++	13876.6	110106
M214	FATTY ACID-BINDING PROTEIN, EPIDERMAL (E-FABP) (PSORIASIS-ASSOCIATED FATTY ACID-BINDING PROTEIN HOMOLOG) (PA-FABP)	-	+	++	-	-	-	-	-	-	15164.5	4557581
M215	MYELOID CELL NUCLEAR DIFFERENTIATION ANTIGEN	-	-	+	-	-	-	-	-	-	45836.3	4505227
M216	protein-L-isoaspartate(D-aspartate) O-methyltransferase (EC 2.1.1.77) splice form II	++	-	+	-	-	-	-	-	-	24679.5	14781911
M217	pancreatic ribonuclease (EC 3.1.27.5) precursor	-	-	+	-	-	-	-	-	-	17239.9	2135882
M218	IG KAPPA CHAIN V-I REGION MEV	-	-	-	++	-	-	-	-	-	11870.2	125776
M219	anti-MSP1 MAD20 block2 ScFv Ig light chain variable region	-	-	-	++	-	-	-	-	-	11668.2	12836991
M220	vimentin	+	-	++	-	+	-	-	+	+	53714	340219

M221	HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, GAMMA CHAIN (HLA-DR ANTIGENS ASSOCIATED INVARIANT CHAIN) (P33) (CD74 ANTIGEN)	-	-	+	-	-	-	-	-	-	33460.7	399888
M226	immunoglobulin rearranged light chain	++	-	++	-	-	-	-	-	-	++	11825.1	2072274
M225	antigen HLA SB beta,MHC II	-	-	+	-	-	-	-	-	-	-	19069.9	224042
M224	p97	-	-	-	-	-	-	-	-	-	-	80170.1	37863308
M223	granulin	-	+	-	-	-	-	-	-	-	-	61441.5	14772463
M222	IMP dehydrogenase	+	++	+	-	-	++	-	-	-	+	55920.4	4504689
M227	kinesin like protein 9	-	++	++	-	-	-	-	-	-	+	89942.6	67544442
M228	PROTEASOME COMPONENT MECL-1 PRECURSOR (MACROPAIN SUBUNIT MECL-1) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT MECL-1)	-	-	++	-	-	-	-	-	-	+	28936.5	4506191
M229	immunoglobulin kappa light chain variable region	-	++	++	++	++	+	-	-	-	+	11005.3	13448025
M230	immunoglobulin light chain	-	-	++	++	-	++	-	-	-	-	11719.1	1905799
M231	IG Lambda Chain V-IV Region Mol	++	-	-	++	-	-	-	-	++	-	11272.3	126570
M232	immunoglobulin variable region used by the ITC48 kappa light chain (subgroup V kappa IV) (anti-cytomeglovirus glycoprotein B (A	-	-	++	-	++	++	-	-	-	++	12618.2	791177
M233	hypothetical protein DKFZp761B15121.1	-	-	-	++	-	-	-	-	-	++	17934.8	147773888
M234	immunoglobulin kappa light chain variable region B3	-	++	++	-	-	-	-	-	-	-	12315.9	5731229

ID	Description											
M235	VON EBNER'S GLAND PROTEIN PRECURSOR (VEG PROTEIN) (TEAR PREALBUMIN) (TP) (TEAR LIPOCALIN) (LIPOCALIN-1)	-	-	-	-	+	-	-	-	-	19250.1	4504963
M236	Ribonuclease Pancreatic Precursor (RNASE 1)	-	-	-	-	-	-	-	-	-	16461	133198
M237	immunoglobulin kappa chain variable region	-	-	++	++	-	++	-	-	-	11159.5	12655532
M238	immunoglobulin kappa light chain variable region	-	++	-	++	-	-	-	-	-	11696.1	4324014
M239	immunoglobulin kappa chain V region	-	++	++	++	+	++	-	++	-	11941.5	416338
M240	Carbonic Anhydrase II (Carbonate Dehydratase II) (CA-II)	-	-	+	-	-	+	-	-	-	29246.2	4557395
M241	HRV Fab 027-VL	-	-	++	++	++	-	-	-	-	12383	2385498
M242	immunoglobulin variable region, kappa light chain	-	-	-	++	-	-	-	-	-	12748.6	2597940
M243	IG Kappa Chain V-II Region MIL	-	-	-	-	++	++	-	-	-	12060.5	125786
M244	364K Golgi complex-associated protein	-	-	+	-	-	-	-	-	-	364299	7441640
M245	histone H2A.5	+	-	-	-	-	+	-	-	-	14059.5	70686
M246	antibody, light chain variable regin to HIV1 p25	-	-	-	++	-	-	-	-	-	12356.8	732744
M247	immunoglobulin heavy-chain subgroup VIII V-D-J region	+	-	+	++	-	++	++	++	+	12854.4	348180
M248	TRYPSINOGEN, CATIONIC PRECURSOR (BETA-TRYPSIN)	-	-	-	-	-	-	-	-	+	25424.9	2507249
M249	putative	-	-	++	-	-	-	++	-	-	26422.2	12963645

ID	Protein										
M250	LOW AFFINITY IMMUNOGLOBULIN GAMMA FC REGION RECEPTOR II-A PRECURSOR (FC-GAMMA RII-A) (FCRII-A) (IGG FC RECEPTOR II-A) (FC-GAMMA-RIIA) (CD32) (CDW32)	-	++	-	-	-	-	-	-	34989.9	399476
M251	immunoglobulin lambda chain variable region	+	-	-	-	-	-	-	-	11519.6	9968388
M252	CYTOCHROME C	-	+	-	-	-	-	-	-	11888	14782885
M253	Ig kappa chain V-IV region (Dep)	-	++	-	-	-	++	-	-	11476.8	106620
M254	immunoglobulin kappa orphon (AA 95)	-	++	-	++	-	-	-	-	10013.1	13353366
M255	immunoglobulin kappa chain variable region	-	-	-	++	++	-	-	-	11192.6	12655663
M256	immunoglobulin kappa light chain variable region	-	-	-	++	++	-	-	-	10627.9	146255921
M257	immunoglobulin lambda light chain variable region	-	++	-	++	-	-	-	-	12685.3	3142565
M258	gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) precursor	-	-	+	-	-	-	-	-	26023.5	13646249
M259	breakpoint cluster region protein 1	-	++	-	-	-	-	-	-	15521.8	3002951
M260	immunoglobulin kappa chain variable region	-	-	-	-	++	-	-	-	10457.6	126555486
M261	BCL3	-	-	-	-	-	-	-	+	46432.3	3928845
M262	immunoglobulin lambda light chain variable region	+	-	-	-	-	-	-	+	11482.7	6643255
M263	immunoglobulin kappa chain variable region	-	++	-	-	++	+	-	++	12131.5	5019539
M264	macrophage migration inhibitory factor	-	++	-	-	-	-	-	-	11428.1	187181

ID	Description											
M265	immunoglobulin kappa chain variable region	-	-	-	-	-	++	-	-	-	12277.8	5578792
M266	unnamed protein product	-	-	-	-	-	-	-	-	-	47994.5	10436374
M267	ribosomal protein S28, cytosolic	-	+	++	+	+	-	-	-	-	2336.6	7440562
M268	MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 2 PRECURSOR (MAGP-2) (MP25)	-	-	-	-	-	-	-	-	+	19611.7	4505089
M269	cathepsin S	-	++	-	-	-	-	-	-	-	37495.9	11427057
M270	lambda-chain C-region C-lambda-2	-	-	-	-	-	-	-	-	++	11515.3	165427
M271	anti-porcine VCAM mAb 3F4 light chain variable region	-	-	-	++	-	-	+	-	-	12178.8	4098515
M272	immunoglobulin lambda-3 variable region	-	-	-	-	++	-	-	-	-	10959.2	13016692
M273	immunoglobulin kappa chain variable region	-	++	++	-	-	-	-	-	++	15757.9	598166
M274	IgM light chain variable region	-	-	-	++	-	-	-	-	-	11707.3	1673593
M275	CATHEPSIN D	+	+	-	-	-	-	-	-	-	44552.5	4503143
M276	immunoglobulin kappa light chain variable region	-	-	-	-	-	-	-	-	++	11451.8	9246439
M277	putative	-	-	-	-	-	++	-	-	-	19274.4	128433372
M278	transaldolase	-	+	-	-	-	-	-	-	-	37540.3	5803187
M279	immunoglobulin V lambda/J lambda light chain	-	-	-	-	-	-	-	-	++	10793.9	6643727
M280	myeloid inhibitory siglec	-	-	-	-	-	-	-	-	++	51760.6	13936734
M281	granulocyte inhibitory protein	-	-	-	-	++	-	-	-	-	2046.3	106167
M282	GROWTH FACTOR RECEPTOR-BOUND PROTEIN 2 (GRB2 ADAPTER PROTEIN) (SH2/SH3 ADAPTER GRB2) (ASH PROTEIN)	+	-	-	-	-	-	-	-	-	25206.5	4504111

M#	Name												
M283	immunoglobulin kappa light chain variable region	-	-	-	-	-	-	-	-	++	10835	43223812
M284	UBIQUITIN-LIKE PROTEIN SMT3B (SENTRIN 2)	++	-	-	-	-	-	-	-	-	10871.3	5902098
M285	immunoglobulin kappa chain	-	-	-	-	-	-	-	-	-	11003.4	7224434
M286	HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, CW-1 CW*0102 ALPHA CHAIN PRECURSOR (CW1.2)	-	+	-	-	-	-	++	-	-	40950.1	231427
M287	40S RIBOSOMAL PROTEIN S17	-	-	++	-	-	-	-	-	-	15550.2	4506693
M288	immunoglobulin kappa light chain variable region	-	++	-	++	-	++	-	-	-	12460	43782994
M289	dJ747L4.1 (Brachyury (T box protein)-LIKE protein	-	-	-	++	-	-	-	-	-	47004.1	3900891
M290	anti-oxidized LDL autoantibody variable kappa chain	++	-	-	-	++	-	-	-	-	11825.3	15277620
M291	immunoglobulin light chain variable region	-	-	+	-	-	-	-	-	-	10721.2	5532843
M292	immunoglobulin kappa light chain variable region	-	-	-	++	++	-	-	-	-	11444.7	9245545
M293	Ig kappa chain	-	-	-	++	-	-	-	-	-	12040.5	346170
M294	immunoglobulin kappa chain variable region	-	-	-	-	-	-	-	++	-	12174.7	5578780
M295	Ig kappa chain V-III region (Lew)	-	-	-	-	++	-	-	-	-	4685.3	106605
M296	similar to TROPOMYOSIN, CYTOSKELETAL TYPE (TM30-NM) (H. sapiens)	-	-	-	-	-	++	-	-	-	16974.3	14786818
M297	immunoglobulin kappa light chain, variable region	-	-	-	-	-	-	-	-	++	9388.3	619686
M298	ZYXIN (ZYXIN 2)	-	-	+	-	-	-	++	-	-	61277.7	4508047
M299	immunoglobulin lambda chain variable region	-	-	-	-	-	-	-	-	-	11057.3	5019492

ID	Description												
M300	ENHANCER OF RUDIMENTARY HOMOLOG	++	-	-	-	-	-	-	-	-	-	12259	47758302
M301	regulator of G-protein signaling 4	-	-	-	-	-	-	-	-	++	-	23255.8	5032039
M302	immunoglobulin lambda light chain variable region	-	-	-	-	-	-	-	-	-	-	11543.7	6643601
M303	immunoglobulin kappa chain	-	-	-	-	++	-	-	-	-	-	9539.7	11137019
M304	immunoglobulin kappa light chain variable region	-	-	-	++	-	-	-	-	-	-	11640.1	4378186
M305	anti-DNA immunoglobulin light chain IgG	-	-	-	-	-	-	-	-	-	+	11047.2	1870506
M306	Ig kappa chain (Vk) V region (VJ)	-	-	-	-	-	-	-	-	+	-	9157.2	861002
M307	UBIQUITIN-LIKE PROTEIN NEDD8	-	+	-	-	-	-	-	-	-	-	9071.6	5453760
M308	immunoglobulin light chain variable region	-	-	-	-	++	-	-	-	-	-	11544	13171344
M309	immunoglobulin lambda light chain variable region	-	-	++	-	++	++	-	-	-	-	11326.5	4324210
M310	immunoglobulin lambda light chain	++	++	-	-	-	-	-	-	-	-	9521.5	4566035
M311	SCRAPIE-RESPONSIVE PROTEIN 1 PRECURSOR (SCRG-1)	-	-	-	-	-	-	-	++	-	-	11081.2	6005870
M312	gonadotropin releasing peptide	-	-	-	+	-	-	++	++	-	-	1651.6	225500
M313	immunoglobulin light chain variable region	-	-	++	-	-	-	-	-	-	-	11709.1	5419695
M314	IG HEAVY CHAIN V-III REGION HIL	-	-	-	++	++	+	-	-	-	-	13566.4	123850
M315	IRT-1	-	++	-	-	-	-	-	-	-	-	14617.3	4758612
M316	recombinant antibody light chain VL domain	-	-	-	++	-	-	-	-	-	-	11556.9	12957386
M317	putative	-	-	-	-	-	-	-	-	++	-	56695	12836433
M318	CYSTATIN M PRECURSOR (CYSTATIN E)	-	-	-	-	-	-	-	-	++	-	16511.2	4503113

ID	Protein											
M319	immunoglobulin rearranged light chain	-	-	-	++	-	-	-	-	-	11815.1	2218124
M320	proteasome activator PA28 beta chain	-	-	-	-	++	-	-	-	-	27348.7	45062237
M321	AGGRECAN CORE PROTEIN PRECURSOR (CARTILAGE-SPECIFIC PROTEOGLYCAN CORE PROTEIN) (CSPCP) (CHONDROITIN SULFATE PROTEOGLYCAN CORE PROTEIN 1)	-	-	-	-	-	++	-	-	-	250194	129886
M322	KIAA0185 protein	-	-	++	-	++	+	-	-	-	57547.8	15298593
M323	hypothetical protein FLJ13465	-	-	-	++	-	-	-	-	-	97949.7	147745846
M324	CARBOXYPEPTIDASE N 83 KDA CHAIN (CARBOXYPEPTIDASE N REGULATORY SUBUNIT)	-	-	-	-	-	-	-	+	-	58649.4	115877
M325	Ig kappa chain	-	-	+	-	-	-	-	-	+	11664	631236
M326	R33729_1	-	-	+	-	-	-	-	-	-	11332.9	3355455
M327	lymphocyte surface antigen precursor CD44	-	++	-	-	-	-	-	-	+	32074.7	106924
M328	PYRIDOXINE KINASE (PYRIDOXAL KINASE)	+	-	-	-	-	-	-	-	-	35102.5	4505701
M329	unnamed protein product	-	-	-	-	-	+	-	-	-	42442.7	104366670
M330	CALPACTIN I LIGHT CHAIN (P10 PROTEIN) (P11) (CELLULAR LIGAND OF ANNEXIN II) (NERVE GROWTH FACTOR INDUCED PROTEIN 42C)	-	-	-	-	-	-	-	-	-	11203.2	4506761
M331	c360B4.1 (PUTATIVE novel protein similar to predicted bacterial and worm proteins)	+	-	++	-	-	-	++	-	++	23267.9	5912545
M332	latent transforming growth factor-beta binding protein 4S	-	-	-	-	-	-	-	++	-	161160	3327808

ID	Description												
M333	hypothetical protein XP_047083	-	-	-	-	-	-	-	-	+	+	49735	14744245
M334	similar to GASTRIN/CHOLECYSTOKININ TYPE B RECEPTOR (CCK-B RECEPTOR) (CCK-BR) (H. sapiens)	++	++	++	-	-	-	-	-	-	+	45421.1	13633718
M335	immunoglobulin kappa chain variable region	-	-	-	-	-	-	++	-	-	-	10304.4	12655482
M336	similar to LINE-1 REVERSE TRANSCRIPTASE HOMOLOG (H. sapiens)	-	-	-	-	-	-	+	-	-	+	16237.5	14766164
M337	TYROSINE-PROTEIN KINASE CSK (C-SRC KINASE)	-	-	-	-	-	-	++	-	++	-	50704.6	4758078
M338	Similar to dystroglycan 1 (dystrophin-associated glycoprotein 1)	-	-	-	-	-	-	-	++	-	-	97541.1	15215308
M339	complement component 1, s subcomponent	-	-	-	-	-	++	-	-	-	-	37337.1	14766592
M340	lysophospholipase II	-	-	-	-	-	-	+	-	-	+	24737.1	9966764
M341	Ig kappa chain V region (V-kappa 3)	-	-	-	++	-	-	+	-	-	+	10009.2	480919
M342	immunoglobulin V lambda/J lambda light chain	++	-	-	-	-	-	-	-	-	-	10942.9	6643633
M343	immunoglobulin kappa light chain variable region	-	-	-	-	-	-	-	-	-	++	11826.3	4378192
M344	TELOMERASE-BINDING PROTEIN P23 (HSP90 CO-CHAPERONE) (PROGESTERONE RECEPTOR COMPLEX P23)	+	-	-	-	-	-	-	-	-	-	18721.5	9790017
M345	immunoglobulin lambda light chain variable region	-	-	-	-	-	++	-	-	-	-	11275.5	4324094
M346	inwardly rectifying potassium channel protein Kir6.2	-	-	-	-	-	-	++	-	-	-	43580.1	2143813

ID	Description	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11		
M347	Ig kappa chain	-	-	-	++	-	-	-	-	-	-	-	26153.4	1220492
M348	immunoglobulin light chain	-	-	-	++	-	-	-	-	-	-	-	13979.9	1813654
M349	dnaJ protein homolog	-	++	-	++	-	-	-	-	-	-	-	30611.7	478645
M350	40S RIBOSOMAL PROTEIN S29	-	++	-	-	-	-	-	-	-	-	-	6676.8	4506717
M351	IgA1 kappa light chain	-	-	++	-	-	++	-	-	-	-	++	13708.5	6110570
M352	MYOGLOBIN	-	-	-	-	-	-	-	-	-	-	+	17042.7	127656
M353	cathepsin X precursor	-	++	-	-	-	-	-	-	-	-	-	33943.2	3650498
M354	unknown	-	++	-	-	-	-	-	-	-	-	-	17297.2	3860020
M355	immunoglobulin lambda chain variable region	+	-	-	-	-	-	-	-	-	-	-	10925	12655626
M356	HYPOTHETICAL PROTEIN CGI-109 PRECURSOR	+	-	-	-	-	-	+	+	+	-	-	24353.8	12585535
M357	LITHOSTATHINE 1 BETA PRECURSOR (REGENERATING PROTEIN I BETA)	+	-	-	-	-	-	-	+	+	-	+	18664.9	10835248
M358	human leucocyte antigen B	-	-	-	-	-	-	++	+	+	-	+	31344.8	90275550
M359	immunoglobulin light chain variable region	-	-	-	-	-	-	-	-	-	-	-	8948.8	5457339
M360	This CDS feature is included to show the translation of the corresponding V_region. Presently translation qualifiers on V_region features are illegal.	-	-	-	-	++	-	-	-	-	-	-	11607	681900
M361	Ig kappa chain V-I region (ISE)	-	-	-	++	++	-	-	-	-	-	-	15481.9	477501
M362	KIAA0336	++	-	-	-	++	-	-	-	-	-	++	184659	7662062
M363	Similar to expressed sequence 2 embryonic lethal	-	-	-	-	-	-	-	-	-	-	++	52604.1	15489206
M364	immunoglobulin kappa light chain variable region	-	-	-	-	-	++	-	-	-	++	-	11884.3	43783310
M365	Ig kappa chain V region (V-kappa 3)	++	-	-	-	-	-	-	-	-	-	-	10302.6	480915

ID	Description												MW	Accession
M366	NEUROBLASTOMA SUPPRESSOR OF TUMORIGENICITY 1 (ZINC FINGER PROTEIN DAN) (N03)	-		-	+	++							19276.9	4885509
M367	Ig kappa chain	-	-	-	-	-	-	-	-	++			14845.1	482015
M368	immunoglobulin lambda chain variable region	-	-	++	-	-	-	-	-	-	-		9719.8	12044111
M369	immunoglobulin light chain variable region	-	-	-	++	-	-	-	-	-	-		11768.1	14573267
M370	putative	-	-	-	-	++	+	-	-	-	-		25193.3	12847919
M371	immunoglobulin light chain VL region	-	-	-	-	+	+	-	-	-	-		13194.5	7716048
M372	alpha 1F calcium channel subunit	-	-	-	++	-	-	+	-	-	+		221137	14669577
M373	sal (Drosophila)-like 2	-	-	-	+	-	-	-	-	-	++		105310	14751528
M374	AF15q14 protein	-	-	++	++	-	-	-	-	-	-		205685	9966807
M375	putative	-	-	-	-	-	-	-	-	-	-		30469.3	12836789
M376	fibroblast growth factor 13 isoform 1y1v	-	-	+++	++	++	++	-	-	++	+++		8239.5	4512024
M377	immunoglobulin heavy chain	-	-	-	-	-	-	-	-	-	++		10787.2	7161009
M378	immunoglobulin heavy chain	-	-	++	-	-	-	-	-	-	-		11041.3	7161005
M379	KIAA0433	+	+	-	-	-	-	-	-	-	++		140408	7662118
M380	anti-c-erbB-2 immunoglobulin light chain V	-	-	-	++	-	++	-	-	-	-		11608.9	1145350
M381	ATP-BINDING CASSETTE, SUB-FAMILY A, MEMBER 2 (ATP-BINDING CASSETTE TRANSPORTER 2) (ATP-BINDING CASSETTE 2)	-	-	++	-	-	-	-	-	-	-		269976	14916523
M382	G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein	-	-	-	++	-	-	-	-	-	-		85231.4	13929158
M383	immunoglobulin kappa chain V-J region	-	-	-	-	-	++	-	-	-	-		12042.6	1235765
M384	Ig kappa chain V region	-	-	-	-	-	-	-	-	-	++		9166.2	7438723

M385	(patient 17) immunoglobulin lambda light chain variable region	-	++	-	-	-	-	-	-	-	-	9469.4	9714348
M386	immunoglobulin lambda chain	++	-	++	-	+	++	-	++	++	++	10019.1	11137154
M387	farnesyl-protein transferase beta chain	-	-	-	-	-	-	-	-	-	-	43087.6	2135098
M388	KIAA1813 protein	-	-	-	++	-	-	-	-	-	-	73090.1	14017843
M389	hypothetical protein FLJ11937	-	-	-	-	-	-	-	-	-	++	117875	13644578
M390	immunoglobulin light chain variable region	-	-	-	-	++	-	-	-	-	-	11592	13171334
M391	ribosomal protein L29	++	-	-	+	+	-	-	-	-	-	17667.1	1082766
M392	Ig kappa light chain (VJC)	-	-	-	-	+	-	-	-	-	-	14464.6	441357
M393	inhibitor PI,alpha1 proteinase	-	+	++	-	-	-	-	-	-	-	2431	223058
M394	dJ467L1.3 (period (Drosophila) homolog 3)	-	-	-	-	-	-	-	++	++	-	126247	6580412
M395	cylindromatosis (turban tumor syndrome)	-	-	-	++	-	-	-	-	-	-	82125.4	14779751
M396	T cell receptor alpha chain V region (clone 2V alpha 23-2)	-	-	-	-	-	-	-	-	-	++	1710	4778461
M397	immunoglobulin lambda light chain variable region	-	-	++	-	-	++	-	-	-	-	11503.7	6643529
M398	Ig kappa chain V-region (V-J2-C)	-	-	-	-	-	+	-	-	-	-	8746.8	185903
M399	anti-pneumococcal Ig L-chain Fab fragment	-	-	-	-	++	-	++	-	-	-	11358.6	3603383
M400	IG HEAVY CHAIN V REGION MOO	-	-	-	++	-	-	-	-	-	-	12703.2	123774
M401	Unknown (protein for MGC:16498)	-	-	-	-	-	+	-	-	-	-	45446.9	15530249
M402	immunoglobulin lambda light chain VJ region	-	++	-	-	-	-	-	-	-	++	11645	3093884
M403	plasma protease (C1) inhibitor precursor	-	-	-	-	-	-	-	-	+	-	55182.5	179619

ID	Description												
M404	similar to INITIATION FACTOR 5A (EIF-5A) (EIF-4D) (REV-BINDING FACTOR) (H. sapiens)	-	-	-	-	-	-	-	-	-	++	16789.2	13642507
M405	Ig light chain VL1 region	+	-	++	-	-	-	-	-	-	-	12477.9	520416
M406	CGI-202	+	-	-	-	-	-	-	-	-	-	13832.6	8895093
M407	Ig kappa chain V-III region (She)	-	-	-	-	++	-	-	-	-	-	2519.9	106612
M408	Ig light chain variable domain	-	++	-	-	-	-	-	-	-	-	12142.7	1864119
M409	alternatively spliced	-	-	-	-	-	-	-	-	-	-	14203.2	2125864
M410	neuronal leucine-rich repeat protein-3	-	-	-	++	-	++	-	-	-	-	79424.7	14751034
M411	Unknown (protein for IMAGE:3587716)	-	-	-	-	-	-	-	-	+	-	71702.7	15277493
M412	PROTEASOME SUBUNIT ALPHA TYPE 1 (PROTEASOME COMPONENT C2) (PROTEASOME COMPONENT C2) (MACROPAIN SUBUNIT C2) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT C2) (PROTEASOME NU CHAIN)	-	++	-	-	-	-	-	-	-	-	29546.7	9910833
M413	NIF-like protein	++	-	-	-	-	-	-	-	-	-	38532.3	15487262
M414	IgM rearranged heavy chain mRNA V-D-J	-	++	+	-	-	++	-	-	-	-	12868.5	688441
M415	unnamed protein product	-	++	+	-	-	-	-	-	+	-	27742.6	10436722
M416	immunoglobulin kappa chain variable region	-	-	-	-	++	-	-	-	-	-	11211.6	12655666
M417	hairy/enhancer of split 6	+	-	-	-	-	+	-	-	+	-	23902	14009498
M418	immunoglobulin kappa light chain	-	-	-	-	-	-	-	-	-	++	11605.1	1561612
M419	sperm tail associated protein	-	-	-	-	-	-	-	-	-	++	119401	9910570
M420	NEURABIN-II (NEURAL TISSUE-SPECIFIC F-ACTIN BINDING PROTEIN II) (SPINOPHILIN) (P130) (PPIBP134)	-	++	++	++	-	-	-	-	+	-	89646.8	13431725

ID	Description											
M421	TFNR	+	-	-	-	-	-	-	-	-	245729	12232589
M422	TROPOMYOSIN 4, EMBRYONIC FIBROBLAST ISOFORM (TM-4)	-	++	-	-	-	-	-	-	-	28509.8	6981672
M423	ZINC FINGER Y-CHROMOSOMAL PROTEIN	-	-	-	-	-	-	-	-	-	90531.5	4507967
M424	CD27L RECEPTOR PRECURSOR (T-CELL ACTIVATION ANTIGEN CD27) (T14)	-	-	-	-	-	+	-	-	-	29156.6	4507587
M425	FIBROLEUKIN PRECURSOR (FIBRINOGEN-LIKE PROTEIN 2) (PT49)	-	+	-	-	-	-	-	+	-	50228.9	5730075
M426	haptoglobin	-	++	++	++	-	+	-	++	++	45205.6	4826762
M427	IgA heavy chain variable region	-	-	-	-	-	-	-	-	-	6205.1	131233502
M428	putative	-	-	++	++	++	+	-	-	-	2213.6	553734
M429	unnamed protein product	-	-	-	-	++	++	-	-	-	94254.2	10435664
M430	immunoglobulin kappa-chain VK-1	-	-	-	-	-	-	++	-	-	13454.4	197425
M431	hypothetical protein	-	-	++	-	-	-	-	-	-	101555	14720628
M432	immunoglobulin kappa light chain variable region	-	++	++	++	++	-	-	-	-	11061.5	43239922
M433	myosin-VIIb	-	-	-	-	-	-	-	-	+	240788	14161694
M434	immunoglobulin light chain variable region	-	-	-	-	+	-	-	-	-	11526.8	6735446
M435	hypothetical protein FLJ20516	++	++	+	-	-	++	-	-	-	344555.4	15300488
M436	similar to ribosomal protein S26 (H. sapiens)	-	-	-	-	-	+	-	-	-	13043.6	13642964
M437	immunoglobulin variable region, kappa light chain	-	-	-	++	-	-	-	-	-	11926.5	25979836
M438	immunoglobulin lambda light chain variable region	-	-	-	++	-	-	-	-	-	11511.7	3142584
M439	C-terminus matches KIAA0559, N-terminus similar to Bassoon protein	-	-	-	-	++	-	-	-	-	375564	45222026

ID	Description												
M440	immunoglobulin lambda light chain variable region	-	-	++	-	-	-	-	-	-	-	11380.6	3142574
M441	arfaptin 1	++	-	-	-	-	-	-	-	+	-	40779.3	11120714
M442	apolipoprotein CI	-	-	-	++	++	-	-	-	-	-	7750.9	178834
M443	dJ591C20.1 (novel protein similar to mouse NG26)	-	-	-	-	-	-	-	+	-	-	52554.9	11125672
M444	VESICLE TRANSPORT V-SNARE PROTEIN VTI1-LIKE 1 (VTI1-RP1)	-	-	-	++	-	-	-	-	-	-	26687.6	13124617
M445	retinoblastoma-associated protein HEC	+	-	-	-	-	-	-	-	-	-	73913.1	5174457
M446	ZINC FINGER PROTEIN GFI-1 (GROWTH FACTOR INDEPENDENCE-1)	++	-	-	++	-	-	-	-	-	-	45586	4885267
M447	5-HYDROXYTRYPTAMINE 5A RECEPTOR (5-HT-5A) (SEROTONIN RECEPTOR) (REC17)	-	-	-	-	-	-	-	-	++	-	40672.8	6981062
M448	This CDS feature is included to show the translation of the corresponding V_region. Presently translation qualifiers on V_region features are illegal	-	-	-	++	-	-	-	-	-	-	11581.9	845530
M449	immunoglobulin lambda light chain variable region	-	-	++	-	-	-	-	-	-	-	11511.7	3091160
M450	Ig kappa chain V-II region (Inc)	-	-	-	++	-	-	-	-	-	-	13106.9	87880
M451	KIAA1664 protein	++	-	-	-	-	-	-	-	-	-	99851.7	13359201
M452	METALLOTHIONEIN-II (MT-II)	-	-	+	-	-	-	++	+	-	-	6042.3	5174764
M453	microseminoprotein beta	-	-	-	-	-	-	++	-	-	-	10651.1	225159
M454	SACSIN	++	-	-	++	-	-	-	-	-	-	436757	7657536
M455	tenascin-R	-	-	-	++	++	-	-	-	-	-	149575	1617316
M456	immunoglobulin kappa chain variable region	-	-	-	-	-	-	-	-	-	-	11352.8	12655503

M457	SERINE PROTEASE INHIBITOR KAZAL-TYPE 5 PRECURSOR (LYMPHO-EPITHELIAL KAZAL-TYPE RELATED INHIBITOR) (LEKTI) [CONTAINS: HEMOFILTRATE PEPTIDE HF6478	-	-	-	++	-	-	-	-	-	-	120760	13959398
M458	CALGRANULIN C (CAGC)	-	+	-	-	-	-	-	-	-	-	10614.1	461678
M459	galactose-specific lectin	+	-	-	-	-	-	-	-	-	-	26148.5	1196442
M460	non-muscle myosin heavy chain	-	-	-	++	-	-	-	-	-	-	72371.4	3205211
M461	DOCK180 protein	-	-	++	-	-	-	-	-	++	-	215377	45033355
M462	serine protease	-	-	-	-	-	-	-	-	-	-	40239.3	3777621
M463	nuclear zinc finger protein Np95	-	-	+	-	-	-	-	-	-	-	89814.4	14764016
M464	LIM protein (similar to rat protein kinase C-binding enigma)	-	-	-	++	-	-	-	-	-	-	63972.5	14250573
M465	SECIS binding protein 2	-	-	++	-	-	-	+	-	-	-	95478.4	14211829
M466	HSPC055 protein	-	-	+	-	-	-	+	-	-	-	83654.5	14775320
M467	immunoglobulin V lambda/I lambda light chain	-	-	-	++	-	-	-	-	-	-	11099.1	66438881
M468	ribosomal protein L14	-	-	-	-	-	-	+	-	-	-	23803.4	4506601
M469	immunoglobulin kappa chain	-	-	-	-	-	++	-	-	++	-	10755.2	722526
M470	chloride channel protein 3, long form	-	-	-	-	-	-	-	-	++	-	91243.1	4502869
M471	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 3 (MAPK/ERK KINASE KINASE 3) (MEK KINASE 3) (MEKK 3)	-	-	-	++	-	-	-	-	-	-	70970.1	4505153
M472	unnamed protein product	-	-	-	-	-	-	-	-	+	-	62332	12383086
M473	anti-HIV gp120 antibody light chain variable region	-	-	-	.	-	-	-	-	++	-	11498.5	460857

Marker	Identity	1	2	3	4	5	6	7	8	9	10	Mass	Accession		
M474	CARBONIC ANHYDRASE IV PRECURSOR (CARBONATE DEHYDRATASE IV) (CA-IV)	-	-	-	-	-	-	-	-	+	-	34394.2	1345657		
M475	hypothetical protein FLJ11016	-	-	+	+	-	-	-	-	-	-	47126.1	13937775		
M476	putative gene with similarities to KIAA1074 and KIAA0565	-	+	+	-	-	-	-	-	-	-	50038.1	7717246		
M477	S-MYC PROTO-ONCOGENE PROTEIN	+	-	-	-	-	-	-	-	-	-	47002.5	11177868		
M478	immunoglobulin kappa light chain variable region	-	-	-	++	-	+	-	-	-	-	11322.7	4378208		
M479	immunoglobulin heavy-chain subgroup VIII V-D-J region	-	-	-	++	-	+	-	-	-	-	13556.2	348178		
M480	unnamed protein product	-	-	-	++	-	-	-	-	-	-	42680.2	10432636		
M481	immunoglobulin lambda light chain	-	-	-	-	-	+	-	-	-	-	9964.2	4566006		
M482	immunoglobulin kappa light chain variable region	-	-	-	-	-	-	-	+	-	+	11412.8	1699304		
M483	proapoliprotein Varient	-	-	+	-	+	-	-	-	-	-	25119.7		1	2
M484	Unknown	-	-	+	+	-	-	-	-	-	+	33413.9		3	4
M485	neutrophil lactoferrin	-	-	+	-	-	-	-	-	-	-	59529.6	186818 (GenPept)		
M486	alpha-2-HS glycoprotein Varient	-	-	-	-	-	-	-	+	-	-	12290.2	10289662 (dbEST)	5	6
M487	MT-11 protein Varient	-	+	-	-	-	-	-	-	+	-	10172.9	7378207 (dbEST)		
M488	immunoglobulin lambda light chain homolog	-	-	+	-	-	-	-	-	-	-	16740.9		7	8
M489	Unknown	-	-	-	-	-	-	-	-	-	-	21461.8			
M490	Unknown	-	-	-	-	-	-	-	-	-	-	20895		9	10

10^10 and above	+++		
10^8 to 10^10	++		
10^6 to 10^8	+		
0	-		

Table 2

Marker	Gene Name	E_51 Br38	E_59 Br26	E_63 Br35	E_67 Br42	E_70 Br43	N_52 Br29	N_54 Br28	N_58 Br34	N_65 Br36	N_66 Br39	MW (Da)	GI number	SEQ ID NO (nts)	SEQ ID NO (AA)
M4	COMPLEMENT C3 PRECURSOR [CONTAINS: C3A ANAPHYLATOXIN]	++	+++	+++	+++	+++	+++	+++	+++	+++	+++	187165	4557385		
M5	proapolipoprotein	+++	+++	+++	+++	+++	+++	++	+++	+++	+++	28961.7	178775		
M7	FIBRINOGEN ALPHA/ALPHA-E CHAIN PRECURSOR	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	94973.5	4503689		
M8	FIBRINOGEN BETA CHAIN PRECURSOR	+++	++	+++	+++	+++	+++	+++	+++	++	++	55928.5	399492		
M10	TRANSTHYRETIN PRECURSOR (PREALBUMIN) (TBPA) (TTR) (ATTR)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	15887.1	4507725		
M12	apolipoprotein A-IV precursor	++	++	+++	+++	+++	+++	+++	+++	++	++	43384.7	178779		
M13	alpha 1-acid glycoprotein	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	23366.1	1197209		
M14	hemopexin	+++	+++	+++	+++	+++	+++	++	+++	++	++	49295.7	1335098		
M15	macroglobulin alpha2	++	+++	++	+++	++	++	++	+++	++	++	160807	224053		
M17	alpha-2-glycoprotein 1, zinc	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	38194.4	14749011		,
M21	ANTITHROMBIN-III PRECURSOR (ATIII)	++	++	+++	+++	++	++	+	+++	++	++	52602.7	4502261		
M22	AMBP PROTEIN PRECURSOR [CONTAINS: ALPHA-1-MICROGLOBULIN (PROTEIN HC) (COMPLEX-FORMING	++	+++	+++	+++	+++	+++	++	+++	+++	+++	38999.7	4502067		

	GLYCOPROTEIN HETEROGENEOUS IN CHARGE)												
M23	PROTHROMBIN PRECURSOR (COAGULATION FACTOR II)	++	+++	+++	+++	+	++	++	++	+++	++	70037.3	4503635
M24	ALPHA-2-HS-GLYCOPROTEIN PRECURSOR (FETUIN-A) (ALPHA-2-Z-GLOBULIN) (BA-ALPHA-2-GLYCOPROTEIN)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	39324.9	4502005
M25	actin beta	++	+++	+++	++	+++	++	++	-	++	++	41737	4501885
M26	CLUSTERIN PRECURSOR (COMPLEMENT-ASSOCIATED PROTEIN SP-40,40) (COMPLEMENT CYTOLYSIS INHIBITOR) (CLI) (NA1 AND NA2) (APOLIPOPROTEIN J) (APO-J) (TRPM-2)	+++	++	++	++	++	+++	+++	+++	+++	++	52494.9	4502905
M27	bA120D12.1 (CD5 antigen-like (scavenger receptor cysteine rich family))	++	++	++	+++	++	+++	++	+++	++	++	38088.1	5174411
M28	fibrinogen gamma-B chain precursor	+++	++	+++	+++	++	+++	+++	+++	++	++	51511.9	71828
M29	polyubiquitin 4	++	+++	++	++	+	++	++	-	-	-	30303.9	2118964
M30	KININOGEN PRECURSOR (ALPHA-2-THIOL PROTEINASE INHIBITOR) [CONTAINS: BRADYKININ]	++	-	-	-	-	++	++	+	++	-	71945.7	125507
M31	CALGRANULIN B (MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 14) (MRP-14) (P14) (LEUKOCYTE L1 COMPLEX HEAVY CHAIN) (S100 CALCIUM-BINDING PROTEIN A9)	+++	+++	+++	+++	+++	+++	+++	++	++	++	13242.1	4506773

ID	Protein												
M32	PLASMA RETINOL-BINDING PROTEIN PRECURSOR (PRBP) (RBP)	+++	++	++	+++	++	+++	+++	+++	+++	+++	22868	5803139
M33	Ig mu chain precursor, membrane-bound (clone 201)	++	+++	++	+++	++	++	+++	-	++	++		
M34	APOLIPOPROTEIN A-II PRECURSOR (APO-AII)	++	+++	++	+++	++	+++	+++	+++	+++	++	68510.5	87919
M35	LEUCINE-RICH ALPHA-2-GLYCOPROTEIN (LRG)	++	+++	++	+++	+++	+++	+++	++	++	+++	11175.1	4502149
M36	dJ34F7.4 (complement component 4A)	++	-	++	+++	++	++	+++	-	-	++	34346.6	112908
M37	similar to phosphoglycerate mutase 1 (brain)	++	++	++	++	++	++	+	++	-	++	192753	7671645
M38	alpha-1-antichymotrypsin precursor	-	++	++	++	++	++	++	-	++	++	28850.2	15301114
M39	ALPHA-1B-GLYCOPROTEIN	++	++	+++	+++	+++	+++	+++	+++	++	++	45482.4	177933
M41	lipoprotein CIII	++	++	++	++	+++	+++	+++	+++	+++	++	51941	112892
M42	TETRANECTIN PRECURSOR (TN) (PLASMINOGEN-KRINGLE 4 BINDING PROTEIN)	++	++	+++	+++	+++	+++	++	+++	+++	+++	8764.7	224917
M43	amyloid related serum protein SAA	++	++	+++	+++	+++	+++	++	-	++	+	22567	4507557
M44	CALGRANULIN A (MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 8) (MRP-8) (CYSTIC FIBROSIS ANTIGEN) (CFAG) (P8) (LEUKOCYTE L1 COMPLEX LIGHT CHAIN) (S100 CALCIUM-BINDING PROTEIN A8)	+++	++	+++	+++	+++	++	+++	++	+	+	11682.8	4506777
M45	C-REACTIVE PROTEIN PRECURSOR	-	+++	++	+++	+++	++	+	-	++	++	10834.6	14729628
												25038.7	14728083

ID	Protein												
M46	RHO GDP-DISSOCIATION INHIBITOR 2 (RHO GDI 2) (RHO-GDI BETA) (LY-GDI)	++	+++	+++	++	++	++	++	-	++	++	22988.1	10835002
M47	PROFILIN I	+++	+++	+++	+++	++	+++	++	++	++	++	15054.3	4826898
M49	APOLIPOPROTEIN D PRECURSOR	++	-	++	++	++	+++	++	++	++	-	21275.7	4502163
M50	inter-alpha-trypsin inhibitor family heavy chain-related protein	++	++	++	++	++	+++	++	++	+++	++	103373	4096840
M51	14-3-3 PROTEIN BETA/ALPHA (PROTEIN KINASE C INHIBITOR PROTEIN-1) (KCIP-1) (PROTEIN 1054)	++	++	++	++	++	-	+	+	-	++	28082.5	4507949
M52	Ig G1 H Nie	-	-	++	++	++	-	-	-	-	-	49207.8	229601
M53	OSTEOPONTIN PRECURSOR (BONE SIALOPROTEIN 1) (URINARY STONE PROTEIN) (SECRETED PHOSPHOPROTEIN 1) (SPP-1) (NEPHROPONTIN) (UROPONTIN)	+	++	++	-	-	-	-	-	-	-	35422.9	14724978
M54	AFAMIN PRECURSOR (ALPHA-ALBUMIN) (ALPHA-ALB)	++	-	++	-	++	++	++	++	++	++	69069.6	4501987
M55	TRIOSEPHOSPHATE ISOMERASE (TIM)	++	++	-	-	++	-	-	-	-	++	26669.6	4507645
M56	pre-serum amyloid P component	++	-	-	-	++	+++	-	-	-	-	25397.3	337758
M57	COMP_HUMAN	++	++	++	-	+	++	++	++	++	-	89149	2623750
M58	prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)	-	-	++	++	-	++	-	-	-	-	50307.8	15298143
M59	VITRONECTIN PRECURSOR (SERUM SPREADING FACTOR) (S-PROTEIN) [CONTAINS: SOMATOMEDIN B]	++	++	++	++	++	++	++	+++	++	++	54305.9	14774022

ID	Protein												
M60	CALGRANULIN C (S100 A12 protein)	++	+++	++	++	++	+	-	-	-	-	10443.9	2146972
M61	cofilin 1 (non-muscle)	++	++	++	++	++	++	++	+++	-	+++	16811.7	14784011
M62	cathepsin B	++	++	++	++	++	-	-	-	-	-	37821.8	4503139
M63	plasmin (EC 3.4.21.7) precursor [validated]	+	+	-	+++	+	+	-	+	+	-	90568.6	6225234
M64	PLASMA GLUTATHIONE PEROXIDASE PRECURSOR (GSHPX-P)	++	++	++	+++	++	+++	+++	++	++	++	25505.6	121672
M65	lumican	-	++	++	++	++	-	++	++	++	++	38429.2	4505047
M66	apolipoprotein C-II	++	+	-	++	-	+++	+++	++	-	-	10183.5	2134777
M67	calmodulin 2 (phosphorylase kinase, delta)	++	++	++	-	++	++	++	+	++	++	16836.7	14250065
M68	THYMOSIN BETA-4	++	+	++	++	++	-	-	++	++	++	5062.7	14730886
M69	uracil DNA glycosylase	++	++	++	++	++	-	-	-	-	-	35492.9	35053
M70	defensin alpha-3 precursor, neutrophil-specific [validated]	+++	+++	+++	+++	+++	++	++	++	++	++	10245	4885179
M71	CD14 antigen	-	-	++	++	++	-	++	-	-	-	40076.4	4557417
M72	peptidylprolyl isomerase (EC 5.2.1.8) A	++	++	++	++	++	-	-	++	++	++	19008.7	12804335
M73	similar to transgelin 2 (H. sapiens)	++	++	++	-	++	++	-	-	-	-	24454	14728128
M74	BETA-2-GLYCOPROTEIN 1 PRECURSOR (APOLIPOPROTEIN H) (APO-H) (B2GPI) (BETA(2)GPI)	++	-	-	++	+++	++	++	-	-	-	38298.4	14711355
M75	complement 9	-	-	-	-	-	++	+	-	-	-	60398.5	2258128
M76	alpha2 plasmin inhibitor (ACTIVATED PROTEIN C-BINDING PROTEIN) (APC INHIBITOR)	++	++	++	++	++	+	++	-	-	-	54596.1	11386143

M77	FICOLIN 3 PRECURSOR (COLLAGEN/FIBRINOGEN DOMAIN-CONTAINING PROTEIN 3) (COLLAGEN/FIBRINOGEN DOMAIN-CONTAINING LECTIN 3 P35) (Hakata Antigen)	-				++		++		++	32889.1	4504331
M78	glutathione transferase	++	++	++	-	++	-	-	-	-	23463.2	14766346
M81	complement factor B	++	++	++	++	+++	++	++	-	-	85505.3	4502397
M82	CALGIZZARIN (S100C PROTEIN) (MLN 70)	++	++	++	++	-	++	-	-	-	11740.5	5032057
M83	BETA-2-MICROGLOBULIN PRECURSOR	++	+++	+++	+++	+++	++	+++	++	++	13714.6	4757826
M84	CYSTEINE-RICH SECRETORY PROTEIN-3 PRECURSOR (CRISP-3) (SGP28 PROTEIN)	+	-	++	++	++	-	++	+	-	276630.5	5174675
M86	megakaryocyte stimulating factor	++	++	++	++	++	++	++	++	++	151092	5031925
M87	inter-alpha-trypsin inhibitor heavy chain H1 precursor	+	-	-	++	+	+	++	-	++	101388	478685
M88	keratin 9, cytoskeletal	-	-	+	-	-	+	-	+	+	62129.7	1082558
M89	FERRITIN HEAVY CHAIN (FERRITIN H SUBUNIT)	-	++	++	-	+	+	+	-	+	21225.8	14784648
M90	HISTONE H1.1	+	++	++	++	+	-	++	+	+	21734.2	356168
M91	keratin 1	-	-	-	-	++	++	+	-	+	66067	11935049
M92	ferritin light subunit	-	++	++	++	+	+	+	++	+	16394.7	182516
M93	PROTEASOME SUBUNIT ALPHA TYPE 2 (PROTEASOME COMPONENT C3) (MACROPAIN SUBUNIT C3) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT C3)	+	++	++	-	-	-	-	-	-	25153.9	12804095
M94	CARBONIC ANHYDRASE I (CARBONATE DEHYDRATASE I) (CA-I)	-	++	++	-	-	-	-	-	++	28870.3	4502517

- 133 -

ID	Protein														
M95	LYMPHOCYTE-SPECIFIC PROTEIN LSP1 (PP52 PROTEIN) (52 KDA PHOSPHOPROTEIN) (LYMPHOCYTE PHOSPHOPROTEIN) (LYMPHOCYTE-SPECIFIC ANTIGEN WP34)	-		-	-	-	-	-	-	-	-	-	-	37191.8	10880979
M96	apolipoprotein F	++	++	++	-	++	++	++	-	-	++	++	-	35399.7	4502165
M98	OSTEOINDUCTIVE FACTOR PRECURSOR (OIF) (OSTEOGLYCIN) (MIMECAN)	-	-	++	-	-	-	-	++	-	-	-	++	33922.4	7661704
M99	APOLIPOPROTEIN E PRECURSOR (APO-E)	-	++	-	+	+	++	++	++	++	++	-	-	36154.3	4557325
M100	PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN (PEBP) (NEUROPOLYPEPTIDE H3) (HIPPOCAMPAL CHOLINERGIC NEUROSTIMULATING PEPTIDE) (HCNP) (RAF KINASE INHIBITOR PROTEIN) (RKIP)	++	+	++	-	-	++	-	-	-	-	-	+	21056.9	4505621
M101	SUPEROXIDE DISMUTASE [CU-ZN]	++	-	+	-	+	++	+	-	-	-	-	++	15935.8	4507149
M102	HISTONE H1A (H1.1)	+	++	++	-	+	-	+	+	+	+	-	-	22178.7	121916
M103	neutrophil lipocalin	++	-	++	-	-	-	-	-	-	-	-	-	20547.6	4261868
M104	serum paraoxonase/arylesterase 1	-	-	-	++	++	-	-	++	-	-	++	-	39731.5	14752059
M105	CYTIDINE DEAMINASE (CYTIDINE AMINOHYDROLASE)	++	-	++	-	-	++	-	-	-	-	-	-	16184.8	11386157
M106	CYSTATIN B (LIVER THIOL PROTEINASE INHIBITOR) (CPI-B) (STEFIN B)	++	++	++	++	++	-	-	+	-	+	-	+	11139.6	4503117
M108	angiotensinogen (serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 8)	-	-	-	-	-	-	-	++	-	++	-	-	53114.4	15079348
M109	COLLAGEN ALPHA 3(VI) CHAIN	-	-	++	++	-	-	-	++	-	++	-	++	343554	4758028

	PRECURSOR												
M110	beta galactoside binding lectin	-	++	-	++	-	-	++	-	-	-	14584.6	227920
M111	SH3BGRL3-like protein	++	++	++	-	-	-	-	-	-	-	10437.8	13775198
M112	proteoglycan link protein 2	-	-	-	++	-	-	-	++	-	-	40165.8	4503053
M113	LYSOZYME C PRECURSOR (1,4-BETA-N-ACETYLMURAMIDASE C)	-	++	-	++	-	-	-	-	-	-	16537.1	4557894
M114	cysteine-rich secreted A12-alpha-like protein 2	-	+	++	++	-	-	-	-	-	-	11419.5	9966777
M115	LEUKOCYTE ELASTASE INHIBITOR (LEI) (MONOCYTE/NEUTROPHIL ELASTASE INHIBITOR) (M/NEI) (EI)	-	++	+	-	-	-	-	-	-	-	42742	13489087
M116	INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 PRECURSOR (IGFBP-4) (IBP-4) (IGF-BINDING PROTEIN 4)	+	+	-	++	++	-	-	++	-	+	27934.2	136533947
M117	LOW AFFINITY IMMUNOGLOBULIN GAMMA FC REGION RECEPTOR III-A PRECURSOR (IGG FC RECEPTOR III-2) (FC-GAMMA RIII-ALPHA) (FC-GAMMA RIIIA) (FCRIIIA) (FC-GAMMA RIID) (FCRIII) (CD16-A) (FCR-10)	++	++	++	++	++	-	++	-	-	++	29089.3	12056967
M118	sex hormone-binding globulin	-	-	+	++	-	-	+	++	-	+	374488	14770624
M119	ANNEXIN I (LIPOCORTIN I) (CALPACTIN II) (CHROMOBINDIN 9) (P35) (PHOSPHOLIPASE A2 INHIBITORY PROTEIN)	-	+	++	++	-	-	++	-	-	-	38714.5	4502101

ID	Protein										
M120	MnSOD precursor	-	-	++	-	+	+	-	+	24721.2	34711
M121	EPIDIDYMAL SECRETORY PROTEIN E1 PRECURSOR (NIEMANN-PICK DISEASE TYPE C2 PROTEIN) (EPI-1) (HE1) (EPIDIDYMAL SECRETORY PROTEIN 14.6) (ESP14.6)	++	++	++	-	-	-	++	-	16570.3	5453678
M123	metastasin	++	++	++	++	-	-	++	-	11846.7	4506765
M124	inter-alpha (globulin) inhibitor, H2 polypeptide	-	++	-	-	++	+	-	-	106464	14742977
M125	alpha-1 type I collagen	-	++	+	++	-	++	++	++	55060.9	179594
M126	GELSOLIN PRECURSOR, PLASMA (ACTIN-DEPOLYMERIZING FACTOR) (ADF) (BREVIN) (AGEL)	-	++	-	-	-	-	++	++	85697.9	4504165
M127	PROTEASOME SUBUNIT ALPHA TYPE 4 (PROTEASOME COMPONENT C9) (MACROPAIN SUBUNIT C9) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT C9) (PROTEASOME SUBUNIT L)	-	++	++	-	-	-	-	-	29484	4506185
M128	Similar to coactosin-like protein	-	++	++	++	-	+	-	-	15945.1	1196417
M129	THIOREDOXIN (ATL-DERIVED FACTOR) (ADF) (SURFACE ASSOCIATED SULPHYDRYL PROTEIN) (SASP)	++	++	++	-	-	+	-	-	11737.6	14740403
M130	K12 protein precursor	-	++	-	++	-	-	++	-	27039.2	4506869

ID	Description												A	B
M131	VITAMIN-K DEPENDENT PROTEIN C PRECURSOR (AUTOPROTHROMBIN IIA) (ANTICOAGULANT PROTEIN C) (BLOOD COAGULATION FACTOR XIV)	-						++		+	-		52071.6	4506115
M132	titin, cardiac muscle [validated]	-											2993535	2136280
M133	MBL-associated protein MAp19	-					-	++	-				20629.3	14726286
M134	EOSINOPHIL CATIONIC PROTEIN PRECURSOR (ECP) (RIBONUCLEASE 3) (RNASE 3)	-	++	++	++	+	++	-	++	++	-	+	18440.5	4506551
M135	This CDS feature is included to show the translation of the corresponding V_region. Presently translation qualifiers on V_region features are illegal	-		++	++	++	-	-	-	++		++	11577.6	886295
M136	enhancer protein	-	++	++	-	-	-	-	-	-		-	22127.5	2135068
M137	cysteine-rich protein 1	-	++	++	++	-	+	-	++	++	++	+	8532.9	4503047
M138	anti-Gd cold agglutinin monoclonal IgMK light chain variable region	-	++	-	++	++	++	++	++	++	-	++	10365.6	545723
M139	CYSTATIN A (STEFIN A) (CYSTATIN AS)	+	-	-	++	++	++	-	-	-	-	-	11006.5	4885165
M140	ANNEXIN II (LIPOCORTIN II) (CALPACTIN I HEAVY CHAIN) (CHROMOBINDIN 8) (P36) (PROTEIN I) (PLACENTAL ANTICOAGULANT PROTEIN IV) (PAP-IV)	-	++	++	-	-	-	-	-	-	-	-	38604.2	47577556
M141	diazepam binding inhibitor	-	++	++	+	-	-	-	-	-	-	-	11793.4	10140853
M142	bA139H14.1 (lymphocyte cytosolic protein 1 (L-plastin))	-	-	++	-	-	-	+	-	-	+	-	70288.8	8217500
M143	heparan sulfate proteoglycan 2 (perlecan)	-	-	-	++	-	-	-	++	++	-	++	122673	14733263

ID	Protein												
M144	cathepsin C	-	-	+	+	-	-	-	-	-	-	51854.1	13631727
M145	MYELOBLASTIN PRECURSOR (LEUKOCYTE PROTEINASE 3) (PR3) (AGP7) (WEGENER'S AUTOANTIGEN) (P29) (C-ANCA ANTIGEN)	+	-	-	-	-	-	-	-	-	-	27807.2	14765501
M146	glutaredoxin	-	+	++	+	++	-	-	-	-	-	11761.8	643695
M147	TRANSLATIONALLY CONTROLLED TUMOR PROTEIN (TCTP)	-	++	++	-	-	+	-	-	-	+	19595.5	4507669
M148	PROTEASOME COMPONENT C13 PRECURSOR (MACROPAIN SUBUNIT C13) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT C13)	-	-	-	-	-	++	-	-	-	-	30354.5	1172602
M149	ENDOTHELIAL PROTEIN C RECEPTOR PRECURSOR (ENDOTHELIAL CELL PROTEIN C RECEPTOR) (ACTIVATED PROTEIN C RECEPTOR) (APC RECEPTOR)	-	++	++	-	-	-	-	-	-	+	26671.6	11420547
M151	D-DOPACHROME TAUTOMERASE (PHENYLPYRUVATE TAUTOMERASE II)	++	+	++	-	+	-	-	-	-	-	127711.8	4503291
M152	p80 protein	-	++	-	-	-	-	-	-	-	++	75356.7	1483131
M153	COLLAGEN ALPHA 1(V) CHAIN PRECURSOR	-	-	++	-	-	-	-	++	-	++	183619	4502957
M155	rho GDP dissociation inhibitor (GDI)	-	-	++	-	-	-	-	-	-	++	23193.2	36038
M156	FIBRONECTIN PRECURSOR (FN) (COLD-INSOLUBLE GLOBULIN) (CIG)	-	-	++	-	+	+	-	-	-	+	262608	2506872

ID	Protein												
M157	FK506-BINDING PROTEIN (FKBP-12) (PEPTIDYL-PROLYL CIS-TRANS ISOMERASE) (PPIASE) (ROTAMASE) (IMMUNOPHILIN FKBP12)	++	++	-	-	-	-	-	-	-	-	11950.8	4503725
M159	similar to osteoclast stimulating factor 1 (H. sapiens)	++	-	-	-	-	-	-	-	-	-	23786.9	14738380
M161	PEROXIREDOXIN 2 (THIOREDOXIN PEROXIDASE 1) (THIOREDOXIN-DEPENDENT PEROXIDE REDUCTASE 1) (THIOL-SPECIFIC ANTIOXIDANT PROTEIN) (TSA) (PRP) (NATURAL KILLER CELL ENHANCING FACTOR B) (NKEF-B)	++	-	+	-	-	-	-	-	-	++	21892	13631440
M162	myosin catalytic light chain LC17b	++	++	-	-	-	-	-	-	-	-	16931.1	10440556
M163	protein SPY75	+	+	-	-	-	-	-	-	-	-	53998.3	4885405
M164	2-phosphopyruvate-hydratase alpha-enolase	-	++	-	-	++	-	-	-	-	-	47109.1	693933
M166	pancreatic secretory trypsin inhibitor	-	+	-	++	+	-	-	-	-	+	6247.1	671743
M167	GLIA MATURATION FACTOR GAMMA (GMF-GAMMA)	++	-	+	++	-	-	-	-	-	-	16801.4	47584440
M168	CALCYCLIN (LUNG 10 KDA PROTEIN)	-	+	++	-	+	+	-	-	-	-	10153.8	11733337
M169	SH3 DOMAIN-BINDING GLUTAMIC ACID-RICH-LIKE PROTEIN	-	++	+	-	-	-	-	-	-	-	12774.3	4506925
M170	CHYMOTRYPSINOGEN A	-	-	-	-	-	-	-	-	-	-	25666.3	117615
M171	DJ-1 protein	++	-	++	-	++	-	-	-	-	-	19847.1	6005749
M172	phosphoprotein enriched in astrocytes 15	-	-	+	-	-	-	-	-	-	-	15040.2	4505705

M173	EGF-CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 1 PRECURSOR (FIBULIN-3) (FIBL-3) (T16 PROTEIN)	-	-	-	++	-	+	-	-	-	+	54641	9665262
M174	superoxide dismutase 3, extracellular	+	-	-	-	-	++	-	-	-	-	25851.1	14733169
M175	CLARA CELL PHOSPHOLIPID-BINDING PROTEIN PRECURSOR (CCPBP) (CLARA CELLS 10 KDA SECRETORY PROTEIN) (CC10) (UTEROGLOBIN) (URINE PROTEIN 1) (UP1)	-	+	+	++	-	-	-	++	-	-	9993.8	4507809
M176	Similar to LIM and SH3 protein 1	+	-	++	-	-	-	-	-	-	-	29658.3	15214662
M177	PROSTAGLANDIN-H2 D-ISOMERASE PRECURSOR (PROSTAGLANDIN-D SYNTHASE) (GLUTATHIONE-INDEPENDENT PGD SYNTHETASE) (PROSTAGLANDIN D2 SYNTHASE) (PGD2 SYNTHASE) (PGDS2) (PGDS) (BETA-TRACE PROTEIN)	+	-	++	++	-	-	++	++	-	++	21028.9	4506251
M178	mannose 6-phosphate/insulin-like growth factor II receptor	-	++	-	-	-	-	-	-	-	-	273400	6981078
M179	OXYGEN-REGULATED PROTEIN 1 (RETINITIS PIGMENTOSA RP1 PROTEIN) (RETINITIS PIGMENTOSA 1 PROTEIN)	-	++	-	-	-	-	-	-	-	-	240663	5454016
M180	SERUM AMYLOID A PROTEIN (SAA) [CONTAINS: AMYLOID PROTEIN A (AMYLOID FIBRIL PROTEIN AA)]	-	-	++	+	+	-	-	-	-	-	12289.5	7531274

	CARGO SELECTION													
M181	PROTEIN TIP47 (47 KDA MANNOSE 6-PHOSPHATE RECEPTOR-BINDING PROTEIN) (47 KDA MPR-BINDING PROTEIN) (PLACENTAL PROTEIN 17)	-	-	++	-	-	-	-	-	-	-	-	47033.1	5032183
M182	adenylyl cyclase-associated protein	++	-	++	-	-	++	-	-	-	-	-	51749.4	15296533
M183	aldolase C	-	++	-	-	-	-	-	-	-	-	-	39456.1	4885063
M184	similar to PROTEASOME SUBUNIT ALPHA TYPE 6 (PROTEASOME IOTA CHAIN) (PROTEASOME IOTA CHAIN) (MACROPAIN IOTA CHAIN) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX IOTA CHAIN) (27 KDA PROSOMAL PROTEIN) (PROS-27) (P27K) (H. sapiens)	-	-	++	-	-	-	-	-	-	-	-	27330.7	14719929
M186	FOLLISTATIN-RELATED PROTEIN 1 PRECURSOR	-	-	+	++	++	++	-	-	-	-	-	34985.7	5901956
M187	GAMMA-INTERFERON INDUCIBLE LYSOSOMAL THIOL REDUCTASE PRECURSOR (GAMMA-INTERFERON-INDUCIBLE PROTEIN IP-30)	-	++	++	-	-	++	++	-	-	-	-	29149.1	12643406
M188	F-ACTIN CAPPING PROTEIN BETA SUBUNIT (CAPZ BETA)	++	++	-	-	-	++	++	++	-	-	-	31350.7	13124696
M189	coagulation factor X	++	-	-	-	-	-	-	-	-	+	-	52535.2	180336
M190	histone H3	-	-	-	-	++	-	++	-	-	-	++	15328	4504279
M191	adiponectin	-	-	-	-	-	-	-	-	-	-	++	26413.8	47757760
M192	16G2	-	+	+	-	-	-	-	++	-	-	-	42055.2	14738192
M195	S-100P PROTEIN	++	+	-	-	+	-	-	-	-	-	-	10400	5174663

ID	Name												
M196	INTERCELLULAR ADHESION MOLECULE-2 PRECURSOR (ICAM-2) (CD102)	-	+	-	++	-	-	-	++	-	+	30653.5	4504557
M197	MANNOSYL-OLIGOSACCHARIDE ALPHA-1,2-MANNOSIDASE (MAN(9)-ALPHA-MANNOSIDASE)	-	-	-	++	-	-	-	-	-	-	70821.3	5174521
M198	NAD+-isocitrate dehydrogenase, alpha subunit	-	-	++	++	-	++	+	++	++	++	39592	5031777
M199	CONNECTIVE TISSUE GROWTH FACTOR PRECURSOR (HYPERTROPHIC CHONDROCYTE-SPECIFIC PROTEIN 24)	-	-	-	-	-	++	-	-	-	-	38069.8	4503123
M200	complement factor H-related protein FHR-2	++	-	++	++	-	++	-	++	++	++	27868.8	21349940
M201	RIBONUCLEASE, SEMINAL PRECURSOR (SEMINAL RNASE) (S-RNASE) (RIBONUCLEASE BS-1)	-	-	-	-	-	++	-	-	-	-	16377.3	133237
M203	putative	+	.	-	-	-	-	-	-	-	-	12859.9	12832737
M204	SERUM AMYLOID A-4 PROTEIN PRECURSOR (CONSTITUTIVELY EXPRESSED SERUM AMYLOID A PROTEIN) (C-SAA)	-	-	-	-	-	++	-	-	-	-	14806.8	10835095
M205	HP1-BP74	-	-	-	-	-	-	+	-	-	+	61207.3	11424882
M206	myristoylated alanine-rich C-kinase substrate	-	-	-	-	-	+	-	-	-	-	3276.6	187385
M207	CORTICOSTEROID-BINDING GLOBULIN PRECURSOR (CBG) (TRANSCORTIN)	-	++	-	-	-	+	-	++	-	+	45141.1	4502595
M208	mannose-binding lectin	++	-	+	-	-	-	-	-	-	-	26090.6	5911809
M209	APOLIPOPROTEIN L PRECURSOR (APO-L)	-	-	-	-	-	-	-	-	++	-	42383.5	14916953

M210	GLUTATHIONE TRANSFERASE OMEGA 1 (GSTO 1-1)	++	++	-	-	-	-	-	-	-	-	27566	47584484
M211	Somatomedin A	-	-	+	-	-	-	-	-	-	-	7578.8	224061
M212	ganglioside M2 activator protein	-	++	-	-	-	-	-	-	+	-	17623.5	106058
M214	FATTY ACID-BINDING PROTEIN, EPIDERMAL (E-FABP) (PSORIASIS-ASSOCIATED FATTY ACID-BINDING PROTEIN HOMOLOG) (PA-FABP)	-	+	++	-	-	-	-	-	-	-	15164.5	45577581
M215	MYELOID CELL NUCLEAR DIFFERENTIATION ANTIGEN	-	-	+	-	-	-	-	-	-	-	45836.3	45505227
M216	protein-L-isoaspartate(D-aspartate) O-methyltransferase (EC 2.1.1.77) splice form II	++	-	+	-	-	-	-	-	-	-	24679.5	147819911
M217	pancreatic ribonuclease (EC 3.1.27.5) precursor	-	-	+	-	-	-	-	-	-	-	17239.9	2135882
M219	anti-MSP1 MAD20 block2 ScFv Ig light chain variable region	-	-	-	++	-	-	-	-	-	-	11668.2	12836991
M220	vimentin	+	-	++	-	+	-	-	-	+	+	53714	340219
M221	HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, GAMMA CHAIN (HLA-DR ANTIGENS ASSOCIATED INVARIANT CHAIN) (P33) (CD74 ANTIGEN)	-	-	+	-	-	-	-	-	-	-	33460.7	399888
M222	IMP dehydrogenase	+	++	+	-	+	-	-	-	-	+	55920.4	4504689
M223	granulin	-	+	-	-	-	-	-	-	-	-	61441.5	14772463
M224	p97	-	-	-	-	++	-	-	-	-	-	80170.1	3786308
M225	antigen HLA SB beta,MHC II	-	-	+	-	-	-	-	-	-	-	19069.9	224042
M227	kinesin like protein 9	-	++	-	-	-	-	-	-	-	+	89942.6	6754442

ID	Protein											
M228	PROTEASOME COMPONENT MECL-1 PRECURSOR (MACROPAIN SUBUNIT MECL-1) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT MECL-1)	++	-	-	-	-	-	-	-	-	28936.5	45506191
M233	hypothetical protein DKFZp761B15121.1	-	-	++	++	+	-	-	++	++	17934.8	147773888
M235	VON EBNER'S GLAND PROTEIN PRECURSOR (VEG PROTEIN) (TEAR PREALBUMIN) (TP) (TEAR LIPOCALIN) (LIPOCALIN-1)	-	-	-	-	+	-	-	-	-	19250.1	4504963
M236	RIBONUCLEASE PANCREATIC PRECURSOR (RNASE 1)	-	-	-	-	-	+	-	-	-	16461	133198
M240	Carbonic Anhydrase II (Carbonate Dehydratase II) (CAII)	-	-	+	-	-	-	-	-	-	29246.2	4557395
M241	HRV Fab 027-VL	-	-	-	++	++	-	-	-	-	12383	2385498
M244	364K Golgi complex-associated protein	-	-	+	-	-	-	-	-	-	364299	7441640
M245	histone H2A.5	+	-	-	-	-	-	+	-	-	14059.5	70686
M246	antibody, light chain variable regin to HIV1 p25	-	-	-	++	-	-	-	-	-	12356.8	732744
M248	TRYPSINOGEN, CATIONIC PRECURSOR (BETA-TRYPSIN)	-	-	-	-	-	-	-	-	+	25424.9	2507249
M249	putative	-	-	++	-	-	-	-	++	-	26422.2	12963645
M250	LOW AFFINITY IMMUNOGLOBULIN GAMMA FC REGION RECEPTOR II-A PRECURSOR (FC-GAMMA RII-A) (FCRII-A) (IGG FC RECEPTOR II-A) (FC-GAMMA-RIIA) (CD32) (CDW32)	-	-	++	-	-	-	-	-	-	34989.9	399476
M252	CYTOCHROME C	-	+	-	-	-	-	-	-	-	11888	14782885

ID	Protein												
M258	gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) precursor	-	·	+	-	-	-	-	-	-	-	26023.5	13646249
M259	breakpoint cluster region protein 1	++	++	-	-	-	-	-	-	-	-	155521.8	3002951
M261	BCL3	-	-	-	-	-	-	-	-	-	+	46432.3	3928845
M264	macrophage migration inhibitory factor	-	++	-	-	-	-	-	-	-	-	11428.1	187181
M266	unnamed protein product	-	-	-	+	-	-	-	-	-	-	47994.5	10436374
M267	ribosomal protein S28, cytosolic	-	+	++	-	+	-	-	-	-	-	2336.6	7440562
M268	MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 2 PRECURSOR (MAGP-2) (MP25)	-	-	-	-	-	+	-	-	-	+	19611.7	4505089
M269	cathepsin S	-	++	-	-	-	-	-	-	-	-	37495.9	11427057
M270	lambda-chain C-region C-lambda-2	-	-	-	-	-	++	-	-	-	++	11515.3	165427
M271	anti-porcine VCAM mAb 3F4 light chain variable region	-	-	-	++	-	-	-	-	-	-	12178.8	4098515
M275	CATHEPSIN D	+	+	-	-	-	-	-	-	-	-	44552.5	4503143
M277	putative	-	-	-	-	-	++	-	-	-	-	19274.4	128433372
M278	transaldolase	-	+	-	-	-	-	-	-	-	-	37540.3	5803187
M280	myeloid inhibitory siglec	-	-	-	-	-	-	-	-	-	++	51760.6	13936734
M281	granulocyte inhibitory protein	-	-	-	-	++	-	-	-	-	-	2046.3	106167
M282	GROWTH FACTOR RECEPTOR-BOUND PROTEIN 2 (GRB2 ADAPTER PROTEIN) (SH2/SH3 ADAPTER GRB2) (ASH PROTEIN)	+	-	-	-	-	-	-	-	-	-	25206.5	4504111
M284	UBIQUITIN-LIKE PROTEIN SMT3B (SENTRIN 2)	-	++	-	-	-	-	-	-	-	-	10871.3	5902098

ID	Description													
M286	HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, CW-1 CW*0102 ALPHA CHAIN PRECURSOR (CW1.2)	-	+	-	-	-	-	-	-	-	-	-	40950.1	231427
M287	40S RIBOSOMAL PROTEIN S17	-	-	++	-	-	-	-	-	-	-	-	15550.2	4506693
M289	dJ747L4.1 (Brachyury (T box protein)-LIKE protein	-	-	-	-	-	-	-	-	-	-	-	47004.1	3900891
M290	anti-oxidized LDL autoantibody variable kappa chain	++	-	-	-	++	-	-	-	-	-	-	11825.3	15277620
M296	similar to TROPOMYOSIN, CYTOSKELETAL TYPE (TM30-NM) (H. sapiens)	-	-	-	-	++	-	-	-	-	-	-	16974.3	14786818
M298	ZYXIN (ZYXIN 2)	-	-	+	-	-	-	-	-	-	-	-	61277.7	4508047
M300	ENHANCER OF RUDIMENTARY HOMOLOG	-	++	+	-	-	-	-	-	-	-	-	12259	4758302
M301	regulator of G-protein signaling 4	-	-	-	-	-	-	-	-	++	-	-	23255.8	5032039
M305	anti-DNA immunoglobulin light chain IgG	-	-	-	-	-	-	-	-	-	-	+	11047.2	1870506
M307	UBIQUITIN-LIKE PROTEIN NEDD8	-	+	-	-	-	-	-	-	-	-	-	9071.6	54537760
M311	SCRAPIE-RESPONSIVE PROTEIN 1 PRECURSOR (SCRG-1)	-	-	-	-	-	-	-	++	-	-	-	11081.2	6005870
M312	gonadotropin releasing peptide	-	-	-	+	-	-	++	++	-	-	-	1651.6	225500
M315	IRT-1	-	++	-	-	-	-	-	-	-	-	-	14617.3	4758612
M316	recombinant antibody light chain VL domain	-	-	-	++	-	-	-	-	-	-	-	11556.9	12957386
M317	putative	-	-	-	-	-	-	-	-	++	-	-	56695	12836433
M318	CYSTATIN M PRECURSOR (CYSTATIN E)	-	-	-	-	-	-	-	++	-	-	-	16511.2	4503113
M320	proteasome activator PA28 beta chain	-	-	-	-	++	-	-	-	-	-	-	27348.7	4506237

	Protein												ID 1	ID 2
M321	AGGRECAN CORE PROTEIN PRECURSOR (CARTILAGE-SPECIFIC PROTEOGLYCAN CORE PROTEIN) (CSPCP) (CHONDROITIN SULFATE PROTEOGLYCAN CORE PROTEIN 1)	-		-		-		++		-		-	250194	129886
M322	KIAA0185 protein	-	-	++	-	-	+	-	++	-	-	-	575547.8	15298593
M323	hypothetical protein FLJ13465	-	-	-	-	-	-	-	-	-	-	-	97949.7	147745846
M324	CARBOXYPEPTIDASE N 83 KDA CHAIN (CARBOXYPEPTIDASE N REGULATORY SUBUNIT)	-	-	-	-	-	-	-	-	+	-	-	58649.4	115877
M326	R33729_1	-	-	+	-	-	+	-	-	-	-	-	11332.9	33554455
M327	lymphocyte surface antigen precursor CD44	-	++	++	++	-	-	-	-	-	-	-	32074.7	106924
M328	PYRIDOXINE KINASE (PYRIDOXAL KINASE)	+	-	-	-	-	-	-	-	+	-	-	35102.5	4505701
M329	unnamed protein product	-	-	-	-	-	+	-	-	-	-	-	42442.7	10436670
M330	CALPACTIN I LIGHT CHAIN (P10 PROTEIN) (P11) (CELLULAR LIGAND OF ANNEXIN II) (NERVE GROWTH FACTOR INDUCED PROTEIN 42C)	-	-	-	-	-	-	++	-	++	-	-	11203.2	4506761
M331	c360B4.1 (PUTATIVE novel protein similar to predicted bacterial and worm proteins)	+	-	-	-	-	-	++	++	++	-	-	23267.9	5912545
M332	latent transforming growth factor-beta binding protein 4S	-	-	-	-	-	-	-	++	-	-	-	161160	3327808
M333	hypothetical protein XP_047083	-	-	-	-	-	-	-	-	-	-	+	49735	14744245

ID	Description											
M334	similar to GASTRIN/CHOLECYSTOKININ TYPE B RECEPTOR (CCK-B RECEPTOR) (CCK-BR) (H. sapiens)	++	++	++	-	-	-	-	-	+	45421.1	13633718
M336	similar to LINE-1 REVERSE TRANSCRIPTASE HOMOLOG (H. sapiens)	-	-	-	-	-	-	-	-	+	16237.5	14766164
M337	TYROSINE-PROTEIN KINASE CSK (C-SRC KINASE)	-	-	-	-	-	-	-	-	-	50704.6	4758078
M338	Similar to dystroglycan 1 (dystrophin-associated glycoprotein 1)	-	-	-	-	++	-	++	++	-	97541.1	15215308
M339	complement component 1, s subcomponent	-	-	-	-	-	++	-	-	-	37337.1	14766592
M344	TELOMERASE-BINDING PROTEIN P23 (HSP90 CO-CHAPERONE) (PROGESTERONE RECEPTOR COMPLEX P23)	+	-	-	-	-	-	-	-	-	18721.5	9790017
M340	lysophospholipase II	-	-	-	-	-	-	-	-	+	24737.1	9966764
M346	inwardly rectifying potassium channel protein Kir6.2	-	-	-	-	-	++	++	-	-	43580.1	2143813
M349	dnaJ protein homolog	-	-	-	++	-	-	-	-	-	30611.7	478645
M350	40S RIBOSOMAL PROTEIN S29	-	++	-	-	-	-	-	-	+	6676.8	4506717
M352	MYOGLOBIN	-	-	-	-	-	-	-	-	+	17042.7	127656
M353	cathepsin X precursor	-	++	-	-	-	-	-	-	-	33943.2	3650498
M354	unknown	-	++	-	-	-	-	-	-	-	17297.2	3860020
M356	HYPOTHETICAL PROTEIN CGI-109 PRECURSOR	-	-	-	-	-	+	+	-	-	24353.8	12585535
M357	LITHOSTATHINE 1 BETA PRECURSOR (REGENERATING PROTEIN 1 BETA)	+	+	-	-	-	+	-	+	+	18664.9	10835248
M358	human leucocyte antigen B	-	-	-	-	-	-	-	-	+	31344.8	9027550

ID	Description											Col A	Col B
M360	This CDS feature is included to show the translation of the corresponding V_region. Presently translation qualifiers on V_region features are illegal.	-	-	-	-	-	-	-	-	-	-	11607	681900
M362	KIAA0336	++	-	-	++	-	-	-	-	-	-	184659	7662062
M363	Similar to expressed sequence 2 embryonic lethal	-	-	-	-	-	-	-	-	++	-	52604.1	15489206
M366	NEUROBLASTOMA SUPPRESSOR OF TUMORIGENICITY 1 (ZINC FINGER PROTEIN DAN) (N03)	-	-	-	+	-	-	-	-	-	-	19276.9	4885509
M370	putative	-	-	-	-	++	++	-	-	-	-	25193.3	12847919
M372	alpha 1F calcium channel subunit	-	-	-	-	-	-	-	-	+	-	221137	14669577
M373	sal (Drosophila)-like 2	-	-	-	-	-	+	-	-	-	-	105310	14751528
M374	AF15q14 protein	-	-	-	++	-	-	-	-	-	+++	205685	9966807
M375	putative	-	-	-	-	-	-	-	-	-	-	30469.3	12836789
M376	fibroblast growth factor 13 isoform 1y1v	-	-	-	+++	++	++	++	++	++	-	8239.5	4512024
M379	KIAA0433	+	+	-	-	-	-	-	-	-	-	140408	7662118
M380	anti-c-erbB-2 immunoglobulin light chain v	-	-	-	++	+	++	-	-	-	-	11608.9	1145350
M381	ATP-BINDING CASSETTE, SUB-FAMILY A, MEMBER 2 (ATP-BINDING CASSETTE TRANSPORTER 2) (ATP-BINDING CASSETTE 2)	-	-	-	++	-	-	-	-	-	-	269976	14916523
M382	G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein	-	-	-	++	-	-	-	-	-	-	85231.4	13929158
M387	farnesyl-protein transferase beta chain	-	-	++	-	+	++	++	++	++	++	43087.6	2135098
M388	KIAA1813 protein	-	-	-	-	++	-	-	-	-	-	73090.1	14017843
M389	hypothetical protein	-	-	-	-	-	-	-	-	++	-	117875	13644578

ID	Description											
	FLJ11937											
M391	ribosomal protein L29	++	-	-	-	+	-	-	-	-	17667.1	1082766
M393	inhibitor PI,alpha1 proteinase	-	-	-	-	-	-	-	-	-	2431	223058
M394	dJ467L1.3 (period (Drosophila) homolog 3)	-	+	++	-	-	-	-	-	-	126247	6580412
M395	cylindromatosis (turban tumor syndrome)	-	-	++	-	-	-	-	-	-	82125.4	14779751
M396	T cell receptor alpha chain V region (clone 2V alpha 23-2)	-	-	-	-	-	-	-	-	-	1710	478461
M399	anti-pneumococcal Ig L-chain Fab fragment	-	-	-	-	-	++	++	-	-	11358.6	3603383
M401	Unknown (protein for MGC:16498)	-	-	-	-	+	-	-	-	-	45446.9	15530249
M403	plasma protease (C1) inhibitor precursor	-	-	-	-	-	-	-	+	-	55182.5	179619
M404	similar to INITIATION FACTOR 5A (EIF-5A) (EIF-4D) (REV-BINDING FACTOR) (H. sapiens)	-	-	-	-	-	-	-	-	++	16789.2	13642507
M406	CGI-202	+	-	-	-	++	-	-	-	-	13832.6	8895093
M409	alternatively spliced	-	-	-	-	-	-	-	-	-	14203.2	2125864
M410	neuronal leucine-rich repeat protein-3	-	-	-	++	-	-	-	-	-	79424.7	14751034
M411	Unknown (protein for IMAGE:3587716)	-	-	-	-	-	-	-	+	-	71702.7	15277493
M412	PROTEASOME SUBUNIT ALPHA TYPE 1 (PROTEASOME COMPONENT C2)(MACROPAIN SUBUNIT C2)(MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT C2)(PROTEASOME NU CHAIN)	-	++	-	-	-	-	-	-	-	29546.7	9910833
M413	NIF-like protein	++	-	-	-	-	-	-	-	-	38532.3	15487262
M415	unnamed protein product	-	++	+	-	-	-	-	+	-	27742.6	10436722
M417	hairy/enhancer of split 6	+	-	-	-	+	-	-	+	-	23902	14009498

- 150 -

ID	Protein												
M419	sperm tail associated protein	-	-	-	-	-	-	-	-	-	-	++	119401	9910570
M420	NEURABIN-II (NEURAL TISSUE-SPECIFIC F-ACTIN BINDING PROTEIN II) (SPINOPHILIN) (P130) (PP1BP134)	++	++	++	++	-	-	-	-	-	-	-	89646.8	13431725
M421	TFNR	-	+	-	-	-	-	-	-	-	-	-	245729	12232589
M422	TROPOMYOSIN 4, EMBRYONIC FIBROBLAST ISOFORM (TM-4)	-	++	++	++	-	-	-	-	-	-	-	28509.8	6981672
M423	ZINC FINGER Y-CHROMOSOMAL PROTEIN	-	-	-	-	-	-	-	-	-	-	-	90531.5	4507967
M424	CD27L RECEPTOR PRECURSOR (T-CELL ACTIVATION ANTIGEN CD27) (T14)	-	-	-	-	-	+	-	-	-	-	+	29156.6	4507587
M425	FIBROLEUKIN PRECURSOR (FIBRINOGEN-LIKE PROTEIN 2) (PT49)	-	+	-	-	-	-	-	-	-	-	-	50228.9	5730075
M428	putative	-	-	-	++	++	+	-	-	-	-	-	2213.6	553734
M429	unnamed protein product	-	-	-	++	-	-	++	-	-	-	-	94254.2	10435664
M431	hypothetical protein	-	-	-	++	-	-	-	-	-	-	-	101555	14720628
M433	myosin-VIIb	-	-	-	-	-	-	-	-	-	+	+	240788	14161694
M435	hypothetical protein FLJ20516	++	++	+	-	-	++	-	-	-	-	-	34555.4	15300488
M436	similar to ribosomal protein S26 (H. sapiens)	-	-	-	-	-	+	-	-	-	-	-	13043.6	13642964
M439	C-terminus matches KIAA0559, N-terminus similar to Bassoon protein	-	-	-	-	-	++	-	-	-	-	-	375564	4522026
M441	arfaptin 1	++	-	-	-	-	-	++	+	-	-	+	40779.3	1120714
M442	apolipoprotein CI	-	-	-	-	-	++	-	-	-	-	-	7750.9	178834
M443	d3591C20.1 (novel protein similar to mouse NG26)	-	-	-	-	-	-	-	-	+	-	-	52554.9	11125672
M444	VESICLE TRANSPORT V-SNARE PROTEIN VTI1-LIKE 1 (VTI1-RP1)	-	-	-	++	-	-	-	-	-	-	-	26687.6	13124617

ID	Description												
M445	retinoblastoma-associated protein HEC	+	-	-	-	-	-	-	-	-	-	73913.1	5174457
M446	ZINC FINGER PROTEIN GFI-1 (GROWTH FACTOR INDEPENDENCE-1)	++	-	-	-	-	-	-	-	-	-	45586	4885267
M447	5-HYDROXYTRYPTAMINE 5A RECEPTOR (5-HT-5A) (SEROTONIN RECEPTOR) (REC17)	-	-	-	-	-	-	-	-	-	-	40672.8	6981062
M448	This CDS feature is included to show the translation of the corresponding V_region. Presently translation qualifiers on V_region features are illegal	-	-	-	++	-	-	-	-	-	++	115581.9	845530
M451	KIAA1664 protein	++	-	-	-	-	-	-	-	-	-	99851.7	13359201
M452	METALLOTHIONEIN-II (MT-II)	-	-	+	++	-	-	-	-	++	-	6042.3	5174764
M453	microseminoprotein beta	-	-	-	-	-	-	-	-	++	-	10651.1	225159
M454	SACSIN	++	-	-	-	-	-	-	-	-	-	436757	7657536
M455	tenascin-R	-	-	-	++	-	-	-	-	-	-	149575	1617316
M457	SERINE PROTEASE INHIBITOR KAZAL-TYPE 5 PRECURSOR (LYMPHO-EPITHELIAL KAZAL-TYPE RELATED INHIBITOR) (LEKTI) [CONTAINS: HEMOFILTRATE PEPTIDE HF6478	-	-	++	-	-	-	-	-	-	-	120760	13959398
M458	CALGRANULIN C (CAGC)	-	+	-	-	-	-	-	-	-	-	10614.1	461678
M459	galactose-specific lectin	+	+	-	-	-	-	-	-	-	-	26148.5	1196442
M460	non-muscle myosin heavy chain	-	-	++	-	-	-	-	-	-	-	72371.4	3205211
M461	DOCK180 protein	-	-	++	-	-	-	-	-	-	-	215377	4503355
M462	serine protease	-	-	-	-	-	-	-	-	++	-	40239.3	3777621
M463	nuclear zinc finger protein Np95	-	-	+	+	-	-	-	-	-	-	89814.4	14764016

ID	Description											
M464	LIM protein (similar to rat protein kinase C-binding protein enigma)	-	-	++	-	-	-	-	-	-	63972.5	14250573
M465	SECIS binding protein 2	-	++	-	-	-	-	-	-	-	95478.4	14211829
M466	HSPC055 protein	-	+	-	-	-	-	+	-	-	83654.5	14775320
M468	ribosomal protein L14	-	-	-	-	-	-	-	-	-	23803.4	4506601
M470	chloride channel protein 3, long form	-	-	-	-	-	-	-	-	++	91243.1	4502869
M471	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 3 (MAPK/ERK KINASE KINASE 3) (MEK KINASE 3) (MEKK 3)	-	-	-	++	-	-	-	-	-	70970.1	4505153
M472	unnamed protein product	-	-	-	-	-	-	-	-	+	62332	12383086
M473	anti-HIV gp120 antibody light chain variable region	-	-	-	-	-	-	-	-	++	11498.5	460857
M474	CARBONIC ANHYDRASE IV PRECURSOR (CARBONATE DEHYDRATASE IV) (CA-IV)	-	-	-	-	-	-	-	-	+	34394.2	1345657
M475	hypothetical protein FLJ11016	-	-	+	-	-	-	-	-	-	47126.1	13937775
M476	putative gene with similarities to KIAA1074 and KIAA0565	-	-	+	-	-	-	-	-	-	50038.1	7717246
M477	S-MYC PROTO-ONCOGENE PROTEIN	+	-	-	-	-	-	-	-	-	47002.5	11177868
M480	unnamed protein product	-	-	-	++	+	-	-	-	-	42680.2	10432636
M483	proapolipoprotein Variant	-	-	+	+	-	-	-	-	-	25119.7	
M484	Unknown	-	-	+	+	-	-	-	-	+	33413.9	
M485	neutrophil lactoferrin	-	-	+	-	-	-	-	-	-	59529.6	186818 (GenPept)
M486	alpha-2-HS glycoprotein Variant	-	-	-	-	-	-	-	-	+	12290.2	10289662 (dbEST)
M487	MT-11 protein Variant	-	+	-	-	-	-	-	-	-	10172.9	7378207 (dbEST)

M488	immunoglobulin lambda light chain homolog	-	-	+	-	-	-	+	-	-	-	16740.9	5	6
M489	Unknown	-	-	-	-	-	-	-	-	+	-	21461.8	7	8
M490	Unknown	-	-	-	-	-	-	-	-	-	-	20895	9	10

10^{10} and above	+++
10^{8} to 10^{10}	++
10^{6} to 10^{8}	+
0	-

Table 3A

Marker	Gene Name	E_51 Br38	E_59 Br26	E_63 Br35	E_67 Br42	E_70 Br43	N_52 Br29	N_54 Br28	N_58 Br34	N_65 Br36	N_66 Br39	MW (Da)	GI number	SEQ ID NO (nts)	SEQ ID NO (AA)
M30	KININOGEN PRECURSOR (ALPHA-2-THIOL PROTEINASE INHIBITOR) [CONTAINS: BRADYKININ]	++	-	-	-	-	++	++	+	++	-	71945.7	125507		
M31	CALGRANULIN B (MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 14) (MRP-14) (P14) (LEUKOCYTE L1 COMPLEX HEAVY CHAIN) (S100 CALCIUM-BINDING PROTEIN A9)	+++	+++	+++	+++	+++	+++	+++	++	++	++	13242.1	4506773		
M37	similar to phosphoglycerate mutase 1 (brain)	++	++	++	++	++	++	++	-	-	++	28850.2	15301114		
M43	amyloid related serum protein SAA	++	++	+++	+++	+++	+++	++	-	++	+	11682.8	4506777		
M44	CALGRANULIN A (MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 8) (MRP-8) (CYSTIC FIBROSIS ANTIGEN) (CFAG) (P8) (LEUKOCYTE L1 COMPLEX LIGHT CHAIN) (S100 CALCIUM-BINDING PROTEIN A8)	+++	++	+++	+++	+++	++	+++	++	+	+	10834.6	14729628		

ID	Name											Acc. 1	Acc. 2
M46	RHO GDP-DISSOCIATION INHIBITOR 2 (RHO GDI 2) (RHO-GDI BETA) (LY-GDI)	++	++	+++	++	++	++	+	-	+	++	229988.1	10835002
M51	14-3-3 PROTEIN BETA/ALPHA (PROTEIN KINASE C INHIBITOR PROTEIN-1) (KCIP-1) (PROTEIN 1054)	++	++	++	++	++	-	-	-	+	++	28082.5	4507949
M52	Ig G1 H Nie	-	++	++	++	++	-	-	-	-	-	49207.8	229601
M53	OSTEOPONTIN PRECURSOR (BONE SIALOPROTEIN 1) (URINARY STONE PROTEIN) (SECRETED PHOSPHOPROTEIN 1) (SPP-1) (NEPHROPONTIN) (UROPONTIN)	+	++	++	-	-	-	-	-	-	-	354422.9	14724978
M55	TRIOSEPHOSPHATE ISOMERASE (TIM)	++	++	++	-	++	++	-	-	++		26669.6	4507645
M58	prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)	-	++	++	++	++	++	-	-	++		50307.8	15298143
M60	CALGRANULIN C (S100 A12 protein)	++	+++	++	++	++	++	++	-	-	++	10443.9	2146972
M62	cathepsin B	++	++	++	++	++	-	-	++	-	-	37821.8	4503139
M66	apolipoprotein C-II	++	+	-	-	++	+++	++	++	-		10183.5	2134777
M68	THYMOSIN BETA-4	++	+	++	++	-	-	-	-	++		5062.7	14730886
M69	uracil DNA glycosylase	++	++	++	-	-	-	-	-	-		35492.9	35053
M70	defensin alpha-3 precursor, neutrophil-specific [validated]	+++	+++	+++	+++	++	++	++	++	++		10245	4885179
M71	CD14 antigen	-	-	++	++	++	-	++	-	-		40076.4	4557417
M72	peptidylprolyl isomerase (EC 5.2.1.8) A	++	++	++	++	++	-	++	++	++		19008.7	12804335
M73	similar to transgelin 2 (H. sapiens)	++	++	++	-	++	+	-	-	-		24454	14728128
M76	alpha2 plasmin inhibitor	++	++	++	++	++	+	++	-	-		54596.1	11386143
M78	glutathione transferase	++	++	++	-	-	++	-	-	-		23463.2	14766346

ID	Protein												
M82	CALGIZZARIN (S100C PROTEIN) (MLN 70)	++	++	++	++	++	-	-	-	+	-	11740.5	5032057
M103	neutrophil lipocalin	++	-	++	-	-	-	-	-	-	-	20547.6	4261868
M106	CYSTATIN B (LIVER THIOL PROTEINASE INHIBITOR) (CPI-B) (STEFIN B)	++	++	++	-	++	-	-	+	-	+	11139.6	4503117
M111	SH3BGRL3-like protein	++	++	++	++	-	-	-	++	-	-	10437.8	13775198
M117	LOW AFFINITY IMMUNOGLOBULIN GAMMA FC REGION RECEPTOR III-A PRECURSOR (IGG FC RECEPTOR III-2) (FC-GAMMA RECEPTOR III-ALPHA) (FC-GAMMA RIIIA) (FCRIIIA) (FC-GAMMA RIII) (FCRIII) (CD16-A) (FCR-10)	++	++	++	++	++	-	++	++	-	++	29089.3	12056967
M121	EPIDIDYMAL SECRETORY PROTEIN E1 PRECURSOR (NIEMANN-PICK DISEASE TYPE C2 PROTEIN) (EPI-1) (HE1) (EPIDIDYMAL SECRETORY PROTEIN 14.6) (ESP14.6)	++	++	++	++	-	-	-	++	-	-	16570.3	5453678
M123	metastasin	++	++	++	-	++	++	+	++	-	-	11846.7	4506765
M128	Similar to coactosin-like protein	-	++	++	++	-	+	+	-	-	-	15945.1	1196417
M131	VITAMIN-K DEPENDENT PROTEIN C PRECURSOR (AUTOPROTHROMBIN IIA) (ANTICOAGULANT PROTEIN C) (BLOOD COAGULATION FACTOR XIV)	-	-	-	-	-	++	+	-	-	-	52071.6	4506115
M151	D-DOPACHROME TAUTOMERASE (PHENYLPYRUVATE TAUTOMERASE II)	++	+	++	+	+	-	-	-	-	-	12711.8	4503291
M180	SERUM AMYLOID A PROTEIN (SAA) [CONTAINS: AMYLOID	-	-	++	+	+	-	-	-	-	-	12289.5	7531274

ID	Protein													
	PROTEIN A (AMYLOID FIBRIL PROTEIN AA)]													
M195	S-100P PROTEIN	++	+	-	-	+	-	-	-	-	-	10400	5174663	
M204	SERUM AMYLOID A-4 PROTEIN PRECURSOR (CONSTITUTIVELY EXPRESSED SERUM AMYLOID A PROTEIN) (C-SAA)	-	-	-	-	-	++	-	-	-	-	14806.8	10835095	
M484	Unknown	-	-	+	+	-	-	-	-	-	+	33413.9	3	4

10^{10} and above	+++
10^8 to 10^{10}	++
10^6 to 10^8	+
0	-

Table 3B

Marker	Gene Name	E_51 Br38	E_59 Br26	E_63 Br35	E_67 Br42	E_70 Br43	N_52 Br29	N_54 Br28	N_58 Br34	N_65 Br36	N_66 Br39	MW (Da)	GI number	SEQ ID NO (nts)	SEQ ID NO (AA)
M31	CALGRANULIN B (MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 14) (MRP-14) (P14) (LEUKOCYTE L1 COMPLEX HEAVY CHAIN) (S100 CALCIUM-BINDING PROTEIN A9)	+++	+++	+++	+++	+++	+++	+++	++	++	++	13242.1	4506773		
M43	amyloid related serum protein SAA	++	++	+++	+++	+++	+++	++	-	++	+	11682.8	4506777		
M44	CALGRANULIN A (MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 8) (MRP-8) (CYSTIC FIBROSIS ANTIGEN) (CFAG) (P8) (LEUKOCYTE L1 COMPLEX LIGHT CHAIN) (S100 CALCIUM-BINDING PROTEIN A8)	+++	++	+++	+++	+++	++	+++	++	+	+	10834.6	14729628		
M60	CALGRANULIN C (S100 A12 protein)	++	+++	++	++	++	++	++	++	-	-	10443.9	2146972		
M180	SERUM AMYLOID A PROTEIN (SAA) [CONTAINS: AMYLOID PROTEIN A (AMYLOID FIBRIL PROTEIN AA)]	-	-	++	+	+	-	-	-	-	-	12289.5	7531274		
M204	SERUM AMYLOID A-4 PROTEIN PRECURSOR (CONSTITUTIVELY EXPRESSED SERUM AMYLOID A PROTEIN) (C-SAA)	-	-	-	-	-	++	-	-	-	-	14806.8	10835095		

10^10 and above	+++
10^8 to 10^10	++
10^6 to 10^8	+
0	-

Table 4

Marker	Gene Name	E_51 Br38	E_59 Br26	E_63 Br35	E_67 Br42	E_70 Br43	N_52 Br29	N_54 Br28	N_58 Br34	N_65 Br36	N_66 Br39	MW (Da)	GI number	SEQ ID NO (nts)	SEQ ID NO (AA)
M31	CALGRANULIN B (MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 14) (MRP-14) (P14) (LEUKOCYTE L1 COMPLEX HEAVY CHAIN) (S100 CALCIUM-BINDING PROTEIN A9)	+++	+++	+++	+++	+++	+++	++	++	++	++	13242.1	4506773		
M43	amyloid related serum protein SAA	++	++	+++	+++	+++	+++	++	-	++	+	11682.8	4506777		
M44	CALGRANULIN A (MIGRATION INHIBITORY FACTOR-RELATED PROTEIN 8) (MRP-8) (CYSTIC FIBROSIS ANTIGEN) (CFAG) (P8) (LEUKOCYTE L1 COMPLEX LIGHT CHAIN) (S100 CALCIUM-BINDING PROTEIN A8)	+++	++	+++	+++	+++	++	+++	-	+	+	10834.6	14729628		
M60	CALGRANULIN C (S100 A12 protein)	++	+++	++	++	++	++	++	++	++	++	10443.9	2146972		
M65	lumican	-	++	++	++	++	-	++	+++	++	++	38429.2	4505047		
M86	megakaryocyte stimulating factor	++	++	++	++	-	++	-	++	++	++	151092	5031925		

Table 5

		10^10 and above	+++
		10^8 to 10^10	++
		10^6 to 10^8	+
		0	-

Marker	Gene Name	E_51 Br38	E_59 Br26	E_63 Br35	E_67 Br42	E_70 Br43	N_52 Br29	N_54 Br28	N_58 Br34	N_65 Br36	N_66 Br39	MW (Da)	GI number	SEQ ID NO (nts)	SEQ ID NO (AA)
M483	proapolipoprotein Varient	-	-	+	-	+	-	-	-	-	-	25119.7		1	2
M484	Unknown	-	-	+	+	-	-	-	-	-	+	33413.9		3	4
M485	neutrophil lactoferrin	-	-	+	-	-	-	-	-	-	-	59529.6	186818 (GenPept)		
M486	alpha-2-HS glycoprotein Varient	-	-	-	-	-	-	-	+	-	-	12290.2	10289662 (dbEST)		
M487	MT-11 protein Varient	-	+	-	-	-	-	-	-	-	-	10172.9	7378207 (dbEST)		
M488	immunoglobulin lambda light chain homolog	-	-	+	-	-	-	-	-	-	-	16740.9		5	6
M489	Unknown	-	-	-	-	-	-	-	-	+	-	21461.8		7	8
M490	Unknown	-	-	-	-	-	-	+	-	-	-	20895		9	10

Table 6 – Calgranulin A protein concentration in pool of SEC fractions 7, 8 and 9 of human serum

Sample Type	[Protein] (ng prot / ml serum) 1st Injection	[Protein] (ng prot / ml serum) 2nd Injection	[Protein] (ng prot / ml serum) 3rd Injection	Average	% RSD
Healthy	7.6	6.0	11.6	8.4	28.0
Non-Erosive	7.0	5.0	5.7	5.9	14.1
Erosive	27.1	28.2	30.0	28.4	4.3

Table 7 – Calgranulin B protein concentration in pool of SEC fractions 7, 8 and 9 of human serum

Sample Type	[Protein] (ng prot / ml serum) 1st Injection	[Protein] (ng prot / ml serum) 2nd Injection	[Protein] (ng prot / ml serum) 3rd Injection	Average	% RSD
Healthy	9.3	10.2	6.8	8.7	16.3
Non-Erosive	9.7	5.6	3.7	6.3	39.4
Erosive	129.1	112.4	127.6	123.0	6.2

Table 8A – Calgranulin C protein concentration in pool of SEC fractions 7, 8 and 9 of human serum (Peptide 1)

Sample Type	[Protein] (ng prot / ml serum) 1st Injection	[Protein] (ng prot / ml serum) 2nd Injection	[Protein] (ng prot / ml serum) 3rd Injection	Average	% RSD
Healthy	5.3	5.5	5.1	5.3	2.9
Non-Erosive	9.1	10.4	9.0	9.5	6.7
Erosive	81.7	78.3	80.2	80.1	1.7

Table 8B – Calgranulin C protein concentration in pool of SEC fractions 7, 8 and 9 of human serum (Peptide 2)

Sample Type	[Protein] (ng prot / ml serum) 1st Injection	[Protein] (ng prot / ml serum) 2nd Injection	[Protein] (ng prot / ml serum) 3rd Injection	Average	% RSD
Healthy	0	0	0	0	0
Non-Erosive	11.7	8.1	8.1	9.3	18.5
Erosive	92.3	69.6	93.2	85.1	12.8

Table 9A - Serum Amyloid A Concentration in Human Serum

Serum Sample	Average SAA concentration (mg/L)	Patient Number (n =)
Healthy	4.8	35
Disease Control	5.5	9
Non-erosive	34.3	16
Erosive	115.8	17

Table 9B - One tail t-test Comparison of the SAA Concentrations of Erosive and Non-Erosive to Healthy and Disease Controls

Sample Comparison	1 tail t-test p value
Erosive vs. Healthy	0.000151
Erosive vs. Disease Control	0.033543
Non-erosive vs. Healthy	0.000001
Non-erosive vs. Disease Control	0.007497

Table 9C - One tail t-test Comparison of SAA concentrations in Erosive and Non-erosive Serum Samples

Sample Comparison	1 tail t-test p value
Erosive vs. Non-erosive	0.034980

What is claimed is:

1.   A method of assessing whether a patient is afflicted with RA, the method comprising:

5   (a)   determining the level of expression of one or more markers in a patient
             sample, wherein the one or more markers are selected from the group
             consisting of markers listed in Table 2;

     (b)   determining the normal level of expression of the one or more markers in a
             control sample; and

10   (c)   comparing the level of expression of the one or more markers in the patient
             sample to the level of expression of the one or more markers in the control
             sample,

wherein a significant difference in the level of expression of the one or more
markers in the patient sample compared to the normal level is an indication that the patient

15   is afflicted with RA.

2.   The method of claim 1, wherein the level of expression is determined by
detecting the amount of marker protein present in the sample.

3.   The method of claim 1, wherein the level of expression is determined by
detecting the amount of mRNA that encodes a marker protein present in the sample.

20   4.   A method of assessing whether a patient is afflicted with RA, the method
comprising:

     (a)   determining the level of expression of a plurality of markers in a patient
             sample, wherein at least one of the markers is selected from Table 3B and
             the one or more additional markers are selected from the group consisting

25   of markers listed in Table 2;

     (b)   determining the normal level of expression of the plurality of markers in a
             control sample; and

     (c)   comparing the level of expression of the plurality of markers in the patient
             sample to the level of expression of the plurality of markers in the control

30   sample,

wherein a significant difference in the level of expression of the plurality of markers in the patient sample compared to the normal level is an indication that the patient is afflicted with RA.

5.   A method of assessing whether a patient is afflicted with erosive RA, the

5   method comprising:

   (a)   determining the level of expression of one or more markers in a patient sample, wherein the one or more markers are selected from the group consisting of markers listed in Table 2;

   (b)   determining the level of expression of the one or more markers in a control

10   sample; and

   (c)   comparing the level of expression of the one or more markers in the patient sample to the level of expression of the one or more markers in the control sample,

   wherein a significant difference between the level of expression of

15 the one or more markers in the patient sample and the control is an indication that the patient is afflicted with erosive RA.

6.   The method of claim 5, wherein the control is the level of expression of the one or more markers in a non-erosive RA patient sample.

7.   The method of claim 5, wherein the level of expression is determined by

20 detecting the amount of marker protein present in the sample.

8.   The method of claim 5, wherein the level of expression is determined by detecting the amount of mRNA that encodes a marker protein present in the sample.

9.   A method of assessing whether a patient is afflicted with RA, the method comprising:

25   (a)   determining the level of expression of one or more markers in a patient sample, wherein the one or more markers are selected from the group consisting of markers listed in Table 3B;

   (b)   determining the level of expression of the one or more markers in a control sample; and

(c)   comparing the level of expression of the one or more markers in the patient

sample to the level of expression of the one or more markers in the control

sample,

wherein a significant difference between the level of expression of the one or more

5   markers in the patient sample and the control is an indication that the patient is afflicted

with RA.

10.   The method of claim 9, wherein the level of expression is determined by

detecting the amount of marker protein present in the sample.

11.   The method of claim 9, wherein the level of expression is determined by

10   detecting the amount of mRNA that encodes a marker protein present in the sample. .

12.   An isolated nucleic acid molecule comprising a nucleotide sequence

selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7 and 9.

13.   A vector which contains the nucleic acid molecule of claim 12.

14.   A host cell which contains the nucleic acid molecule of claim 12.

15   15.   An isolated polypeptide which is encoded by a nucleic acid molecule

comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3,

5, 7 and 9.

16.   An antibody which selectively binds to the polypeptide of claim 15.

17.   An isolated polypeptide comprising an amino acid sequence selected from

20   the group consisting of SEQ ID NOs: 2, 4, 6, 8 and 10.

18.   An antibody which selectively binds to the polypeptide of claim 17.

SEQUENCE LISTING

<110> Millennium Pharmaceuticals, Inc.
      Guild, Braydon Charles
      Liao, Hua
      Jones, Michael Dean
      Zolg, Johannes Werner
      Wu, Jiang

<120> COMPOSITIONS, KITS, AND METHODS FOR
  IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF
  RHEUMATOID ARTHRITIS

<130> MPM01-032P1RNWOM

<150> US 60/341,942
<151> 2001-12-19

<160> 10

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 1136
<212> DNA
<213> Homo Sapiens

<400> 1
gtagaaggga ttacaaagtg gaaatagaca ccaaatctta ctggaaggca cttggcatct 60
ccccattcca tgagcatgca gaggtggtat tcacagccaa cgactccggc ccccgccgct 120
acaccattgc cgccctgctg agcccctact cctattccac cacggctgtc gtcaccaatc 180
ccaaggaatg agggacttct cctccagtgg acctgaagga cgagggatgg gatttcatgt 240
aaccaagagt attccatttt tactaaagca gtgtttttcac ctcatatgct atgttagaag 300
tccaggcaga gacaataaaa cattcctgtg aaaggcaaaa aaaaaaaaa aaaactcgag 360
gtcgacggta tcgataagct tgatatcgaa ttcggcacga gcggcccttc aggatgaaag 420
ctgcggtgct gaccttggcc gtgctcttcc tgacggggag ccaggctcgg catttctggc 480
agcaagatga accccccccag agccctgggg atcgagtgaa ggacctggcc actgtgtacg 540
tggatgtgct caaagacagc ggcagagact atgtgtccca gtttgaaggc tccgccttgg 600
gaaaacagct aaacctaaag ctccttgaca actgggacag cgtgacctcc accttcagca 660
agctgcgcga acagctcggc cctgtgaccc aggagttctg ggataacctg gaggccaagg 720
tgcagcccta cctggacgac ttccagaaga gtggcagga ggagatggag ctctaccgcc 780
agaaggtgga gccgctgcgc gcagagctcc aagagggcgc gcgccagaag ctgcacgagc 840
tgcaagagaa gctgagccca ctgggcgagg agatgcgcga acgcgcgcgc gcccatgtgg 900
acgcgctgcg cacgcatctg gcccccctac agcgacgagc tgcgccagcg cttggccgcg 960
cgcccttgag gctctcaagg agaacggcgg cgccagactg gccgagtacc acgccaaggc 1020
caccgagcat ctgagcacgc tcagcgagaa ggccaagccc gcgctcgagg acctcccgcc 1080
aggcctgctg cccgtgctgg agagcttcag gtcagctcct gagactctcc aagata 1136

<210> 2
<211> 216
<212> PRT
<213> Homo Sapiens

<400> 2
Tyr Arg Ile Arg His Glu Arg Pro Phe Arg Met Lys Ala Ala Val Leu
1   5   10   15
Thr Leu Ala Val Leu Phe Leu Thr Gly Ser Gln Ala Arg His Phe Trp
            20   25   30
Gln Gln Asp Glu Pro Pro Gln Ser Pro Trp Asp Arg Val Lys Asp Leu
        35   40   45
Ala Thr Val Tyr Val Asp Val Leu Lys Asp Ser Gly Arg Asp Tyr Val
    50   55   60
Ser Gln Phe Glu Gly Ser Ala Leu Gly Lys Gln Leu Asn Leu Lys Leu
65   70   75   80
Leu Asp Asn Trp Asp Ser Val Thr Ser Thr Phe Ser Lys Leu Arg Glu
                85   90   95
Gln Leu Gly Pro Val Thr Gln Glu Phe Trp Asp Asn Leu Glu Ala Lys
            100   105   110
Val Gln Pro Tyr Leu Asp Asp Phe Gln Lys Lys Trp Gln Glu Glu Met
        115   120   125

1

```
Glu Leu Tyr Arg Gln Lys Val Glu Pro Leu Arg Ala Glu Leu Gln Glu
    130                 135             140
Gly Ala Arg Gln Lys Leu His Glu Leu Gln Glu Lys Leu Ser Pro Leu
145                 150             155                 160
Gly Glu Glu Met Arg Glu Arg Ala Arg Ala His Val Asp Ala Leu Arg
                165             170                 175
Thr His Leu Ala Pro Leu Gln Arg Arg Ala Ala Pro Ala Leu Gly Arg
            180             185             190
Ala Pro Leu Arg Leu Ser Arg Arg Thr Ala Ala Pro Asp Trp Pro Ser
            195             200             205
Thr Thr Pro Arg Pro Pro Ser Ile
    210             215
```

<210> 3
<211> 1868
<212> DNA
<213> Homo Sapiens

<400> 3
```
ctcccagcaa ggccggatgc cagtttaggg catgatgttg gcgacgctcc tccacagggc 60
gggaaggttg atgaaaggcg tgttgaccga ggccccagag gctaacggcg tggttgtgcc 120
cctccttgat ggctggaaga tccgctttga tggttgccat tcagcagctg gttggcctcc 180
ttgctggctt ggttgacccc attatgagca ttctgcagct ccttcccggc ctggccagca 240
gcatggtggg caccttggcc aagcttctcc acttcctttc cagcctggtc agcagcatgg 300
ttgaccccct ggccaagttt ctctgcttcc ttccagcct ggtggacccc agtgtggaac 360
ccttggaccg ctttgtctgc ttccttccg gcctgttcaa gggtatggtg aactccctgg 420
ccaaactgcc ctgcctcctt cccggcctcg tggaccccag gttggacacc atgaactgct 480
atgtctccct ctttcccagc ctgccctgct gtgtggtgaa gtcgtggcc aaactgcccc 540
ccctcccttc cagcctgact aacgccatga tgcgaggcct tgggacgcac tgctgtgcgt 600
gcctgccttc cgccatccgt gcgagtgcag catggtggac atccctggcc aaacttctct 660
gcttccttcc aggcctcatt aaccccaggg tggacccccag ggccgagctt ctctgtttcc 720
ttcccaaatt gactggcagc atggtggacc ccctggccaa acttctctgt ctccttccag 780
ccctcactga gaccatgggg gaccccgctg ggcccaacct ccaagcctca tttccggcct 840
gccccgcagc agtggtgggc cccctggcca aatctccctt gcctcatttc cgggcctgcc 900
ccgcagcatg gtgggccccc tggccaaact ctctgcctc cttcccaacc tgaccagcag 960
tatggtggac cccctggcca aacttctctg tctccttcca gccctcactg agaccatggt 1020
ggaccccctg gccaaatctc cctgcctcat ttccggcctg ccccgcagca tggtgggccc 1080
cctggccaaa cttctctgcc tccttcccaa cctgaccggc agcatggtgg atcccctggc 1140
caaacttctc tgtctccttc agccctcac tgagaccatg gtgggccccc tggccaaatc 1200
tcccagcctc atttccggcc tgccctgcag catggtggac tccctggcca aacctcccag 1260
cctcatttcc ggcctgccct gcagcatggt ggactccctg ccaaacctc cagcctcat 1320
ttccagcctg ccctgcagca ttgtcgactc cctggccaaa cttccctgcc tcacttccg 1380
cctggttggc ccgtgatgg accccatgat ggatcagttt gtctgcctcc ttcccaacct 1440
gtccagcagc gttgttgacc ccatggccaa gcttctctgc ttcctttcct gcttgtccaa 1500
taccatggtt gatctcatgg gcaaccttgt ccatgccgtg gttgagcccc cggacgcctt 1560
tgtccaactc cttgccggtg tggctcccca tgttgctaag tccgttgaaa accttctcca 1620
cttcccttcc ggcatgcgtg attccactgt tgatgccatc cagggccttg cccacctctc 1680
tctctgcatt gctcagccct cggttgatcc cttcaatgac cttctcaatg gggtcatcgc 1740
tggccgccca tccagacagg gcccccagta gcagaaggag ggagcaggag ccgaccagac 1800
gtgcaagatg catattgctg ggaaggtcgg gaaggatgca gagaggagcc agggaagcca 1860
cgctgcta                                                           1868
```

<210> 4
<211> 327
<212> PRT
<213> Homo Sapiens

<400> 4
```
Ser Ser Val Ala Ser Leu Ala Pro Leu Cys Ile Leu Pro Asp Leu Pro
1               5               10              15
Ser Asn Met His Leu Ala Arg Leu Val Gly Ser Cys Ser Leu Leu Leu
            20              25              30
Leu Leu Gly Ala Leu Ser Gly Trp Ala Ala Ser Asp Asp Pro Ile Glu
        35              40              45
Lys Val Ile Glu Gly Ile Asn Arg Gly Leu Ser Asn Ala Glu Arg Glu
    50              55              60
Val Gly Lys Ala Leu Asp Gly Ile Asn Ser Gly Ile Thr His Ala Gly
65              70              75              80
Arg Glu Val Glu Lys Val Phe Asn Gly Leu Ser Asn Met Gly Ser His
```

2

```
                    85                  90                  95
Thr Gly Lys Glu Leu Asp Lys Gly Val Arg Gly Leu Asn His Gly Met
                100                 105                 110
Asp Lys Val Ala His Glu Ile Asn His Gly Ile Gly Gln Ala Gly Lys
                115                 120                 125
Glu Ala Glu Lys Leu Gly His Gly Val Asn Asn Ala Ala Gly Gln Val
    130                 135                 140
Gly Lys Glu Ala Asp Lys Leu Ile His His Gly Val His His Gly Ala
145                 150                 155                 160
Asn Gln Ala Gly Ser Glu Ala Gly Lys Phe Gly Gln Gly Val Asp Asn
                165                 170                 175
Ala Ala Gly Gln Ala Gly Asn Glu Ala Gly Arg Phe Gly Gln Gly Val
                180                 185                 190
His His Ala Ala Gly Gln Ala Gly Asn Glu Ala Gly Arg Phe Gly Gln
    195                 200                 205
Gly Val His His Ala Ala Gly Gln Ala Gly Asn Glu Ala Gly Arg Phe
    210                 215                 220
Gly Gln Gly Ala His His Gly Leu Ser Glu Gly Trp Lys Glu Thr Glu
225                 230                 235                 240
Lys Phe Gly Gln Gly Ile His His Ala Ala Gly Gln Val Gly Lys Glu
                245                 250                 255
Ala Glu Lys Phe Gly Gln Gly Ala His His Ala Ala Gly Gln Ala Gly
                260                 265                 270
Asn Glu Ala Gly Arg Phe Gly Gln Gly Val His His Gly Leu Ser Glu
    275                 280                 285
Gly Trp Lys Glu Thr Glu Lys Phe Gly Gln Gly Val His His Thr Ala
    290                 295                 300
Gly Gln Val Gly Lys Glu Ala Glu Lys Phe Gly Gln Gly Ala His His
305                 310                 315                 320
Ala Ala Gly Gln Ala Arg Lys
                325
```

```
<210> 5
<211> 468
<212> DNA
<213> Homo Sapiens

<220>
<221> misc_feature
<222> (1)...(468)
<223> n = A,T,C or G

<400> 5
acgcgtccgg gaagcaacac tggtggtgcc tcagccatgg cctggaccgt tctcctcctc 60
ggcctcctct ctcactgcac aggctctgtg acgtccaatg tgctgactca gccaccctcg 120
gtgtcagtgg ccccaggaag gacggccagg atcacctgtg agagagacaa cattgaaagt 180
aaaagtgttc actggtacca gcagaagcca ggccaggccc ctgtgttggt cgtctacgat 240
gatcgtgagc ggccctcagg gatccctgac cggttctctg ctccaactc tgggaacacg 300
gccatcctca ccatcagcag ggtcgaagcc ggggatgagg ccgactattt ttgtcacgtg 360
tgggatggtg acagagatca agcgcatgtg gttttcggcn ggggaccaa gctgaccgtc 420
ctagtcagcc caaggctgcc ccctcggtca ctctgttccc gccctcct         468

<210> 6
<211> 156
<212> PRT
<213> Homo Sapiens

<220>
<221> VARIANT
<222> (1)...(156)
<223> Xaa = Any Amino Acid

<400> 6
Thr Arg Pro Gly Ser Asn Thr Gly Gly Ala Ser Ala Met Ala Trp Thr
1                   5                   10                  15
Val Leu Leu Leu Gly Leu Leu Ser His Cys Thr Gly Ser Val Thr Ser
                20                  25                  30
Asn Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Arg Thr
    35                  40                  45
```

```
Ala Arg Ile Thr Cys Glu Arg Asp Asn Ile Glu Ser Lys Ser Val His
    50                  55                  60
Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp
65                  70                  75                  80
Asp Arg Glu Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Asn
                85                  90                  95
Ser Gly Asn Thr Ala Ile Leu Thr Ile Ser Arg Val Glu Ala Gly Asp
                100                 105                 110
Glu Ala Asp Tyr Phe Cys His Val Trp Asp Gly Asp Arg Asp Gln Ala
            115                 120                 125
His Val Val Phe Gly Xaa Gly Thr Lys Leu Thr Val Leu Val Ser Pro
    130                 135                 140
Arg Leu Pro Pro Arg Ser Leu Cys Ser Arg Pro Pro
145                 150                 155
```

```
<210> 7
<211> 564
<212> DNA
<213> Homo Sapiens

<400> 7
cgcgatctag aactgacaag tccaactctt accggcatcg tgaagtctct ttcttggcat 60
tggatgaaca gaaagtttgc tccgctcagg atgttgccag ggattactcc aatcccaaat 120
gggatgaaac ctcacttggc ttcctcgaaa agcaaagtga tcttgaagag gtgaaaggac 180
aagaaacagt tgctcccagg ctcagcaggg gaccgctgag agtggacaag catgaaatcc 240
cccaggagtc actggatgga tgttgcttga ctccttccat ccttcctgac ctgactccct 300
cctaccaccc ttattggagc actttgtact cttttgaaga caagcaagtc agcttggctc 360
ttgtagacaa aattaaaaag gatcaagagg agatagaaga ccaaagccca ccatgcccca 420
ggctcagcca ggagctgcca gaggtgaagg agcaggaagt cccagaggac tctgtgaatg 480
aagtttactt gactcccctca gttcaccatg acgtgtctga ctgccaccag ccttatagca 540
gcaccttgtc ctcattggag gatc                                        564
```

```
<210> 8
<211> 188
<212> PRT
<213> Homo Sapiens

<220>
<221> VARIANT
<222> (1)...(188)
<223> Xaa = Any Amino Acid

<400> 8
Arg Ser Arg Thr Asp Lys Ser Asn Ser Tyr Arg His Arg Glu Val Ser
1                   5                   10                  15
Phe Leu Ala Leu Asp Glu Gln Lys Val Cys Ser Ala Gln Asp Val Ala
                20                  25                  30
Arg Asp Tyr Ser Asn Pro Lys Trp Asp Glu Thr Ser Leu Gly Phe Leu
            35                  40                  45
Glu Lys Gln Ser Asp Leu Glu Glu Val Lys Gly Gln Glu Thr Val Ala
    50                  55                  60
Pro Arg Leu Ser Arg Gly Pro Leu Arg Val Asp Lys His Glu Ile Pro
65                  70                  75                  80
Gln Glu Ser Leu Asp Gly Cys Cys Leu Thr Pro Ser Ile Leu Pro Asp
                85                  90                  95
Leu Thr Pro Ser Tyr His Pro Tyr Trp Ser Thr Leu Tyr Ser Phe Glu
                100                 105                 110
Asp Lys Gln Val Ser Leu Ala Leu Val Asp Lys Ile Lys Lys Asp Gln
            115                 120                 125
Glu Glu Ile Glu Asp Gln Ser Pro Pro Cys Pro Arg Leu Ser Gln Glu
    130                 135                 140
Leu Pro Glu Val Lys Glu Gln Glu Val Pro Glu Asp Ser Val Asn Glu
145                 150                 155                 160
Val Tyr Leu Thr Pro Ser Val His His Asp Val Ser Asp Cys His Gln
                165                 170                 175
Pro Tyr Ser Ser Thr Leu Ser Ser Leu Glu Asp Xaa
                180                 185
```

```
<210> 9
<211> 870
<212> DNA
<213> Homo Sapiens

<220>
<221> misc_feature
<222> (1)...(870)
<223> n = A,T,C or G

<400> 9
nngtatcccg gggagtaaga acctagggta cagtgtcccc catgggaaag cagtgcttac  60
cctcttggat gtagcttggg accacagtaa cagaagtatt tacagtttga tttttgtaac 120
aggagaaatc atattttcct ctaagttgag acacattctt ccatcttcct accttacacc 180
ctcccccatt cctggcagct ctgaaacact tgctcaagcc ttgcttaata tagcaaaagc 240
agctaatctg ttatcatctg aggtcagaac taacattcag aaagttctcc taagggtttg 300
ggtcttcatt ccaagtcagt catcctaccc aggagaccac acctcaccca ccttcatgca 360
ctccacactc caatcccaca caccttctcc ccactccccc cccacacaaa ccctaaaccc 420
taagcagaat gacattaaga taataatttg taattgcaat acacacagca ggcattcaaa 480
aatggaagaa gaaaggaaaa gctgcagaaa aatctttaag tactccacaa actggcacaa 540
gccacagacg gattggaatt aatcaacgct ggactttcct agggaaaata gcattggcta 600
tttaaaacag gctggagtca tccaaatatt aggcagttat aaaccaaact ttctacatca 660
tccagtctag tgggtctggc aaacataccc tatggaccag gtccaacctg gctggcctgg 720
tttttggtaa atttaactgg gtcatcaggg cataacttca cacccatttg gtttacctgg 780
ctaatctggt aaacagaagt ttcagcggaa tagttccctc ttttaaaagc agagttgaat 840
agttctggag agtaggctct gcagggatgn                                 870

<210> 10
<211> 186
<212> PRT
<213> Homo Sapiens

<220>
<221> VARIANT
<222> (1)...(186)
<223> Xaa = Any Amino Acid

<400> 10
Xaa Ile Pro Gly Ser Lys Asn Leu Gly Tyr Ser Val Pro His Gly Lys
1               5                   10                  15
Ala Val Leu Thr Leu Leu Asp Val Ala Trp Asp His Ser Asn Arg Ser
            20                  25                  30
Ile Tyr Ser Leu Ile Phe Val Thr Gly Glu Ile Ile Phe Ser Ser Lys
        35                  40                  45
Leu Arg His Ile Leu Pro Ser Ser Tyr Leu Thr Pro Ser Pro Ile Pro
    50                  55                  60
Gly Ser Ser Glu Thr Leu Ala Gln Ala Leu Leu Asn Ile Ala Lys Ala
65                  70                  75                  80
Ala Asn Leu Leu Ser Ser Glu Val Arg Thr Asn Ile Gln Lys Val Leu
                85                  90                  95
Leu Arg Val Trp Val Phe Ile Pro Ser Gln Ser Ser Tyr Pro Gly Asp
            100                 105                 110
His Thr Ser Pro Thr Phe Met His Ser Thr Leu Gln Ser His Thr Pro
        115                 120                 125
Ser Pro His Ser Pro Pro Thr Gln Thr Leu Asn Pro Lys Gln Asn Asp
    130                 135                 140
Ile Lys Ile Ile Ile Cys Asn Cys Asn Thr His Ser Arg His Ser Lys
145                 150                 155                 160
Met Glu Glu Glu Arg Lys Ser Cys Arg Lys Ile Phe Lys Tyr Ser Thr
                165                 170                 175
Asn Trp His Lys Pro Gln Thr Asp Trp Asn
                180                 185
```